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Summary 
Pre-eclampsia is a pregnancy-specific, multi-system disorder of placental origin. 
Affecting between 2-8% of women, it is one of the leading causes of both maternal 
and fetal morbidity and mortality in the United Kingdom. Although the disorder 
presents after 20 weeks gestation with the classic symptoms of hypertension and 
proteinuria, the pathological process(es) leading to this syndrome initiate early in the 
first trimester. In current clinical practice, prediction of those who will get the disease 
and those who will have a poor outcome once it develops is poor. 
This thesis focuses on novel ways to enhance the prediction of the development of 
pre-eclampsia and poor outcome once the syndrome manifests. 
Firstly, the current risk factors for pre-eclampsia were challenged. Racial variation in 
these risk factors has demonstrated the importance of considering maternal ethnicity 
when assessing the likelihood of developing the disease.  Obese Black women were 
more likely to develop pre-eclampsia than obese white women (aOR 2.06 (95%CI 
1.34-3.23) p=0.002).  In the normal BMI group Black women were less likely to 
develop pre-eclampsia than White women (aOR 0.421 (95%CI 0.24-0.73) p<0.001).  
Younger (<20 years of age) Black women were less likely to develop pre-eclampsia 
than younger white women (aOR 0.628 (95%CI 0.49-0.83) p<0.001).  Conversely, 
older (>35 years of age) Black women were more likely to develop pre-eclampsia 
than older White women (aOR 1.67 (95%CI 1.39-1.99) p<0.001). 
Secondly, first trimester maternal plasma studies have identified a cohort of potential 
disease (and pathophysiological) markers that may allow for the development of an 
early screening test for pre-eclampsia.  The ratio of angiotensinogen to Kallikrein is 
raised in the first trimester of pregnancies that later develop pre-eclampsia 
(p<0.001).  The receiver operator curve (ROC) for the ratio of angiotensinogen to 
kallikrein had an area under the curve (AUC) of 0.81 (SE=0.05).  A cut-off value of 
>0.27 has a sensitivity of 0.9 (95% CI = 0.74 – 0.97), a specificity of 0.5 (95% CI = 
0.24-0.65), positive predictive value (PPV) 0.63 (95%CI = 0.47-0.75) and negative 
predictive value (NPV) of 0.87 (95% CI = 0.53-0.96) in predicting the onset of pre-
eclampsia.     
Common haematological and biochemical tests are presented as markers for both 
the development of the disease and poor outcome when it occurs.  The ratio of 
Neutrophil to Lymphocyte (NLR) is raised in the first trimester of pregnancies that 
develop pre-eclampsia (p<0.001).  The ROC of the ratio to Neutrophil to Lymphocyte 
has an AUC of 0.84 (95% CI = 0.85-0.95).  A cut off value of 2.53 has a sensitivity of 
0.92 (95%CI = 0.85-0.95), specificity of 0.6 (95%CI = 0.51-0.67), PPV 0.68 (95%CI = 
0.6-0.74) NPV 0.87 (95%CI = 0.8-0.93) for predicting the onset of pre-eclampsia.  At 
the time of diagnosis of pre-eclampsia, a raised NLR predicts poor maternal 
outcome and the need for a caesarean section due to fetal distress (p<0.05).  In 
addition, a reduced level of bilirubin predicts both poor fetal and maternal outcome 
and the need for a caesarean section (p<0.05).   
! xx!
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Chapter 1 
Introduction 
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1.  Introduction 
 
Some form of hypertension occurs in 15-20% of pregnancies (James et al, 
2003).  These hypertensive disorders of pregnancy are a leading cause of 
maternal and fetal/neonatal morbidity, with the main cause being pre-
eclampsia.   
Pre-eclampsia is a multi-organ, pregnancy specific condition characterised 
by hypertension, proteinuria ± oedema (Walker et al, 2000) and in the 
western world affects 2-8% of all pregnancies (North et al, 2011).  It is a 
spectrum disorder.  Some women develop mildly raised blood pressure with 
proteinuria at term, requiring no further action other than enhanced 
surveillance.  Others need to be delivered early in the third trimester due to 
a fulminating form of the disease potentially leading to multi organ failure 
and seizures.  The classic triad of symptoms of headache, visual 
disturbance and epigastric pain represent abnormal cerebral perfusion / 
retinal arteriolar spasm or oedema / hepatic capsular distension 
respectively and are the commonest symptoms that precede an eclamptic 
fit (James et al, 2003).  However, even at it’s worst, the disease can be 
surprisingly symptomless.  Given how severe the disease can be, much of 
the standard United Kingdom (UK) antenatal practice is geared towards 
detecting it, with every woman having her blood pressure checked and a 
urinalysis performed at each clinical visit.  With appointments only occurring 
every 3 weeks until 34 weeks gestation, then 2 weeks until 38 weeks 
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(www.choices.nhs.uk), detection of the disease can be troublesome.  
Although blood pressure can be managed by a variety of agents, the only 
“cure” for pre-eclampsia is delivery of the placenta and fetus.  In view of 
this, there has been a move to improve prediction rates of women who will 
develop pre-eclampsia and if deemed high risk, offer some form of 
prophylaxis or intervention such as enhanced care (NICE, 2010).   
In this chapter I will discuss current ideas regarding the classification of the 
disease, its pathophysiology, the current standard screening methods and 
those novel screening methods that have been suggested in the literature.   
 
1.1 Definition and diagnostic criteria  
 
1.1.1 Defining preeclampsia 
 
The standard definition of pre-eclampsia being hypertension, proteinuria ± 
oedema occurring after 20 weeks gestation is universally accepted.  
However, the differing cut-offs for defining both hypertension and 
proteinuria have not been so standard.  The international society for the 
study of hypertension in pregnancy (ISSHP) therefore defined, via a 
consensus working group in 2000, pre-eclampsia as being: 
• Hypertension = Systolic Blood Pressure (SBP) >140mmHg and / or a 
Diastolic Blood Pressure (DBP) of > 90mmHg on two consecutive 
readings 6 hours apart. 
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• Proteinuria = ≥300mg/l/24 hrs or a protein: creatinine ratio of 
>30mg/mmol, and where this test is not available, a 1+ proteinuria on 
a urine dipstix, with both occurring after 20 weeks and returning to 
normal postnatally (Brown et al, 2001).   
Whilst this has been taken to be the standard definition of pre-
eclampsia, definitions for characterising severe pre-eclampsia and early 
onset pre-eclampsia remain somewhat arbitrary (Tranquilli et al, 2013). 
 
1.1.2 Defining severe pre-eclampsia 
 
The National Institute for Health and Care Excellence (NICE) define severe 
pre-eclampsia as being pre-eclampsia with severe hypertension and/or with 
symptoms, and/or biochemical and/or haematological impairment with a sub 
definition for severe hypertension as being a systolic BP ≥160mmHg and/or 
a diastolic blood pressure ≥ 110mmHg (NICE, 2010).   
The American College of Obstetrics and Gynaecology (ACOG) have also 
issued guidance on the definition of severe pre-eclampsia.  They define pre-
eclampsia as “Blood pressure of 140 millimeters of mercury (mmHg) 
systolic or higher or 90 mmHg diastolic or higher that occurs after 20 weeks 
of gestation in a woman with previously normal blood pressure and 
proteinuria defined as urinary excretion of 0.3 grams (g) protein or higher in 
a 24-hour urine specimen”.  To be classified as severe they suggest one or 
more of the following features: 
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• Blood pressure of 160 mm Hg systolic or higher or 110 mm Hg diastolic or 
higher on two occasions at least 6 hours apart while the patient is on bed 
rest  
• Proteinuria of 5 g or higher in a 24-hour urine specimen or 3+ or greater on 
two random urine samples collected at least 4 hours apart  
• Oliguria of less than 500 millilitres (mL) in 24 hours  
• Cerebral or visual disturbances  
• Pulmonary edema or cyanosis  
• Epigastric or right upper-quadrant pain  
• Impaired liver function  
• Thrombocytopenia  
• Fetal growth restriction  
The ACOG definition has been adopted by many clinicians and 
researchers.  Whilst it is useful to have guidance for the definition of both 
pre-eclampsia and severe pre-eclampsia, the ACOG guidance does not 
address the problem of pre-eclampsia as a result of pre-existing medical 
disorders, including pre-existing hypertension, the so-called ‘superimposed 
pre-eclampsia’.  Both the ISSHP and NICE have addressed this and split 
hypertensive disorders of pregnancy into different categories (NICE, 2010, 
Tranquilli et al, 2013).  These are: 
• Chronic hypertension (hypertension detected at booking or before 20 weeks 
gestation, or women taking anti-hypertensive medication pre-pregnancy) 
!! 6!
• Gestational hypertension (hypertension occurring after 20 weeks gestation 
without significant proteinuria)  
•  Pre-eclampsia (hypertension occurring after 20 weeks gestation with 
significant proteinuria).   
 
1.1.3  Defining early and late onset pre-eclampsia 
 
The timing of the development of pre-eclampsia is also categorised.  It is 
thought that early and late onset pre-eclampsia are heterogeneous 
pathophysiological processes that lead to the clinical syndrome of pre-
eclampsia (Raymond et al, 2011).  Outcomes vary according to the timing 
of onset of the disease, with those women affected by early onset pre-
eclampsia suffering from a more aggressive form of the syndrome.  They 
are more likely to have lower birth weight babies and suffer more morbidity 
themselves (Vatten et al, 2004).     In view of this, most researchers define 
pre-eclampsia into either the early onset or late onset disease categories.  
Whilst definitions alter, the ISSHP have defined early onset pre-eclampsia 
as pre-eclampsia occurring less than 34 weeks of gestation, and late onset 
occurring after 34 weeks of gestation.   
 
For the purpose of this thesis, I have defined pre-eclampsia, severe pre-
eclampsia and early onset pre-eclampsia in line with the above ISSHP 
definition.   
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1.2 Epidemiology 
 
Pre-eclampsia is a common disorder in pregnancy, occurring in 2-8% of 
pregnancies (North et al, 2011) and it is estimated that a woman in her first 
pregnancy has a 1:250 chance of delivering preterm due to pre-eclampsia 
(Hernandez-Diaz et al, 2009).  The majority of these cases occur at late 
gestations of pregnancy and have only a negligible increased risk for 
adverse pregnancy outcome (Raymond et al, 2011).   
 
1.2.1 Maternal mortality and morbidity 
 
Despite this, pre-eclampsia represents one of the largest killers of mothers, 
both in the UK and worldwide.  Consistently, hypertensive disorders are in 
the top three causes of maternal death in the UK and the last Centre for 
Maternal and Child Enquires (CMACE) triennial report from 2006-2008 
revealed that it was the second leading cause of direct maternal deaths 
(that is, a death due to a complication of pregnancy, rather than a pre-
existing condition leading to death (indirect maternal death)) after sepsis.  
The incidence of pre-eclampsia is almost 7 times higher in the developing 
world than in the developed with 63000 women dying from the disease in 
2000 (representing 12% of maternal deaths) (CMACE, 2011).  Pre-
eclampsia also represents a leading cause of morbidity in mothers.  It has 
been estimated that one-third of significant maternal morbidity is due to pre-
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eclampsia (Waterstone et al, 2001) with 5% of women with pre-eclampsia 
requiring intensive care unit (ICU) admission (Tuffnell et al, 2005). 
 
1.2.2  Fetal morbidity and mortality  
 
The effect on the fetus is also significant.  In stillbirths that occur to non-
anomalous fetuses, 1 in 20 are due to pre-eclampsia (CMACE, 2011).  
Babies born to mothers with pre-eclampsia are also at greater risk of being 
born growth restricted.  20-25% of babies born preterm (and 14-19% of 
those born at term) to pre-eclamptic mothers have birth weights on the 10th 
centile or less (Rasmussen et al, 2006).  The preterm birth rate is also 
proportionally raised in women with pre-eclampsia, with 10% of pre-term 
births being attributable to pre-eclampsia (Sibai et al, 2011).   
 
1.3 Risk factors  
 
Several risk factors have been identified for developing pre-eclampsia:    
 
1.3.1  Nulliparity and primipaternity 
 
Notably pre-eclampsia is often referred to as a disease of the first 
pregnancy.  The incidence increases in those with a limited exposure to the 
paternal sperm before conception.  After a previous early pregnancy loss 
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(iatrogenic or spontaneous) or a healthy term delivery, the risk decreases, 
but this protection is lost with a change of partner (Broughton-Pipkin et al, 
1994).  Whole population studies have shown that fathers who have 
fathered pre-eclamptic pregnancies are almost twice as likely to father a 
pre-eclamptic pregnancy in other women, irrelevant of their parity (Lie et al, 
1998).  It is estimated that nulliparity triples the risk of developing pre-
eclampsia with a large systematic review from Duckitt et al suggesting an 
odds ratio of 2.91 (with confidence interval (C.I.) = 1.28-6.61) for nulliparous 
women developing the disease (Duckett et al, 2005).  
 
1.3.2  Age 
 
Whilst extremes of age are commonly given as a risk factor for developing 
pre-eclampsia the above mentioned systematic review by Duckitt suggested 
that mothers less than the age of 17 years were not significantly at risk of 
developing pre-eclampsia (odds ratio 2.98, CI 0.39:22.76).  Despite this, it 
has been suggested by other authors that younger women are more likely 
to develop the condition, possibly due to their limited exposure to sperm 
before conception.  It is well established that women over the age of 40 are 
at higher risk of developing the disease, furthermore this has been shown to 
be irrelevant of her parity (NICE, 2010, Broughton-Pipkin et al, 1994).  
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1.3.3  Obesity 
 
It is abundantly clear that there is a causal link between obesity and pre-
eclampsia (RCOG, 2010).  The risk of developing pre-eclampsia increases 
as body mass index (BMI) increases, and for every 5-7kg/m2 increase in 
BMI there is doubling of the incidence of the disease.  This has been seen 
in studies that have controlled for both blood pressure and other risk factors  
(O’Brien et al, 2003). It could be suggested that this link is due to insulin 
resistance which is associated with obesity.  Possible explanations for the 
link between obesity and pre-eclampsia include: increased stress due to the 
hyperdynamic circulation associated with obesity; dyslipidaemia or 
increased cytokine-mediated oxidative stress; and direct haemodynamic 
effects of hyperinsulinaemia (increased sympathetic activity and increased 
tubular sodium desorption) (Dekker et al, 2001). 
 
1.3.4  Ethnicity  
 
Different ethnic groups have different risks of developing pre-eclampsia and 
this is discussed in later chapters.   
 
1.3.5  Fertility treatment 
 
Women who conceive via artificial reproductive techniques (ART) are more 
likely to develop pre-eclampsia.  Generally these women are older, more 
!! 11!
obese (+/- polycystic ovarian syndrome (PCOS)) and therefore the cohort 
themselves are at greater risk of developing pre-eclampsia, irrespective of 
conception method.  In addition, ART themselves can increase the 
likelihood of developing pre-eclampsia.  Methods that introduce gametes 
that the woman has previously not been exposed to before (such as ovum, 
semen or embryo donation) may have an effect on the fetal-maternal 
immune interaction, and as such increase the risk of developing pre-
eclampsia. ART increases the possibility of having multi-fetal pregnancies, 
which itself predispose to developing the disease (Sibai et al, 2005).    
 
1.3.6  Multi-fetal gestation 
 
Multi-fetal gestations increase the risk of developing pre-eclampsia.  This is 
thought to be due to the larger placental mass inducing a greater degree of 
first trimester inflammation (Redman et al, 2000).  A primigravidae who is 
pregnant with twins is 5-times more likely than a primigravidae with a single 
fetus to develop pre-eclampsia and for multiparous women, this is as high 
as 10-times greater (MacGillivray et al, 1998).   
 
1.3.7  Pre-existing maternal medical conditions  
 
There are several medical conditions that predispose women to developing 
pre-eclampsia.  Whilst these disorders may affect several different organ 
systems, those that have pathological effects on endothelium and/or 
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increase systemic inflammation appear to be the main causes.  These 
conditions are summarised in table 1.   
 
 
Table 1: Summary of medical conditions associated with pre-eclampsia.  
(a=Middleton, 2010; b=Kingdom, 2011; c=Paez, 2013; d=Vellanki, 2013)   
 
1.4  Pathophysiology 
 
The true pathophysiological mechanism which causes pre-eclampsia 
remains elusive.  Although pre-eclampsia is a systemic, multi-organ 
disorder, it is widely accepted that it originates from the placenta (as pre-
eclampsia can occur in molar pregnancies where there is no fetus and the 
condition resolves when the placenta is delivered).  As previously 
mentioned, although the clinical manifestation of the disease is the same, 
that is, hypertension and proteinuria after 20 weeks gestation, there 
Disease  Increased incidence of PET 
 
 
Diabetes Mellitus (DM) 
 
15-18% of type 1 DMa 
 
 
Thrombophilia 
 
5 fold increaseb 
 
Systemic Lupus Erythamatous 
(SLE) 
 
2 fold increasec 
 
Renal disease 
 
3 fold increased 
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appears to be distinct pathological mechanisms in disease development 
(Huppertz et al, 2008).  In late onset pre-eclampsia there is 
• A normally grown baby with no signs of growth restriction 
• Normal or only slightly altered behaviour of the uterine arteries 
• No changes in blood flow of the umbilical arteries 
• An increased risk for pregnant women displaying an enlarged 
placental mass or surface (diabetes, multiple pregnancies etc.)  
This is in contrast to early onset pre-eclampsia, which comprises of:  
• An inadequate and incomplete trophoblast invasion of maternal spiral 
arteries 
• Change of blood flow within the uterine artery, suggesting impedance 
in the uterine spiral arteries 
• An increased peripheral resistance of placental vessels that leads to 
abnormal waveform in umbilical artery Dopplers 
• Clear signs of fetal growth restriction.   
 Generally, early onset pre-eclampsia can be seen as a two-stage disorder.  
The first (sub-clinical) stage is characterised by poor placental perfusion, 
which results in maternal endothelial dysfunction characterising the second 
(clinical) stage (Huppertz et al, 2008).   
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1.4.1  Normal placental development  
 
The trophoblast is the first cell linage to differentiate at the stage of the 
blastocyst, occurring at about 6 days post conception (Huppertz et al, 2005).  
This then further differentiates into 2 different types, the villous and the 
extravillous trophoblasts.  The human placenta is haemochorial; implying 
that maternal vascular integrity is disrupted by the invasive extravillous 
cytotrophoblast (EVT) cells, bringing maternal blood into direct contact with 
the placenta (Kingdom et al, 2011).  This process is takes place under low 
oxygen tension (to avoid oxygen toxicity during embryogenesis) and is 
achieved by to effective (but controlled) haemostasis.  
 The EVT is a differentiated cell lineage possessing a unique phenotype 
and is specialized for adhesion, degradation, and migration through uterine 
stromal extracellular matrix and restructuring uterine spiral arteries.  The 
EVT cells move within the spiral arteries, replacing the endothelium and 
acquiring a pseudoendothelial phenotype as they do so.  Uteroplacental 
blood flow increases exponentially in the second trimester of pregnancy, far 
exceeding the required rate needed for adequate oxygenation and nutrient 
deliverance, and the replaced endothelium allows this process to occur at 
relatively low pressure (Hubbertz et a, 2008) (Figure 1).   
 
 
 
 
!! 15!
 
    
 
Figure 1 
Normal placental development.   Extravillous cytotrophoblasts proliferate in 
anchoring columns to successfully invade through the decidua (1) and 
transform the distal spiral arteries (2). These changes mediate high volume 
flow at low pressure into the intervillous space (3). The placental villi are 
covered by the villous trophoblast compartment (4), comprising 
cytotrophoblasts that proliferate to generate the outer syncytiotrophoblast in 
direct contact with maternal blood (reproduced from Kingdom et al, 2011). 
!! 16!
 
 
1.4.2  Placental development in pre-eclampsia   
The pathogenesis of pre-eclampsia is largely thought to be poor invasion of 
the uterine spiral arteries by the trophoblast, leading to hypoperfusion, 
necrosis and a high resistance circulation (figure 2).   
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Figure 2 Uteroplacental vascular insufficiency. Extravillous cytotrophoblasts 
are less successful in invading the maternal decidua and may be removed 
by the maternal immune system (1). Consequently the distal spiral arteries 
are narrower (2) and diseased, accompanied by atherosis or local fibrin 
deposition (3) and reduced endovascular invasion (4). Hypoxia or hypoxia-
reoxygenation injury (5) has direct effects on the villous trophoblast 
compartment, reducing syncytial fusion (6) that may trigger the formation of 
syncytial knots (7). These accumulate but may fragment and shed into 
maternal blood (8), whereas areas deficient in syncytial fusion may exhibit 
focal necrosis (9).  (Adapted from Kingdom et al, 2011).   
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The method by which this occurs remains unclear, although there does 
appear to be genetic factors, immune abnormalities and other factors (such 
as oxidative stress) involved. 
 
1.4.3  Genetic factors 
 
The majority of cases of pre-eclampsia occur in nulliparous women with no 
family history of the disease.  However, as previously mentioned there does 
appear to be some genetic link, with the incidence of pre-eclampsia 3-4 
times higher in women with a first degree relative affected (Duckett et al, 
2005).  This, combined with “the paternal factor” in the pathogenesis of pre-
eclampsia, suggests a potential genetic link.  
 Dekker et al suggest that genomic imprinting results in involvement of 
paternal genes in the control of invasion and placental growth, whereas 
maternal genes inhibit it and are responsible for the adaptive immune 
response of pregnancy (Dekker et al, 2011).  These epidemiological-genetic 
links have led researchers to try to discover “the pre-eclampsia gene”.  
Goddard et al (2007) studied 775 single-nucleotide polymorphisms (SNP) in 
190 genes, in 350 women and offspring pairs with pre-eclampsia and 600 
control pairs.  They detected six genes with a significant maternal-fetal 
genotype interaction related to pre-eclampsia in IGF1, IL4R, IGF2R, GNB3, 
CSF1, and THBS4 (table 2). 
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Table 2: Genes associated with increased incidence of pre-eclampsia  
 
These and others findings suggest a multifactorial polygenic inheritance 
with a genetic component in the development of this disease (Valenzuela et 
al, 2012).   
 
1.4.4  Immune factors 
 
As previously discussed, women who have less exposure to paternal 
semen are more at risk of developing the condition, suggesting pre-
eclampsia may be due to an impaired maternal response to fetal antigens.  
Gene Function SNP 
IGF1 Codes for insulin 
like growth factor 1 
rs5742620 
IL4R Interleukin 4 
receptor 
rs3024678 
IGF2R insulin-like 
growth factor 2 
receptor 
rs2274849 
GNB3 Guanine 
nucleotide-
binding protein 
43188143 
CSF1 Macrophage 
colony-
stimulating factor 
rs1058885 
THBS4 Thrombospondin 
4 
rs256439 
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The immune environment of the uterus is such that, in pregnancy it allows a 
semi-allogenic entity to survive and thrive.  In order for this to happen, there 
must obviously be a change within immune pathways.  From studying 
women who have human immunodeficiency virus (HIV), it appears that an 
intact innate immune system is required.  Women who have untreated HIV 
are less likely to develop pre-eclampsia, but when treated with anti-retroviral 
medications, their risk returns to the level of the non-HIV population (Hall et 
al, 2007).   
Natural Killer (NK) cells, macrophages and dendritic cells are mediators of 
innate immunity, with macrophages and dendritic cells being the major 
antigen presenting cells within the uterus.  The presence of these cells 
allows adaption of the maternal immune system and prevents pregnancy 
loss.  Studies of placental macrophages have shown that in pregnancies 
affected by pre-eclampsia there are significantly more macrophages in this 
cohort’s placentae, and it has been suggested that macrophage infiltration 
is implicit in impaired trophoblast invasion (Zhang et al, 2013).  
NK cells have been shown to initiate smooth muscle remodeling of the 
maternal spiral arteries (Robson et al, 2011) and genetic studies of 
polymorphisms in the killer immunoglobulin receptors (KIRs) on maternal 
NK cells and the fetal human leukocyte antigen (HLA)-C haplotype suggest 
patients with the KIR-AA genotype and the fetal HLA-C2 genotype are at a 
significant risk of developing pre-eclampsia (Hubbertz et al, 2008).   
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1.4.5  Inflammation and oxidative stress 
 
Redman et al have shown that normal pregnancies are associated with a 
maternal systemic inflammatory response, and suggest that this response is 
exaggerated in pre-eclamptic pregnancies (Redman et al, 2003).  This 
inflammatory state activates several associated pathways, including those 
involved in oxidative stress.  Reactive Oxygen Species (ROS) are widely 
used as second messengers to propagate pro-inflammatory or growth 
stimulatory signals. In consequence, oxidative stress and exaggerated 
inflammation are related, and perhaps are an inseparable phenomena 
(Redman et al, 2000).  Oxidative stress has been shown to be involved in 
vasculopathy and has therefore been postulated to be involved in pre-
eclampsia development.  Some work has looked at the link with prevention 
of pre-eclampsia with anti-oxidants such as vitamins C and E.  This work is 
described later.   
Although several mechanisms have been postulated as being a cause of 
pre-eclampsia, the placental under perfusion leading to ischaemia and 
necrosis/infarction is agreed to be the end point that results in the systemic 
syndrome.  The injured placental villi release splice variant decoy receptor 
proteins such as soluble fms-like tyrosine kinase (sFLT1), which 
antagonises the actions of proangiogenic growth factors such as vascular 
endothelial growth factor (VEGF) and placenta-like growth factor (Hubbertz 
et al, 2008).  By binding with these growth factors, sFLT1 prevents their pro-
angiogenic effect.  Other vascular angiogenic proteins are also deranged in 
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pre-eclampsia.  Soluble endoglin (sEng) is a truncated form of endoglin, a 
cell surface receptor for Transforming Growth Factor Beta (TGF-β).  sEng 
amplifies vascular damage mediated by sFLT1 and studies have shown, 
that when administered to rodents it induces a severe pre-eclampsia like 
disorder (Maynard et al, 2011).   
It is thought that these deranged angiogenic proteins, cause systemic 
vascular dysfunction, capillary leaking and vasospasm, which in turn leads 
to the clinical spectrum of pre-eclampsia (figure 3). 
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Figure 3  Summary of the pathogenesis of preeclampsia. Genetic factors, 
immune abnormalities [natural killer (NK) cell/human leukocyte antigen 
(HLA)-C axis], and other factors such as oxidative stress may cause 
placental dysfunction, which in turn leads to the release of antiangiogenic 
factors [such as soluble fms-like tyrosine kinase 1 (sFlt1) and soluble 
endoglin (sEng)] and other inflammatory mediators to induce hypertension, 
proteinuria, and other complications of preeclampsia. Abbreviations: AT1-
AA, angiotensin type II receptor; COMT, catechol-O-methyltransferase; 
HELLP, hemolysis, elevated liver enzymes, and low platelet syndrome; 
PlGF, placental growth factor; VEGF, vascular endothelial growth factor 
(adapted from Young et al, 2010) 
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1.5  Current screening methods for pre-eclampsia 
 
Several attempts have been made to predict those women who are at risk 
of developing pre-eclampsia.  If we could accurately identify these women, 
then interventions could be implemented with the aim of preventing disease 
progression.   
 
1.5.1  Maternal History 
 
Although a poor predictor of pre-eclampsia, NICE recommend screening for 
pre-eclampsia according to clinical history.  However, this guideline has 
only moderate ability to predict pre-eclampsia, as it identifies roughly 60% 
of pregnant women as high-risk with only 30% of those deemed high risk 
developing the disease (NICE, 2010).  A large prospective international 
study looked at phenotypic characters aimed at predicting those at risk of 
developing the disease.  The Screening for Pregnancy Endpoints (SCOPE) 
study reviewed healthy nulliparous women with the aim of stratifying them 
into high and low risk of developing pre-eclampsia.  They developed a 
referral framework (figure 4) based on assessment of several clinical risk 
factors, but warned that it would only moderately predict pre-eclampsia and 
further validation models are required.  The clinical risk factors included; 
decrease of >5 years of age*, increase of 5mmHg in mean arterial blood 
pressure*, increase of 5 of BMI*, family history of pre-eclampsia, family 
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history of coronary heart disease, decrease of 500g in maternal birth 
weight, > 5days of vaginal bleeding, bilateral notching of the uterine artery 
Doppler and an increase of 0.1 of the mean uterine artery resistance index 
(RI) (* from the mean of the group) (North et al, 2011).   
 
Figure 4: Framework for specialist referral when estimated risk of pre-
eclampsia is ≥15% in model or presence of clinical risk factor with abnormal 
result on uterine artery Doppler scan. 
 
1.5.2  Blood pressure  
 
Subtle changes in blood pressure in the first and second trimester have 
been suggested to predict the onset of pre-eclampsia.  A systematic review 
by Cnossen suggested that mean arterial pressure (that is, twice the 
diastolic plus the systolic blood pressure, divided by three) of greater than 
90 mmHg obtained in the second trimester predicts the onset of pre-
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eclampsia in low risk women, with a positive likelihood ratio of 3.5 and a 
negative likelihood ratio of 0.39.  In high risk populations a diastolic blood 
pressure of 75 mm Hg or more at 13 to 20 weeks’ gestation best predicted 
pre-eclampsia, although the accuracy of prediction was modest (positive 
likelihood ratio 2.8; negative likelihood ratio 0.39).  Systolic blood pressure; 
an increase of systolic blood pressure or increase of diastolic blood 
pressure, or both, predicted pre-eclampsia poorly (area under the curve 
<0.70) (Cnossen et al, 2008). 
 
1.5.3  Uterine Artery Doppler  
 
In the non-pregnant state, uterine artery Doppler waveforms are 
characterised by a rapid rise and fall of uterine artery velocity in systole, and 
the high resistance spiral arteries cause notching of the velocity in early 
diastole.  During normal pregnancy, the high resistance system is replaced 
by a low resistance system, which leads to loss of this diastolic notching 
(figure 5). 
 
!! 27!
 
Figure 5: Uterine artery Doppler at 24 weeks gestation (adapted from 
Nicolaides, 2000) 
 
In pre-eclamptic pregnancies, the impaired trophoblastic invasion of the 
spiral arteries leads to a persistence of the high resistance state.  This 
placental dysfunction is characterised by the presence of notching of the 
uterine artery velocity during early diastole, and an increase in resistance 
index (RI) and pulsatility index (PI) (where the RI = maximum-minimum 
velocity divided by the maximum velocity, representing the resistance to 
blood flow in a vascular bed distal to the site of measurement and PI = 
maximum-minimum velocity / mean velocity, representing the average flow 
of blood) (Nicolaides et al, 2000). 
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Figure 6: Flow velocity waveform from the uterine artery at 24 weeks of 
gestation in a pregnancy with impaired placentation; in early diastole there 
is a notch (yellow arrow) and in late diastole there is decreased flow 
(orange arrow) (adapted from Nicolaides et al, 2000) 
 
Cnossen showed that Severe pre-eclampsia in low-risk patients was best 
predicted in the second trimester by an increased pulsatility index (positive 
likelihood ratio 15.6, 95% CI 13.3–17.3; negative likelihood ratio 0.23, 95% 
CI 0.15–0.35) and bilateral notching (positive likelihood ratio 13.4, 95% CI 
8.5–17.4); negative likelihood ratio 0.4 (95% CI 0.2–0.6).  Among high-risk 
patients, pre-eclampsia was best predicted in the second trimester by 
unilateral notching (positive likelihood ratio 20.2, 95% CI 7.5–29.5; negative 
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likelihood ratio 0.17, 95% CI 0.03–0.56) and an increased pulsatility index 
with notching (positive likelihood ratio 21.0, 95% CI 5.5–80.5; negative 
likelihood ratio 0.82, 95% CI 0.72–0.93).  These results from 2008, studying 
79517 women, challenged previously held ideas about the lack of sensitivity 
of uterine artery Doppler to predict pre-eclampsia.  However, due to the 
high false positive rate, the authors do offer caution in using uterine artery 
Doppler to predict pre-eclampsia in high-risk women (Cnossen et al, 2008).   
 
1.6  Biomarkers 
 
Given the significant morbidity that pre-eclampsia can bring, many people 
have sought to find the elusive perfect screening test(s) which can predict 
the development of pre-eclampsia, much in the same way that screening for 
trisomy 21 is undertaken. 
 
1.6.1  Angiogenic factors 
 
As previously described, one of the hallmarks of the pathogenesis of pre-
eclampsia is alteration in angiogenesis in the ischaemic placenta.  The 
hypoxic placenta releases a host of angiogenic factors, with alteration in the 
normal equilibrium of pro-angiogenic versus anti-angiogenic factors 
detectable in maternal blood from as early as the first trimester of 
pregnancy (Myatt et al, 2012). 
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Vascular Endothelial Growth Factor (VEGF) can promote endothelial cell 
proliferation, migration and survival, and exerts its biologic effects through 
two high-affinity tyrosine kinase receptors: VEGFR-1 (VEGF receptor-1 also 
known as fms-like tyrosine kinase-1 (FLT-1)) and VEGFR-2 (VEGF 
receptor-2 or KDR/Flk-1 also known as kinase domain receptor). VEGFR-1 
has two isoforms: a transmembranous form and a soluble form (sVEGFR-
1). The latter is generated by a splice variant of the VEGFR-1 gene and 
contains the extracellular ligand-binding domain, while lacking the signaling 
tyrosine kinase domain. Thus, this isoform binds VEGF and inhibits its 
biological activities (Shibuya et al, 2013).  A similar pro-angiogenic protein 
secreted in pregnancy is placental growth factor (PlGF).  PlGF is a member 
of the VEGF family and shares 42% of the amino acid sequence identity 
with VEGF and they also share significant structural similarity (Sibiude et al, 
2012).  Both VEGF and PlGF rise gradually in pre-eclampsia and reach a 
peak concentration at 29-32 weeks gestation (Chen, 2009).  Placental cells 
also secrete a soluble isoform of FLT-1 (sFLT-1), which is generated 
through alternative splicing of the messenger RNA and acts as an anti-
angiogenic factor by interacting with, and thereby neutralising, PlGF and 
VEGF (Monte et al, 2011). There is strong evidence for the occurrence of 
higher placental expression of sFLT-1 in pre-eclampsia.  There are also 
elevated circulating levels of sFLT-1 and reduced free bioactive PlGF and 
VEGF and it has therefore been suggested that a part of this excess of 
circulatory sFLT-1 may in fact stem from the placenta (Chen et al, 2009).  In 
women who develop pre-eclampsia, sFLT-1 is elevated from the second 
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trimester onwards (Monte et al, 2011), with lower levels of VEGF and PlGF 
detected even as early as the first trimester of pregnancy (Romano et al, 
2008).  Soluble endoglin (sEng), a circulating antagonist to TGF-β, has 
been found to be increased in both the placenta and serum of women with 
preeclampsia. Exogenous sEng exacerbated proteinuria, hypertension, and 
resulted in a HELLP-like syndrome in a rat model of sFLT1-induced 
preeclampsia, suggesting sEng may contribute to the pathogenesis of the 
disease (Hladunewich et al, 2007). Subsequent studies have verified that 
sEng, in addition to sFLT1 and PlGF, are altered several weeks prior to the 
clinical manifestations of pre-eclampsia in healthy, nulliparous women 
(Chen et al, 2009).  A further systematic review by Kleinrouweler reviewed 
32 studies that identified angiogenic factors as potential biomarkers for 
predicting pre-eclampsia.  Although PlGF, sFLT1 and sENG showed 
modest but significantly different concentrations before 30 weeks of 
gestation in women who developed pre-eclampsia, test accuracies of all 
four markers remain too poor for an accurate prediction of women who will 
ultimately develop pre-eclampsia in clinical practice (Kleinrouweler et al, 
2012). 
 
1.6.2  Uric acid  
 
Siemons et al were the first group to show the link between pre-eclampsia 
and raised plasma uric acid levels (Siemons, 1917).  Uric acid is a product 
of purine breakdown and with an increasing cell turn over in the placental 
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bed with advancing gestation, plasma concentration rises naturally as a 
pregnancy advances.  However, several studies have shown that plasma 
uric acid concentration is raised further during pre-eclampsia.  This has 
been suggested to be the case for two reasons.  Firstly, the injured placenta 
has an increase in cell breakdown with an associated increase in purine 
breakdown.  Secondly, absorption of uric acid from the loop of Henle is 
impaired in pre-eclampsia.  Thangaratinam undertook a systematic review 
of 18 articles that analysed the ability of uric acid to predict outcomes in 
women with pre-eclampsia.  They concluded that uric acid is a poor 
predictor of maternal and fetal complications in women with pre-eclampsia 
(Thangaratinam et al, 2008).  Work has also been undertaken to review 
whether uric acid can be used as a predictor of disease development.  
Cnossen undertook a systematic review and meta-analysis of 5 articles 
consisting of 572 women, 44 of whom had pre-eclampsia.  Their review was 
unable to identify uric acid having the ability to predict those who will 
develop the condition (Cnossen et al, 2005).   
 
1.6.3  Plasma protein 13 (PP13) 
 
PP13 is produced predominantly by the syncytiotrophoblast and is thought 
to play a major role in the implantation of the blastocyst.  From the first-
trimester onward, levels of PP13 slowly increase in healthy pregnancies. 
First-trimester concentrations of PP13 have been shown to be significantly 
lower in the first trimester, but higher in the second and third trimesters in 
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association with pre-eclampsia (Sammar et al, 2011). More specifically, 
several studies reported significant differences between the median PP13 
Multiples of Median (MoM) of early onset pre-eclampsia and control 
pregnancies in the first trimester of pregnancy (Chafetz et al, 2007).  
Schneuer et al performed analysis of 2678 women, 71 who had pre-
eclampsia.  They showed that PP13 had a moderate ability to predict the 
onset of pre-eclampsia (area under the curve (AUC) = 0.72).  However, in 
the same study they undertook a systematic review of PP13 and whether it 
could predict the onset of pre-eclampsia.  Despite their own relatively 
significant results, they were unable to reproduce this from a meta-analysis 
of 8 papers.  They therefore concluded that PP13 is unable to predict the 
onset of pre-eclampsia (Schneuer et al, 2012).   
 
1.6.4  ADAM 12  
 
ADAM 12 is a member of the A Disintegrin And Metalloproteinase (ADAM) 
family.  It has been identified in pregnancy, but not in non-pregnant women, 
and is thought to be involved in trophoblast development.  Studies have 
shown that ADAM 12 is significantly reduced in first trimester plasma 
samples of women who go on to later develop pre-eclampsia (Laigaard et 
al, 2005).   However, other studies have contradicted these findings (Poon 
et al, 2008), and therefore further work (or a systematic review and meta 
analysis) is required to confirm its ability to predict pre-eclampsia.   
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1.6.5  Human Chorionic Gonadotropin and Pregnancy Associated 
Plasma Protein-A  
 
These two proteins are currently tested in the first trimester of pregnancy as 
part of the national Down syndrome screening programme.  Human 
chorionic gonadotropin (hCG) is released by the syncytiotrophoblast and 
promotes:  
• Progesterone production by corpus luteum cells;  
• Angiogenesis in uterine vasculature;  
• The fusion of cytotrophoblast cell and differentiation to make 
syncytiotrophoblast cells; 
• The blockage of any immune or macrophage action by mother on foreign 
invading placental cells 
• Uterine growth parallel to fetal growth;  
• Suppression of any myometrial contractions during the course of 
pregnancy;  
• Growth and differentiation of the umbilical cord;  
• Signals to the endometrium about forthcoming implantation;  
•  Receptor stimulation in mother's brain causing hyperemesis gravidarum,  
And also promotes growth of fetal organs during pregnancy (Cole et al, 
2010).  Given its role as a marker of pregnancy and it’s altered 
concentration in trisomic pregnancies, hCG has been studied as to whether 
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it is altered in pre-eclampsia (both during the clinical syndrome and prior to 
the onset of the clinical disease).  Studies from early in pregnancy (during 
the first or second trimester) have shown that before the disease state, 
women with high levels of hCG are more at risk of developing pre-
eclampsia, than those who do not (Basirat et al, 2006, Olsen et al, 2012).  
This is thought to be due to placental injury releasing more of the 
syncytiotrophoblast derived hCG into the maternal circulation.  
PAPP-A is a metalloproteinase that is involved in the function of insulin like 
growth factors and local proliferative processes.  It has been shown to be 
reduced in pregnancies that go on to develop pre-eclampsia, and this 
reduction is consistent across all trimesters (Yaron et al, 2002).  
Morris et al undertook a systematic review and meta analysis to see 
whether markers currently used to predict Down’s syndrome can be used to 
predict pre-eclampsia.  21 studies identified hCG as a possible candidate, 
with all but 3 of the studies using second trimester samples.  hCG > 2.0 
MoM in the second trimester was the best marker to predict the risk of 
developing pre-eclampsia (LR+ 2.45 (1.57,3.84), LR- 0.89 (0.83,0.96)).  16 
studies, all from first trimester samples, studied whether PAPP-A has the 
ability to predict the onset of pre-eclampsia.  The most accurate predictor 
was PAPP-A<5th centile (LR+ 2.10 (1.57,2.81), LR- 0.95 (0.93,0.98)).  
However, they concluded that Down serum screening analytes had a low 
predictive accuracy for pre-eclampsia. They advised that they maybe a 
useful means of risk assessment or be of use in prediction when combined 
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with other tests, and advised that further studies were required (Morris et al, 
2008).  
 
1.7  Factors that reduce the risk of developing pre-eclampsia  
 
Currently there is no cure for pre-eclampsia.  When the clinical syndrome 
develops, a risk-benefit decision is made regarding the benefit of prolonging 
the pregnancy to improve fetal maturity, which is done mainly by managing 
hypertension and the risk of continuing the pregnancy and worsening of the 
maternal disease and fetal consequences.  There has been a move to 
prevent the disease in women who are at high risk of developing the 
condition, and this prevention occurs before the clinical syndrome has 
developed.    
 
1.7.1  Aspirin 
 
Pre-eclampsia is associated with reduced production of prostacyclin, a 
powerful vasodilator, and an increase in thromboxane, a vasoconstrictor 
and a stimulant for platelet aggregation (Briceno-Perez et al, 2009).  Given 
this, there has been much work on the effects of anti-platelet agents on pre-
eclampsia and their use in preventing disease development.  Aspirin is a 
cyclooxygenase (COX) inhibitor.  By preventing COX from irreversibly 
catalysing the transformation of arachidonic acid into thromboxane, aspirin 
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prevents platelet aggregation in the placental bed.  A Cochrane review of 59 
trials, consisting of 37560 women, suggests an overall 17% reduction in 
pre-eclampsia (relative risk 0.83, 95% confidence interval (CI) 0.77 to 0.89).  
Women at high risk of developing pre-eclampsia had a significant increase 
in the absolute risk reduction of pre-eclampsia for high risk (risk difference 
(RD) -5.2% (-7.5, -2.9), NNT 19 (13, 34)) compared with moderate risk 
women (RD -0.84 (-1.37, -0.3), NNT 119 (73, 333)) (Duley et al, 2007).  
Since this cochrane review, others have tried to emulate their findings.  Villa 
et al (2013) performed a randomised placebo control trial assessing 
whether aspirin could prevent pre-eclampsia in high risk women, and in 
addition undertook a further systematic review and meta-analysis.  Whilst 
their trial suggested no significant difference in pre-eclampsia rates 
between the placebo and the treatment group, their meta-analysis 
suggested aspirin could reduce the incidence of pre-eclampsia in high risk 
women (Villa, 2013).  NICE have adopted this policy for advising the 
prescribing of aspirin to some groups of women in pregnancy (NICE, 2010).  
They recommend that women who are at high risk of developing pre-
eclampsia should start aspirin at 12 weeks of gestation until birth of their 
baby.  They define high risk women as a woman with any of the following: 
• Hypertensive disease during a previous pregnancy 
• Chronic kidney disease 
• Autoimmune disease such as systemic lupus erythematosus or 
antiphospholipid syndrome 
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In addition, they suggest that women who are at moderate risk of 
developing pre-eclampsia should also take aspirin from 12 weeks of 
gestation.   Women with more than one moderate risk factor for pre-
eclampsia should take 75 mg of aspirin daily from 12 weeks until the birth of 
the baby. Factors indicating moderate risk are: 
• first pregnancy 
• age 40 years or older 
• pregnancy interval of more than 10 years 
• body mass index (BMI) of 35 kg/m2 or more at first visit 
• family history of pre-eclampsia 
• Multiple pregnancies. 
 
1.7.2  Calcium supplementation 
 
An inverse relationship between calcium intake and hypertensive disorders 
of pregnancy was first described in 1980 but the exact mechanism by which 
calcium may reduce pre-eclampsia remains uncertain (Belizan et al, 1980).  
Calcium may increase blood pressure by stimulating either parathyroid 
hormone or renin release, thereby increasing intracellular calcium in 
vascular smooth muscle and leading to vasoconstriction. A possible mode 
of action for calcium supplementation is that it reduces parathyroid release 
and intracellular calcium and so reduces smooth muscle contractility 
(Hofmeyr et al, 2004).   
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A Cochrane review in 2010 concluded that calcium supplementation could 
reduce the incidence of pre-eclampsia by almost half (Hofmeyr et al, 2006).  
Thirteen studies of good quality (involving 15,730 women) were included in 
the review. The average risk of high blood pressure was reduced with 
calcium supplementation rather than placebo (twelve trials, 15,470 women: 
risk ratio (RR) 0.65, 95% confidence interval (CI) 0.53 to 0.81). There was 
also a reduction in the average risk of pre-eclampsia associated with 
calcium supplementation (thirteen trials, 15,730 women: RR 0.45, 95% CI 
0.31 to 0.65). The effect was greatest for women with low baseline calcium 
intake (eight trials, 10,678 women: RR 0.36, 95% CI 0.20 to 0.65) and those 
selected as being at high risk (five trials, 587 women: RR 0.22, 95% CI 0.12 
to 0.42).   
 
 
1.7.3  Heparin 
 
As discussed previously, the placenta in pre-eclamptic pregnancies is 
associated with thrombosis, necrosis and infarction.  In view of these 
findings it has ben suggested that heparin might be used to prevent these 
pathological changes and potentially prevent development of the disease.  
Heparin is a large, complex macromolecule that has been used in 
pregnancy to improve perinatal outcomes.  This was initially thought to be 
via its broad anticoagulation properties.  However, heparin has several non-
anticoagulant effects on the placenta (Kingdom et al, 2011): 
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• Heparin promotes cytotrophoblast proliferation: Heparin facilitates 
dimerisation of FGFs to enhance mitotic signalling. This action of heparin 
may reduce the risk of severe pre-eclampsia by promoting the production of 
cytotrophoblasts for syncytial fusion and maintenance of a healthy outer 
syncytiotrophoblast in contact with maternal blood. 
• Suppression of complement pathway activation. Women destined to 
develop pre-eclampsia have elevated circulating levels of complement-
activation factor Bb, but not C3a or sC5b-9.  Because Bb levels are 
associated with maternal obesity, complement activation may be a 
dominant pathway in the maternal phenotype of pre-eclampsia.  By 
suppressing factor Bb this may reduce systemic and endometrial 
inflammation.  
Unfortunately the findings from randomised trials have failed to show 
significant reduction in pre-eclampsia when treated with heparin (Kingdom 
et al, 2011).  
 
1.7.4  Vitamin D 
 
Vitamin D is a fat-soluble protein that has anti-inflammatory and immune 
modulation effects.  Several large studies have showed the link between 
vitamin D deficiency and the increased incidence of pre-eclampsia (Tebesh 
et al, 2013).  Given the theory that pre-eclampsia involves an exaggerated 
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inflammatory process and the importance of immune factors in the disease 
pathogenesis, one could suggest the link between the two factors.   
A Cochrane review from 2012 studied the effect of vitamin D 
supplementation on pregnancy outcomes.  Although they studied 6 trials 
with a total of 1023 women, only 1 trial (n=400 women) specifically had the 
primary outcome for reducing the incidence of pre-eclampsia.  Women who 
received 1200 IU vitamin D along with 375 mg of elemental calcium per day 
were as likely to develop pre-eclampsia as women who received no 
supplementation (average risk ratio (RR) 0.67; 95% confidence interval (CI) 
0.33 to 1.35) (De-Regil et al, 2012).  Further work is needed to assess the 
effect vitamin D supplementation has on reducing the incidence of pre-
eclampsia, the correct dose of supplementation and the safety of 
supplementation.  
 
1.7.5  Vitamins C and E  
 
Pre-eclampsia is associated with marked oxidative stress.  Given that 
Vitamins C and E are powerful antioxidants, several studies were 
undertaken to identify whether supplementation with these vitamins can 
reduce the incidence of pre-eclampsia.  Chappell et al published a 
promising trial that randomised 283 women to receive vitamin C and E 
supplementation or placebo.  In the cohort who completed the study (81 
placebo group, 79 vitamin group), the odds ratio for pre-eclampsia was 0·24 
(0·08–0·70, p=0·002) (Chappell et al, 1999).  These exciting findings were 
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then studied further in a large multicentre trial that was appropriately 
powered.  The Vitamins in Pregnancy (ViP) trial was published in 2006.  
This randomised placebo-controlled trial randomised 2410 women equally 
into placebo or treatment group.  They were unable to reproduce the 
reduction in the incidence of pre-eclampsia in the treatment group.  
However, in the treatment group, more babies were born with low birth 
weight (adjusted odds ratio 1·15 95%) confidence interval [1·02–1·30]) 
(Poston et al, 2006).  Given these findings, vitamin C and E 
supplementation cannot be advocated as a treatment to prevent the 
development pre-eclampsia.   
 
 
1.8  Aims of this thesis 
 
Pre-eclampsia remains one of the most serious morbidities of pregnancy.  It 
has an impact on maternal and fetal/neonatal health with a growing body of 
evidence suggesting its link to long-term cardiovascular and renal disease.  
Although there are current mechanisms in clinical practice aimed at 
predicting the onset of pre-eclampsia, none of these have developed a tool 
which will do so accurately in all cohorts of women.  Secondly, in those 
women who develop pre-eclampsia, there are few methods to predict those 
who will suffer worse outcomes.  The overall aim of this work is to contribute 
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to our ability to accurately predict women who will ultimately develop pre-
eclampsia.   
1)  The first hypothesis that this thesis will test is that known risk factors for 
developing pre-eclampsia can be used together to identify previously 
unidentified links.  Identifying a subset of women who can be more 
accurately predicted to develop pre-eclampsia would allow enhanced 
surveillance of this group, and offer appropriate prevention strategies.  To 
test this hypothesis I shall undertake one of the largest epidemiological 
studies in England and analyse a database covering a large ethnically 
diverse group.  
2)  The second hypothesis that this thesis will test is that proteomics can be 
used to identify markers that are altered in the first trimester of pregnancy 
between women who develop pre-eclampsia and those who do not.  These 
alterations can be used to further the development of a screening test for 
pre-eclampsia.  To test this hypothesis I shall use plasma proteomics of 
individual plasma samples. 
3)  The third hypothesis that this thesis will test is that standard clinical tests 
can be used to detect subtle differences in the inflammatory state during 
early pregnancy in women who go on to develop pre-eclampsia.  In doing 
so, this may allow us to further understand the pathogenesis of the disease 
and could potentially offer a novel disease marker.  To test this hypothesis I 
shall undertake a large retrospective case-control study from a large 
ethnically diverse cohort.      
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4)  The fourth hypothesis that this thesis will test is that we can predict poor 
outcome in women who develop pre-eclampsia using biochemical 
parameters that already form part of clinical investigation during the 
diagnosis of pre-eclampsia.  To test this hypothesis I shall undertake a 
retrospective cohort study.     
             
        
  
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Chapter 2 
 
Racial variation in risk factors for developing 
pre-eclampsia  
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2.1  Introduction 
Ethnicity can have a huge impact on health and health outcomes. According 
to genetic studies, human DNA can be clustered into groups that 
correspond to their ancestral geographic origins and this variation may 
account for the health disparities between populations (Balchin, 2011).  For 
example, People from South Asia (SA) are more susceptible to type 2 
Diabetes Mellitus (T2DM) than their European counterparts.  Given this 
variation, it is important for different prevalence and risk factors for diseases 
to be identified amongst different ethnic groups, and tailor management 
accordingly.   
 
2.1.1 Ethnicity  
2.1.2  Definition  
Ethnicity refers to “the cultural practices and outlooks of a given community 
of people that set them apart from others” and is derived from the ancient 
Greek word, Ethos, meaning custom (Giddens, 1997).  The subjective 
nature of this definition lends itself to controversy, as it represents a 
person’s self-identity and can therefore be liable to change.  
 
2.1.3  Measuring ethnicity  
Measuring ethnicity can be difficult but it provides vital information for 
government, policy makers and researchers and therefore it is vital it is 
done as robustly as possible.  The current mechanism of measurement is 
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based on the classification of ethnicity from the 2011 UK Census (shown in 
figure 7).   
 
 
 
Figure 7: classification of ethnicity from the 2011 UK Census. 
 
2.1.4 Ethnicity and pregnancy outcomes 
Women from an ethnic minority (that is; a group within a community 
which has different national or cultural traditions from the main 
population) who live in the UK are more likely to have an adverse 
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pregnancy outcome than their European counterparts (Balchin, 2007).  In 
the last triennial report into maternal death in the UK, Black women were 
three times more likely to die than white or SA women.  There is also a 
higher rate of perinatal mortality amongst ethnic groups with black women 
being twice as likely and SA women being 1.6 times more likely to have a 
stillbirth or neonatal death than mothers of white ethnic origin (CMACE, 
2009).  Medical complications are also higher amongst mothers from an 
ethnic minority background.  Gestational diabetes is one of the commonest 
medical conditions affecting pregnancies in the UK and there is a huge 
racial disparity in the prevalence across ethnic groups with an 11-fold 
increase amongst SA women, and 3-fold increase in Black women 
compared to their White counterparts (Dornhorst, 1992). 
 
   2.1.5  Ethnicity and pre-eclampsia  
There is an obvious link between ethnicity and pre-eclampsia and it is well 
established that black women are more at risk of developing the disease.  In 
a large American cohort study, black women were more at risk (odds ratio 
1.41, 95% CI 1.25-1.62) (Caughey, 2005) and Asian women were less likely 
to develop pre-eclampsia than white women.  A similar UK study showed 
black women at higher risk of the disease (Wright, 2012).   
Being black also increases the likelihood of a recurrence of pre-eclampsia.  
This increase may be due to the direct effect of ethnicity or factors 
associated with ethnicity, such as deprivation (Sibai, 2005). 
! 48!
 
2.1.6  Obesity  
Obesity is a worldwide epidemic that is worsening year on year.  It has an 
impact on almost all aspects of clinical medicine from cardiovascular 
disease to cancer and it results from a complex interaction between the 
environment, genetic predisposition and human behaviour (Nguyan, 2010).   
 
2.1.7  Definition of obesity  
The World Health Organisation (WHO) defines obesity as “an abnormal or 
excessive fat accumulation that may impair health” however, to define 
obesity clinically, the Body-Mass Index (BMI) scale is used (table 3).  
 
BMI Weight Status  
 
Below 18.5 Underweight 
18.5 – 24.9 Normal 
25.0 – 29.9 Overweight 
30 – 34.9 Obese (mild, Class I) 
35-39.9 Obese (moderate, Class II) 
40+ Obese (severe, Class III) 
 
Table 3: Body-Mass Index  
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2.1.8  Obesity in pregnancy  
 
Obesity in pregnancy is defined as a Body Mass Index (BMI) of 30 kg/m2 or 
more at the first antenatal consultation. 
The prevalence of obesity in pregnancy has increased markedly from the 
early 1990s where it was 9-10% to the late 2000s where it is 16-19% 
(CMACE/RCOG, 2010) (Figure 8). 
 
Figure 8 Prevalence of obesity in the UK amongst pregnant women since 
1993 (Public Health England, 2013) 
 
Obesity is now one of the most commonly occurring risk factors to affect 
obstetric practice and is associated with an increase in a number of serious 
adverse outcomes including miscarriage, fetal anomaly, thromboembolism, 
gestational diabetes, labour dystocia, postpartum haemorrhage, wound 
infections, stillbirth and pre-eclampsia (CMACE/RCOG, 2010). 
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2.1.9  Obesity and pre-eclampsia  
 
The link between obesity and pre-eclampsia is well established.  A 
systematic review suggested that, when compared to a normal BMI, an 
increased BMI at booking doubled the risk of pre-eclampsia and a BMI of > 
40 increased the risk of developing pre-eclampsia 4-fold (Duckitt, 2005).   
 
2.1.10  The West-Midlands  
 
The West Midlands (WM) is an area of 13000 square kilometres and shares 
its borders with the Southeast, the South West, the East Midlands and 
North West regions of England and with Wales (Medland, 2011).  It contains 
some of the largest urban areas outside of London and is home to some of 
the countries most deprived areas (based around Birmingham, Coventry 
and Stoke-on-Trent) and some of the most affluent (Such as Solihull and 
Warwickshire) (See figure 9).     
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Figure 9: Map of the West Midlands region (adapted from 
picturesofengland.com) 
 
2.1.11  The West-Midlands’ population 
 
The WM had a population of just over 5.4 million in 2009, with the highest 
proportion of children under the age of 16 in the UK.  It also has the largest 
non-white population outside of London, with 14 per cent of the population 
being classified as a non-white ethnicity.  Asian or British Asian people 
make up 8.5% and Black or British Black make up 2.7 per cent of the 
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population.  In addition, the WM consist of some of the most and least 
deprived areas in the country with Birmingham and Coventry accounting for 
those areas where the largest deprivation is seen (Medland, 2011). 
 
2.1.12  Measuring Deprivation 
 
The indices of deprivation are a method of measuring deprivation based on 
a concept that deprivation refers to more than just poverty; Poverty is not 
having enough money to get by on where as deprivation refers to a general 
lack of resources and opportunities (UK government, 2010).  It is based on 
38 separate indicators covering areas such as income, employment, health, 
education, crime access to services and living environment with each UK 
postcode generating its own index of multiple deprivation (IMD) on a scale 
of 1-5 (1 being the least deprived and 5 being the most deprived). 
  
2.1.13  The Perinatal Institute 
 
The Perinatal Institute (PI) is a not-for-profit organisation set up to improve 
the quality and safety of maternity care.  This achieved via numerous 
avenues 
• Provision and training of standardised maternity note and note-keeping 
• Perinatal audit 
• Fetal growth assessment 
! 53!
 
 
2.1.14  Standardised Maternity notes 
 
The PI maternity notes provide complete coverage of events in a woman’s 
pregnancy, including the antenatal, intrapartum and postpartum periods.  
The antenatal notes form part of the mother’s hand held documentation of 
her pregnancy care and whilst there is currently no consensus on a layout 
or style of how these notes should structured (with each maternity unit able 
to use their own version of maternity notes), over half of maternity units in 
the UK use the PI notes, accounting for two thirds of all pregnant women.   
 
2.1.15  Perinatal audit 
 
Perinatal mortality and morbidity in the WM is amongst the highest in the 
UK.  To try and reduce this, the PI has been funded to a) audit the care of 
women who have the babies in the WM and b) introduce a robust fetal 
growth surveillance programme.  In order to undertake the perinatal audit, 
the pregnancy details of the women where uploaded to the NHSnet based 
perinatal episode electronic record (PEER) database.   
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2.1.16  Perinatal episode electronic record (PEER) database.   
 
Collection for the PEER database was undertaken prospectively from the 
handheld maternity notes, used by the 19 maternity units in the WM, from 
April 2009.  Trained data-entry clerks transferred the information from the 
notes onto the database at the end of the pregnancy, with a robust quality 
assurance programme through the use of training workshops and regular 
on-site data quality audits.  87 data items were collected including age, 
parity, ethnic origin, and maternal height and weight (expressed as body 
mass index); social factors, including employment status of the mother and 
her partner, consanguinity with the partner, and index of multiple 
deprivation; history of mental health problems, pre-existing diabetes or 
hypertensive disease, or previous stillbirth; smoking status, alcohol 
consumption, non-prescription drugs, folic acid intake, and time of first visit 
in pregnancy (the information for all these previous variables was usually 
recorded at the early pregnancy booking visit); complications in pregnancy, 
including gestational diabetes, antepartum haemorrhage, pregnancy 
induced hypertension, and pre-eclampsia and fetal or neonatal 
characteristics, including sex, gestational age and weight at birth, and 
estimated weight during pregnancy (Gardosi, 2013).  
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2.2  Aim 
 
The aim of this work is to identify ethnic variations of risk factors for 
developing pre-eclampsia and whether there are variations in poor outcome 
once the clinical syndrome has established.   
 
 
 
2.3  Methods  
 
2.3.1  Study design  
 
This work was part of a much larger prospective observational study.  An 
observational study is one “in which no intervention is made (in contrast to a 
experimental study) and such studies provide estimates and examine 
associations of events in their natural settings without recourse to 
experimental intervention” (Mann, 2003).  There are many different types of 
observational studies such as cross-sectional (where the prevalence is 
calculated and any determining risk factor identified at one specific point in 
time), case-control (comparing those with a disease; the case, with those 
who do not; the control) and cohort studies.  A cohort study follows a 
defined group of people and they are generally seen as the best way of 
determining incidence and natural history of a condition (Mann, 2003).  This 
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work studies a group of women, all of who have pre-eclampsia, and is 
undertaken retrospectively by interrogating a pre-existing database.  It is 
therefore a retrospective cohort study.     
Retrospective cohort studies can provide powerful results.  They are 
advantageous when assessing rare disorders or groups and have the 
benefit of being able to examine multiple outcomes.  However, they are only 
as good as the data collected.  Poorly collected or incomplete data can limit 
the study findings and this can lead to selection bias.  The PEER database 
prospectively collects data regarding nearly all of the clinical and social 
aspects of a woman’s pregnancy.  Interrogating such a robust database 
allows for all potential cofounders and exposures to be assessed and 
reduces any potential recall bias as data is collected prior to the follow up 
and without any knowledge of any hypotheses being tested (Baron, 2000). 
Ethical approval was not required; data were collected with patient consent 
and were pseudonymised before analysis (Gardosi, 2013). 
 
 
2.3.2  Cohort Identification 
 
Data was obtained on women from April 2009 to August 2011 who were 
recorded as having pre-eclampsia during their first pregnancy.  This 
prevented women who had pre-eclampsia in several pregnancies being 
included multiple times.  For the purpose of this study the ISHHP definition 
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of pre-eclampsia was used (chapter 1).  The diagnosis of pre-eclampsia 
was made by clinical staff, and recorded in the patient’s records.  A trained 
data clerk extrapolated data and the inclusion and exclusion criteria of the 
search are listed in table 4.     
 
 
 
Inclusion Criteria Exclusion Criteria 
Diagnosis of pre-eclampsia 
Primigravidae 
Singleton pregnancies 
Multiparity 
Multiple pregnancies 
 
 
Table 4:  Entry criteria during patient selection  
 
After a woman self-identified her ethnicity, this was then grouped into White, 
Black, South Asian Middle-Eastern or Other.  In order to assess the racial 
variation of certain risk factors for developing pre-eclampsia, a list of other 
known risk factors was developed and obtained from the database. These 
are listed in table 5.  
 
 
 
 
! 58!
Risk factor for developing pre-eclampsia 
Age  
Pre-existing medical conditions (diabetes / hypertension) 
Smoking history 
 
Table 5: Risk factors for developing pre-eclampsia  
 
2.3.3  Statistical analysis  
 
Logistic regression models with the outcome pre-eclampsia and the null 
hypothesis that model coefficients are not different between racial groups 
were used to generate odds ratios to test the difference in rates of pre-
eclampsia between racial groups.  The predictor variables were racial 
groups, using white women as a reference, and body mass index.  Odds 
ratios were corrected for confounding factors of known clinical relevance 
and from previous publications (Duckitt, 2005) and included age, previous 
medical history and smoking history.  
Frequency and percentages were calculated to show the distribution of the 
study variables. Cross tabulation was used to show the comparisons 
between key study variables. Variables were treated as categorical to 
account for potentially non-linear relationships.  Χ2 was used to analyse 
categorical variables and Mann-Whitney U was used to analyse continuous 
variables.  Variables were entered using the manual stepwise (forward-
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backward) method, and those reaching a 0.05 significance level were 
retained in the model.  There was no correction for multiple testing because 
these variables has strong association with pre-eclampsia (p=<0.001) and 
therefore would be significant even if the Bonferroni rule were applied 
(Perneger, 1998).   
In addition, the outcomes in the women diagnosed with pre-eclampsia were 
studied.  The predictor variables were racial groups (again, using white 
women as a reference) and fetal and maternal outcomes.  The presence of 
intrauterine growth restriction was established on the basis of a birth weight 
below the 10th weight for gestational age centile, using the gestation related 
optimal weight standard (GROW)(Gardosi,1992), with coefficients derived 
from the West Midlands population. This method defines the fetal growth 
potential by excluding pathological factors such as smoking and diabetes, 
and individual adjustment or “customisation” for the baby’s sex and the 
mother’s height, weight, ethnic origin, and parity (Gardosi, 1995. Gardosi, 
2012).  A weight that is small for gestational age after such adjustment by 
growth potential has been shown to represent pathological smallness and is 
referred to as fetal growth restriction. We applied the 10th centile as the cut-
off, as it is in standard clinical use and has been validated through receiver 
operator curves as being close to optimal for predicting pathology by 
customised centiles.   
 The SpSS computer programme (SpSS v19, Chicago, USA) was used for 
the statistical analysis and statistical significance was defined as p<0.05.   
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2.4  Results 
 
2.4.1  Maternal demographics  
 
A total of 109576 women were initially identified for the selection period 
between April 2009 and August 2011.  There were 1756 multiple 
pregnancies and therefore excluded, leaving a population of 107820 
women.  Of these there were 83237 (77.2%) white women, 18005 (1.7%) 
SA women and 6578  (6.1%) Black women.  The maternal demographics of 
the group are featured in table 6.    
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Demographic feature 
 
 
Number (%) 
 
Body Mass Index (kg/m2) 
<18.5 
18.5-24.9 
25-29.9 
30-34.9 
>35 
Missing 
 
 
3493 (3.3) 
51550 (48.7) 
29533 (27.9) 
13443 (12.7) 
7833 (7.4) 
1968 (1.8) 
 
 
 
Maternal age (years) 
<20 
20-24 
25-29 
30-34 
≥35 
Missing 
 
 
 
7548 (7.1) 
23950 (22.4) 
31504 (29.5) 
26851 (25.1) 
17035 (15.9) 
932 (0.9) 
 
Parity 
0 
1 
2 
≥3 
Missing 
 
 
 
 
45191 (42.4) 
34853 (32.7) 
15668 (14.7) 
10871(10.2) 
1237 (1.1) 
Table 6: Demographic features of the women in the perinatal institute’s 
database !
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Demographic feature 
 
 
Number (%) 
 
Index of Multiple Deprivation 
(fifths) 
1-3 (least deprived) 
4 
5 (most deprived) 
 
 
 
 
40109 (37.2) 
22750 (21.1) 
44961 (41.7) 
!
Pre-existing DM 
No 
Yes 
Missing 
 
                         
                        105627 (99.2) 
852 (0.8) 
1791 (1.6) 
 
 
Pre-existing Hypertension 
No 
Yes 
Missing 
 
 
 
103484 (97.3) 
2871 (2.7) 
1465 (1.4) 
 
       Smoking 
No 
Yes 
Passive Smoking 
Missing 
 
       
      61362 (61.5) 
20853 (20.9) 
17461 (17.6) 
8144 (7.5) 
 
 
 
Developed Gestational DM 
 
No 
Yes 
Missing 
 
 
 
103002 (96.8) 
3405 (3.2) 
1413 (1.3) 
Table 6 (continued) Demographic features of the women in the perinatal 
institute’s database  
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2.4.2  Fetal and neonatal characteristics  
 
The fetal and/or neonatal characteristics from the cohort that are associated 
with pre-eclampsia are summarised in table 7.  Overall the mean birth 
weight was 3343.1grammes (Standard deviation ±569.1).  The median 
gestational age at delivery was 280 days (Interquartile range 272-286), with 
8455 babies being born before 37 weeks gestation (representing a pre-term 
birth rate of 7.83%).   
 
 
Fetal / Neonatal characteristic 
 
Number (%) 
Sex 
Boy 
Girl 
Missing 
 
 
55262 (51.7) 
52462 (48.3) 
96 (0.09) 
Gestation Related Optimised 
Weight (GROW) Centile 
Median (IQR) 
≤10 
10-90 
>90 
Missing 
 
 
 
41.5 (19.5-67.5) 
13075 (13.3) 
77934 (79.2) 
7310 (7.5) 
9501 (8.8) 
 
Table 7: Fetal and neonatal characteristics of the babies born to the women 
from the perinatal institute’s database !
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2.4.3  The pre-eclampsia population  
 
2.4.4  Maternal characteristics  
 
Women who had been diagnosed with pre-eclampsia were identified 
(n=7655) and of these, 6813 were primigravid.  These were then separated 
according to ethnicity and BMI group (see figure 10).  Within this group, 
6109 were identified as White, Black or South-East Asian.  The remaining 
704 of these women were either Middle-Eastern (n=105), mixed-
unclassified (n=112) or their ethnicity was not recorded (n=487).  Given the 
low number of Middle-Eastern women, they were not included in the study.  
The maternal, fetal and neonatal characteristics are featured in tables 8 and 
9.        
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!
!109576! !107820! !6803! !6109! !White!(n=4643)!
!SE!Asian!(n=927)!
!Black!(n=539)!
BMI!!<18.5!!!(n=3)!BMI!18.5B24.9!(n=119)!BMI!25B29.9!!!!(n=221)!BMI!30B34.9!!!(n=87)!BMI!!>35!(n=111)!
BMI!!<18.5!(n=70)!BMI!18.5B24.9!(n=1895)!BMI!25B29.9!(n=1393)!BMI!30B34.9!(n=399)!BMI!>35!!!(n=886)!
BMI!!<18.5!(n=41)!BMI!!18.5B24.9!(n=332)!BMI!!25B29.9!(n=291)!BMI!!30B34.9!(n=152)!BMI!!>35(n=111)!
Multi!preg!! Normotensive!! Multiparous!!
n!=!1756
!
n!=!101017
!
n!=!694
!
Figure'18:'Schematic'diagram'flow'for'determining'the'final'cohort.''109576'
women'were'identified'in'the'database,'1756'were'multiple'pregnancies'(multi'
preg),'leaving'107820'women.''Of'these,'6803'had'preGeclampsia.''Of'the'preG
eclampsia'group,'6109'were'primigravid.''These'were'then'separated'by'ethnicity,'
and'each'ethnic'group'was'subdivided'into'their'BMI.'''
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Table 8: Maternal characteristics of the women who developed pre-
eclampsia 
 
Demographic feature 
 
 
       Number (%) 
 
Odds Ratio (95% C.I.)* 
 
Body Mass Index 
(kg/m2) 
 
<18.5 
18.5-24.9 
25-29.9 
30-34.9 
>35 
 
 
 
 
 
114 (1.8) 
       2402 (39.3) 
       1655 (27.1) 
982 (16.1) 
956 (15.7) 
 
 
 
 
 
 
0.576 (0.477-0.696) 
Reference 
1.833 (1.729-1.943) 
3.49 (3.205 – 3.806) 
3.383  (3.106 – 3.685) 
 
 
 
Maternal age 
(years) 
<20 
20-24 
25-29 
30-34 
≥35 
 
 
 
 
 
968 (15.8) 
        1173 (19.2) 
819 (13.5) 
        1411 (23.1) 
        1738 (28.4) 
 
 
 
 
1.262 (1.149 –1.386) 
0.99 (0.9 – 1.08) 
Reference 
1.264 (1.158 – 1.379) 
2.195 (1.876 – 4.093) 
                  
Index of Multiple 
Deprivation (fifths) 
 
1-3 (least deprived) 
4 
5 (most deprived) 
 
 
 
 
 
 
1808 (29.6) 
1057 (17.3) 
3244 (53.1) 
 
 
 
 
 
Reference 
1.108 (0.972 – 1.581) 
2.694 (2.501 – 2.942) 
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!
Table 8 cont’d: Maternal characteristics of the women who developed pre-
eclampsia  
 
Demographic 
feature 
 
 
Number (%) 
 
Odds Ratio (95% C.I.)* 
 
Pre-existing 
Diabetes 
No 
Yes 
Missing 
 
 
 
 
 
5979 (97.9) 
110 (1.8) 
20 (0.3) 
 
 
 
Reference 
2.324 (1.902 – 2.839) 
 
Pre-existing 
Hypertension 
No  
Yes 
Missing 
 
 
 
 
5582 (91.5) 
516 (8.5) 
11 (0.18) 
 
 
 
Reference 
3.332 (3.022 – 3.673) 
 
 
Smoking 
No 
Yes 
Passive 
 
 
4172 (68.3) 
1006 (16.5) 
931 (15.2) 
      
 
 
 
 
Reference 
0.745 (0.695-0.799) 
0.847 (0.788 – 0.909) 
Developed 
GDM 
 
No 
Yes 
Missing 
 
 
5817 (96.3) 
225 (3.7) 
67 (1.1) 
 
 
Reference 
1.17 (1.020-1.343) 
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Table 9: Fetal/neonatal characteristics of the women who developed pre-
eclampsia 
  
 
Demographic 
feature 
 
 
Number (%) 
 
Odds ratio (95% C.I.)* 
 
Sex 
Male 
Female 
 
 
3138 (51.4) 
2971 (48.6) 
 
 
Reference  
0.99 (0.943-1.045) 
GROW Centile 
 
Median (IQR) 
≤10 
10-90 
>90 
Missing 
 
 
 
38 (12.5-54.5) 
1879 (31.3) 
3812 (63.6) 
307 (5.1) 
111(1.8) 
 
 
 
2.974 (2.808-3.150) 
Reference 
1.119 (0.703-1.895) 
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2.4.5  Body Mass index and the risk of pre-eclampsia 
 
On the whole, Black women were significantly more likely to develop pre-
eclampsia than white women (p=0.002, aOR 1.613 (CI 95% = 1.42 - 
1.756)).  There was no significant difference in pre-eclampsia rates between 
White and SA women (p=0.48 OR=1.113 (95%CI=0.849 - 1.457)).  Black 
women who had a normal BMI (18.5-24.9) were significantly less likely to 
develop pre-eclampsia, than white women with a normal BMI (p=0.001, 
aOR 0.267[95% C.I. = 0.21-0.]).  When overweight (BMI= 25-29.9), Black 
women were more likely to develop pre-eclampsia, than white women 
(p=0.001 aOR 2.06 [1.34-3.23]).  Once in the obese group, pre-eclampsia 
rates were not significantly different across the racial groups (table 10).       !
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Body 
Mass 
Index 
Ethnicity 
 
White 
(Reference) 
     N= 4623 
     Black 
 
   N= 539 
OR 
(C.I.) 
aOR 
(C.I.) 
p 
value 
S 
Asian 
        N= 947 
 
OR 
(C.I.) 
aOR 
(C.I.) 
p 
value 
<18.5 70 
 
3    41    
18.5-
24.9 
1895 115 0.39 
(0.32-
0.48) 
 
0.421 
(0.24-
0.73) 
0.002 392 1.1 
(0.91- 
1.22) 
0.99 
(0.7-
1.41) 
0.94 
24-
29.9 
1193 211 2.1 
(1.76-
2.55) 
 
2.06 
(1.34-
3.23) 
<0.001 251 0.96 
(0.83-
1.13) 
1.27 
(0.9-
1.84) 
0.23 
30-
34.9 
729 101 1.24 
(0.98-
1.56) 
 
0.84 
(0.47-
1.50) 
0.66 152 1.02 
(0.84-
1.24) 
0.89 
(0.38-
1.93) 
0.12 
>35 736 109 1.08 
(0.86-
1.34) 
 
1.33 
(0.78-
2.23) 
0.37 111 0.83 
(0.67-
1.03) 
0.67 
(0.40-
1.12 
0.07 
 
Table 10: Effect of ethnicity on the association of body mass index and pre-eclampsia 
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2.4.6  Maternal age and the risk of pre-eclampsia  
 
Advanced maternal age (>35 years of age) is a risk factor for developing pre-
eclampsia (relative risk = 2.195 (1.876 – 4.093)).  However, there is racial 
variation of rates of pre-eclampsia across different ages groups.  Young (<20 
years of age) Black women are less likely to develop pre-eclampsia than their 
White counterparts.  This relationship is reversed when maternal age is >35, 
with Black women at more risk of developing the disease than white women.  
When aged between 30 and 35, SA women are more at risk of developing 
pre-eclampsia than White women (See table 11).  This trend however is not 
continued when SA women are aged over 35. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 !
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Age Ethnicity Number OR (95% CI) Adjusted OR (95% CI) p value  
<20 White 735 Reference Reference   
S Asian 147 0.873 (0.686-1.112) 1.903 (0.905-1.320) 0.38 
Black 86 0.240 (0.176 - 0.329) 0.628 (0.490 – 0.803) <0.001 
20-24 White 876 Reference Reference  
S Asian 197 0.549 (0.447 – 0.674) 0.965 (0.823-1.113) 0.64 
Black 113 0.314 (0.249 – 0.397) 0.635 (0.518 – 0.777) <0.001 
25-29 White 622 Reference Reference   
S Asian 186 0.980 (0.782 – 1.276) 0.884 (0.725 – 1.077) 0.24 
Black 59 0.856 (0.680 – 1.801) 1.044 (0.797 – 1.369) 0.81 
30-34 White 1334 Reference Reference  
S Asian 202 0.965 (0.830 – 1.122) 1.428 (1.227 – 1.661) <0.001 
Black 125 1.020 (0.738-1.255) 0.845 (0.699 – 1.022) 0.091 
>35 White 1076 Reference Reference   
S Asian 195 0.958 (0.851 – 1.079) 1.15 (0.98 – 1.347) 0.089 
Black 156 1.77 (1.590-1.973) 1.67 – 1.397-1.996 <0.001 
 
Table 11:  Effect of ethnicity on the association of age and pre-eclampsia 
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2.4.7  Maternal and Fetal outcomes 
 
Whilst demonstrating a clear racial variation in two of the strongest risk 
factors for developing pre-eclampsia (BMI and maternal age), I studied 
whether there was also racial variation in the maternal and fetal outcomes 
(tables 13 and 14).   
 
2.4.8  Preterm birth 
 
Preterm birth (PTB) was defined as delivery less than 37 completed weeks.  
The PTB rate for the whole cohort was 7.8% (8409 births).  In the pre-
eclampsia group the overall PTB rate was 19.65% (1201 births) of which the 
majority (94.7%) were iatrogenic deliveries (that is, deliveries based on 
medical grounds)(1140 births).  The racial variation of the iatrogenic births is 
shown in table 12 (overleaf).   
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Ethnicity Number  RR Adjusted 
RR 
p 
value 
 
White 
 
866 
 
Reference 
 
 
Black 
 
 
101 
 
1.670 
(1.397-
1.996) 
 
1.587  
(1.268 – 
1.987) 
 
<0.001 
 
S Asian 
 
173 
 
0.792 
 (0.668-
0.938) 
 
0.836 
(0.706-
0.989) 
 
0.04 
     
 
 
 
 
Table 12: Racial variation in the relative risk (RR) for preterm birth.  Adjusted 
relative risk adjusted for BMI, smoking, maternal age and Gestation Related 
Optimised Weight (GROW) centile.    
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2.4.9  Maternal complications of pre-eclampsia 
 
 
Complication 
  
Ethnicity 
 
N 
RR 
(95% CI) 
 Adjusted RR 
(95% CI) 
p 
value  
 
 
 
 
 
Placental 
abruption  
 
White 
 
221  
 
Reference 
 
Black 
 
 
48 
 
2.92 
(2.152-3.976) 
 
1.73 
       (1.527-1.963) 
 
0.001 
 
S Asian 
 
 
43 
 
1.163 
(0.790-1.691) 
 
1.144 
       (0.996-1.313) 
 
0.062 
 
 
 
 
 
HELLP 
syndrome 
 
White 
 
 
285 
 
Reference 
 
 
Black 
 
 
32 
 
0.556 
(0.468-0.661) 
 
0.75 
(0.587-0.956) 
 
0.025 
 
 
 
S Asian 
 
44 
 
0.420 
(0.423-0.608) 
 
0.635 
(0.491-0.820) 
 
0.001 
 
Table13: Racial variation in the relative risk (RR) for maternal complication in 
women with pre-eclampsia.  Adjusted relative risk adjusted for BMI, smoking, 
maternal age and Gestation Related Optimised Weight (GROW) centile 
(N=number).    
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2.4.10  Fetal complications of pre-eclampsia 
  
Complication Ethnicity N RR Adjusted RR p value  
 
 
 
 
Fetal growth 
restriction 
White  
735 
 
Reference 
 
 
Black 
 
 
75 
 
1.10  
(0.975-1.26) 
 
1.087 
(0.954-1.239) 
 
0.7 
 
S Asian 
 
 
183 
 
1.323  
(1.165-1.500) 
 
1.278 
(1.126-1.450) 
 
0.002 
 
 
 
 
Admission  
to  
NNU 
 
White 
 
740 
 
Reference 
 
 
Black 
 
 
78 
 
0.892 
(0.769-1.036) 
 
0.871 
(0.751-1.118) 
 
0.073 
 
S Asian 
 
176 
 
1.364 
(1.137-1.636) 
 
1.25 
(1.042-1.520) 
 
0.017 
 
 
Table 14: Racial variation in the relative risk (RR) for fetal/neonatal 
complications in women with pre-eclampsia.  Adjusted relative risk adjusted 
for BMI, smoking, maternal age and Gestation Related Optimised Weight 
(GROW) centile (N=number).    
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2.5  Discussion 
 
In this cohort study consisting of 109576 women, I studied previously 
identified risk factors for developing pre-eclampsia and assessed whether 
there is variation in these risk factors across different ethnicities.  In addition 
to studying the risk factors for developing pre-eclampsia, I also investigated 
whether there was a difference in maternal and fetal/neonatal outcomes 
once the disease was diagnosed.      
 
2.5.1  Summary and discussion of key findings   
 
The overall rate of pre-eclampsia was 6.98%.  This is in keeping with 
standard worldwide range of between 2-7% that is widely quoted (Sibai et 
al, 2005). Whilst the rate of 6.98% is higher than other Northern European 
groups have identified (In a Swedish study the overall risk of developing 
pre-eclampsia was 4.1% Hernandez-Diaz et al (2009)), this most likely 
represents the difference in population.  The West-Midlands have some of 
the most deprived and obese mothers in Europe with a much greater 
variation in ethnicity across the population (Public Health England, 2013).  
The risk of developing pre-eclampsia in my cohort is similar to other UK 
based cohort studies (Bramham et al, 2011). 
 This cohort study corroborated previous work that showed that Black 
women were significantly more likely to develop pre-eclampsia.  Caughey et 
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al (2005) undertook a similar sized retrospective study based on a 
Californian cohort that showed that Black women had an odds ratio of 1.41 
(95% CI 1.25-1.62) when compared to white women, (which is synonymous 
with this study, RR 1.613 (CI 95% = 1.42 - 1.756)).  However, this study did 
not study South Asian women.  Work undertaken by the Fetal Medicine 
Foundation (London), studied a population in South London (n=76158).  
Again, they confirmed the link between Black ethnic origin and pre-
eclampsia.  However, unlike this study, they found SA women were at 
higher risk of developing pre-eclampsia also (RR 1.73 95% CI (1.39 – 2.15)) 
(Khalil et al, 2013).  One possible reason for this is the smaller number of 
SA women included in their study (n=6314) compared to this study 
(n=18005).   
As mentioned in the introduction, it is widely acknowledged that the risk of 
pre-eclampsia increases with increasing maternal BMI.  This link has been 
confirmed in this cohort study.  Once in the obese group, the risk of 
developing pre-eclampsia is three fold.  This reiterated the findings of a 
large study from the east coast of the USA (Roberts et al, 2011).  One 
possible reason why obesity predisposes to development of pre-eclampsia 
is the increase in insulin resistance that is found in obese people.  Insulin 
resistance is thought to be involved in pathogenesis of pre-eclampsia 
(Kaaja, 1998) and appears to remain, even many months after the delivery 
of the fetus and placenta (Lampinin, 2008).  Given the link between insulin 
resistance and cardiovascular disease, this residual insulin resistance may 
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be responsible for the long-term cardiovascular morbidity seen in women 
with previous pre-eclampsia (Carty et al, 2010). 
Pre-eclampsia is commonly thought to affect the “extremes of reproductive 
age” (Dekker et al, 2001).  The results of this cohort study would support 
this idea.  My results showed a “U” shaped distribution, with teenagers 
being at an increased risk of developing pre-eclampsia (RR - 1.262 (95% 
1.149-1.386) p=0.002), when compared to women aged 25-29.  This risk 
becomes non significant when a woman is in her early twenties.  However, 
this risk increases again when a woman is in her thirties, and when over 35 
the RR of developing pre-eclampsia doubles (2.195 (1.876-4.093, 
p=<0.001).  Although this distribution is widely reported in literature (Sibai et 
al, 1995, Conde-Agudelo et al, 2000) the mechanisms by which these two 
age groups develop pre-eclampsia are most likely to be different.  
Teenagers are thought to get pre-eclampsia through unfamiliar sperm 
exposure, which causes the heightened maternal inflammatory response to 
paternal antigens in the placenta seen in pre-eclampsia (Robillard et al, 
1999).  Whilst older women may develop pre-eclampsia due to their 
vascular endothelium adapting poorly to the inflammatory response of 
normal pregnancy (Redman et al, 1999) due to subclinical chronic vascular 
disease.    
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2.5.2  Racial variation in the association of risk factors and developing 
pre-eclampsia 
 
2.5.3  Body Mass Index and Pre-eclampsia 
 
This study showed that, once obese, there is no additional racial variation in 
risk of PE accorded to ethnicity.  However, in those women whose BMI lies 
below the obese range (those overweight and of normal weight) there are 
clear ethnic variations. Table 10 within the results section demonstrates 
these variations and is demonstrated graphically in figure 11. 
 
Figure 11: Racial variation of the link between body mass index and 
ethnicity (* = statistically significant).   
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It appears that when their BMI is within the normal range, Black women are 
less likely to develop pre-eclampsia, when compared to White women.  This 
“protection” against developing pre-eclampsia is lost when overweight and 
when in this range, Black women appear more susceptible to developing 
the disease than their white counterparts.  There is no significant variation 
in the risk of developing pre-eclampsia amongst obese women, regardless 
of their ethnicity.   
Whilst initially puzzling, these findings maybe explained by the racial 
variation in fat distribution.  It has been well described that different 
ethnicities carry body fat differently, with Black women carrying more fat 
around their trunk and hips than White or S Asian women (Stults-
Kolehmainen et al, 2012).  In addition, Lear et al (2007) found that BMI 
underestimated visceral adipose tissue in Black women.  Visceral adipose 
tissue is functionally different from cutaneous fat; it produces more CRP (c-
reactive protein) and other inflammatory cytokines and less leptin, 
contributing to more oxidative stress (Roberts et al, 2011).  Black women, 
who are overweight but not obese, may have a heightened subclinical 
systemic inflammation than other ethnicities at a comparable BMI.  It could 
therefore be argued that this leads to a more aggressive inflammatory 
response during early pregnancy, which has been proposed as a precursor 
for the development of pre-eclampsia (Redman et al, 1999).  
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2.5.4  Age and pre-eclampsia 
 
The link between age and pre-eclampsia is still apparent when separated 
across ethnicities.  However, despite the “U” shaped distribution appearing 
across the three ethnicities, there were significant differences between the 
groups.  These are described in table 11 and represented graphically below 
in figure 12. 
 
 
Figure 12: Ethnic variation of the link between maternal age and pre-
eclampsia (*=statistically significant) 
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As mentioned previously, it is thought that teenage women are at greater 
risk of developing pre-eclampsia than older women due to their lack of 
exposure to their partner’s semen.  The reasons why girls become sexually 
active during their teenage years are complex and involve many 
psychological and social issues that go beyond the measurable parameters 
within the perinatal institute’s database.  There is however, clear evidence 
of racial variation in the sexual activity of teenagers.  Black teenage girls are 
more likely to have coitus earlier than White teenage girls (Smith et al, 
1985) and in those girls who are sexually active, whilst contraception use is 
lacking across all ethnic groups, White teenagers are more likely to use 
barrier contraception than Black teenagers (Coles et al, 2011).  It could be 
suggested that sexually active Black teenage girls have more exposure to 
semen and this may account for their reduced incidence of pre-eclampsia.      
The increased risk of developing pre-eclampsia with advancing maternal 
age spanned all ethnicities.  However, South Asian women were more likely 
to develop pre-eclampsia than White women in the 30-34 age group and 
Black women were at greater risk of developing pre-eclampsia than White 
women in the >35 age group. This suggests a difference in vascular aging 
in different ethnicities. Pre-eclampsia has been described as a disorder of 
the maternal endothelium (Powe et al, 2011), so to investigate possible 
explanations for this racial variation, we need to look at racial variation of 
endothelial dysfunction in the general population.  Healthy older Black 
adults are more likely to have overall greater endothelial dysfunction (with 
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significant impairment to microvascular vasodilatatory function and greater 
arterial stiffness) than White adults (Morris et al, 2013) which has been 
attributed to the higher incidence of cardiovascular disease in this 
population (Mulukutla et al, 2010).  On a whole the South Asian populations 
in their late 30’s and early 40’s have a greater insulin resistance when 
compared to White populations (Mente et al, 2010) and this insulin 
resistance can lead to impairment of circulating angiogenic progenitor cell 
function and a delay in endothelial repair (Kahn et al, 2011).  When pre-
existing vascular endothelium is damaged or impaired, the mild 
inflammatory state of “normal” pregnancy is enhanced leading to a) a more 
aggressive systemic inflammation (Redman et al, 1999) and b) greater 
circulating concentrations of anti-angiogenic proteins (Powe et al, 2011) 
both of which have been identified as possible mechanisms in the 
development of pre-eclampsia.     
 
2.5.5  Racial variation in the Maternal and Fetal outcomes when 
diagnosed with pre-eclampsia 
 
2.5.6  Preterm birth in pre-eclamptic pregnancies 
 
In the pre-eclampsia group, Black women were more likely to be delivered 
earlier than White women  (aRR 1.587 (95% CI 1.268-1.987)).   Iatrogenic 
delivery in women with pre-eclampsia occurs either because there is 
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significant maternal morbidity or there is evidence of fetal compromise.  S. 
Asian women were more likely to deliver due to concerns over fetal health 
(p<0.001) than white women (with no difference in the deliveries due to fetal 
compromise in the Black cohort (p=0.07)).  However, Black women were 
more likely to deliver early due to concerns about maternal morbidity 
(p=0.002) than White women (there was no significant difference in the risk 
of delivering early due to maternal morbidity between Asian women and 
White women (p=0.81)).  
To my knowledge, this is the first study to assess the racial variation of 
iatrogenic PTB in pre-eclamptic pregnancies.  Why this variation exists, is 
not completely clear.  As discussed in this thesis’s introduction, whilst the 
diagnosis of pre-eclampsia is based on clinical criteria, the pathophysiology 
leading to the clinical syndrome is most likely via different mechanisms.  It is 
therefore not unreasonable to suggest that some ethnicities may be 
susceptible to different pathophysiological processes than others causing a 
fetal compromise dominant picture in one group and a maternal syndrome 
dominance in another (Ness et al, 2006).  
2.5.7  Maternal Outcomes and pre-eclampsia  
 
2.5.8  Placental abruption  
 
Placental abruption (premature separation of the placenta from the uterine 
wall whilst the fetus is still in utero) was more common in Black women who 
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had pre-eclampsia, when compared to White women (aOR 1.73 (95% CI 
1.527 – 1.963, p=0.001).  This was after controlling for confounding factors 
such as smoking, BMI and maternal age.  The link between ethnicity and 
placental abruption has been reported before with both Shen et al (2008) 
and Balchin et al (2009) reporting that placental abruption was higher in 
Black women, although this is the first study to confirm the link in pre-
eclamptic pregnancies.   
The pathogenesis of placental abruption is complicated but there does 
seem to be at least two distinct clinical pathways 1) acute inflammation, and 
2) chronic vasculopathic processes, such as chronic hypertension and 
smoking (Shen et al, 2008).  As mentioned earlier, Black women are more 
likely to have endothelial dysfunction than White women.  It could therefore 
be suggested that the acute inflammation associated with the clinical 
syndrome of pre-eclampsia combined with pre-existing endothelial damage 
puts Black women at greater risk of preeclampsia than White women.   
 
2.5.9  HELLP syndrome  
 
White women were more likely to develop HELLP syndrome than both 
Black and SA women.  The clinical presentation of pre-eclampsia lies on a 
spectra of signs and symptoms with HELLP syndrome lying at the severe 
end of that spectrum, being associated with significant maternal morbidity 
and mortality.  These findings concur with the findings from a small 
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American study, which assessed the variation between Black and White 
women (but not S Asian women) (Goodwin, 2005).  An understanding of the 
pathophysiology behind HELLP syndrome remains elusive, with several 
theories about the diseases origin.  One of the strongest theories is that 
placenta-mediated anti-angiogenic factors are released which cause 
vasoconstriction and endothelial damage to the hepatic microcirculation.  
Fibrin deposition within these small damaged vessels, leads to reduction in 
hepatic blood flow.  This causes hepatic necrosis with the endothelial 
damage leading to consumption of circulating platelets (Eastabrook et al, 
2011).  The reason why this may occur more frequently in White women 
than Black women remains unclear.   
 
2.5.10  Fetal outcome in pre-eclamptic pregnancies 
  
2.5.11  Fetal growth restriction 
 
South Asian women were more likely to have a growth-restricted infant (that 
is, a baby that is less than the 10th GROW centile) than White women 
(p=0.002) with no significant difference between infants born to Black and 
White women.  This is in contrast to studies of fetal growth restriction 
without pre-eclampsia that show both Black and S Asian women were at 
higher risk of FGR than White women (Balchin et al, 2007; Reagan et al, 
2007).   However this is the first study to assess the racial variation of fetal 
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growth restriction in women from the UK with pre-eclampsia.   Whilst both 
fetal growth restriction and pre-eclampsia are disorders of poor 
placentation, it is thought that they arise from different mechanisms (Ness 
et al, 2006, Egbor et al, 2006).  It could be argued that (as previously 
discussed) different ethnicities, with their differences in insulin sensitivity, 
pre-existing endothelial dysfunction and genetic variations, have different 
“types” of pre-eclampsia, with SA women tending towards the fetal growth 
restriction (“fetal”) type of placentation and Black women tending towards 
the severe hypertension and systemic endothelial damage (“maternal”) end. 
 
2.5.12  Strengths of this study  
 
The greatest strength of this study is the large dataset that included a large 
non-White population giving the study high statistical power.  In addition the 
database was well constructed, with paid data entry clerks meaning that 
there was minimal missing data.   
The robust dataset allowed many potentially confounding variables to be 
studied together, and on reviewing the literature, few studies are able to 
control for age, BMI, ethnicity, social class, smoking history and socio- 
economic status. 
Another significant strength of this study is in the fact that the database 
spans all hospitals in the West-Midlands ranging from inner city highly 
deprived areas, such as Coventry to rural high-income areas such as 
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Warwick.  This span of ethnicity and socio-economic status allows us to use 
this data as a snapshot of modern day Britain.   
 When self-reporting weight and height pregnant women are likely to 
underestimate, leading to potential study bias (Gorber et al, 2007).  In view 
of this, there is a region wide policy of measuring height and weight at 
booking, with weighing scales being calibrated regularly.   
 
2.5.13  Weaknesses of this study  
 
The demographic variables (BMI, smoking history, etc.) used in this study 
were recorded at the booking appointment.  They did not account for 
changes, for example, of excessive weight gain in pregnancy or smoking 
cessation.  Excessive weight gain in pregnancy is reported to increase 
maternal morbidity, even in normal and overweight BMI ranges (Savitz et al, 
2011) and a large cohort study reported that women who stopped smoking 
by 15 weeks gestation had the same perinatal outcomes as non-smokers 
(McCowan et al, 2009).  Additionally, smoking status is self reported and 
not tested objectively, which may have lead to confounding results.  
However, the findings in the study (that is, the reduced rate of pre-
eclampsia in smokers) are supported by the literature, suggesting that any 
underreporting, if any, is small.   
Given how large this dataset is there was a huge choice of possible 
predictors for pre-eclampsia and this could have led to variable selection 
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bias.  However, the clinical risk factors and their strength of association with 
pre-eclampsia found in this study are consistent with other international 
studies. 
 
 
 
2.6  Conclusion 
 
This chapter reviewed the racial variation of the known risk factors for 
developing, and the outcomes associated with, pre-eclampsia.  Using a 
large database, I have been able to identify previously unreported 
associations; 
•  BMI had a complex interaction with ethnicity in terms of developing 
pre-eclampsia  
• There were different indications for iatrogenic preterm delivery in PE 
for women with different ethnicities.   
 
The clinical manifestations of pre-eclampsia represent a variety of 
pathophysiological processes. Biochemical markers that allow prediction of 
the disease would be useful but may be specific to different populations, 
such as Black, Asian, obese or older women.    !
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Chapter Three 
 
A study of plasma proteomics to predict  
pre-eclampsia   
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3.1  Introduction 
 
3.1.1  Proteomics 
 
Proteomics is the study of the proteins, their structure and function, within a 
cell/system/organism (Gramolini et al 2008) and has emerged as an 
important tool in several different fields of medical research for early 
disease detection, for assessment of response to treatment and for 
unraveling underlying pathophysiological processes (Wheelock et al 2013).   
After Richard Levine’s work showed how circulating angiogenic factors are 
altered in pre-eclamptic pregnancies up to five weeks before the onset of 
the clinical syndrome, many groups have aimed to identify “biomarkers” 
(biological markers) for predicting the onset of pre-eclampsia (Levine et al 
2004).  It is hoped that by discovering these biomarkers we can accurately 
predict the onset of the disease and study potential interventions that may 
reduce the severity of the disease, or prevent its development altogether.   
The identification of one unique protein that could accurately diagnose pre-
eclampsia is, perhaps, unrealistic.  Given that trisomy 21 is screened by 
combination of several biochemical factors and an ultrasound parameter, 
the same could be hoped of for pre-eclampsia.   
The quest for a clinically utilizable biomarker is split into two processes (see 
figure 13).  The first aims to discover the potential marker.  This involves 
choosing the appropriate biological sample, reducing the complexity of the 
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sample (this can involve removing the abundant proteins and/or separating 
the proteins according to their molecular weight), analyzing the sample 
using mass spectrometry, interpreting the results using a defined database 
and selecting the candidate protein/peptide(s) for further study.  The next 
stage involves prospective confirmation of these candidate 
proteins/peptides as biomarkers, using a larger and more diverse study 
group (Gramolini et al 2008).  Only when these have been shown to: a) be 
reproducible across a wide selection of patients b) have the appropriate 
sensitivity and specificity c) be clinically useful at either predicting diagnosis 
or prognosis of a disease state can a candidate protein/peptide be called a 
biomarker (Figure 13).   
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Figure 13 
A proteomics-based biomarker discovery pipeline. A potential biomarker 
discovery platform could combine global proteomic profiling in tissue 
(discovery phase) with sensitive quantitation by target-driven mass 
spectrometry (MS) (target-driven validation) of putative biomarkers directly 
in plasma. ELISA, enzyme-linked immunosorbent assay; LC-MS, liquid 
chromatography–MS; MRM-MS, multiple reaction monitoring mass 
spectrometry; MudPIT, multidimensional protein identification technology 
(from Gramolini et al 2008) 
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3.1.2  Sample choice 
 
Most human tissue types can provide a platform for proteomic analysis.  In 
pre-eclampsia research plasma, urine and placental tissue have all been 
studied with a significant focus on plasma studies in the quest for an early 
pregnancy pre-eclampsia biomarker (Horgan et al 2011).  Whilst Plasma is 
an ideal medium for detecting systemic markers of a disease process, its 
use in proteomics is fraught with challenges.  95% of the plasma proteome 
is made up of just 14 proteins and this highly abundant group prevents 
adequate study of the remaining 5% where the potential biomarker(s) 
probably lie (Millioni et al 2011).  In addition, the complexity of the plasma 
proteome and the role genotype and environmental influences play on the 
individual plasma proteomes means that researchers need to overcome 
significant inter-person variation (Molloy et al 2003).  Plasma proteomics 
can generate huge amounts of data.  Without the correct analysis platforms 
and the ability to link (patho)physiological processes and the 
peptides/proteins can mean researchers are searching for the elusive 
needle in the proteomic haystack.             
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3.1.3  Protein identification by mass spectrometry  
 
Mass spectrometry is an analytical process by which a the content of a 
sample is separated according to the mass-to-charge ratio of the ionized 
molecules contained within it.  The resulting spectra of these mass-to-
charge ratios are then used to identify and quantify the molecules.  These 
molecules can then be interrogated in large databases, allowing the content 
of the original sample to be discovered (El-Aneed et al 2006).   
Before a biological sample undergoes mass spectrometry, it needs to 
undergo preparation to allow a more efficient analysis and production of 
relevant data that can be studied further.  This preparation can consist of 
separating the proteins according to their mass and digesting the proteins 
into peptides that allow for easier ionization.  Some of the commonest 
preparation methods are discussed in the following paragraphs.        
    
3.1.4  2 Dimensional gel electrophoresis  
 
2 dimensional (2D) gel electrophoresis separates proteins according to their 
mass and their isoelectric point.  The sample to be studied is placed in a 
gel-based matrix.  The matrix contains a proteolytic agent, digesting the 
protein into ionised peptides.  Across the matrix there are different pH 
gradients, with one end of the gel being more positive than the other.  When 
a charge is applied, the peptide moves towards the different the end with 
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the charge opposite to that of its own.  It eventually stops at the pH where it 
has no net charge, this is known as the isoelectric point of the protein.  As 
some peptides are heavier than others, the lighter ones are able to travel 
further through the gel matrix.  This occurs at a 90° angle from the 
isoelectric filter.  The resulting “spots” which represents a specific peptide 
are then extracted and undergo mass spectrometry analysis.  Drawbacks of 
2D gel electrophoresis include the inability to analysis large complex 
solutions and it’s poor reproducibility (Issaq et al, 2008).     
 
3.1.5  Liquid Chromatography  
 
Liquid chromatography (LC) is “the separation of components of a mixture 
based upon the rates at which they elute from a stationary phase over a 
mobile phase gradient”.  The sample is introduced to a solvent (the mobile 
phase, as the solvent moves through the equipment) and crosses fixed 
columns containing the chromatographic medium.  Separation occurs 
according to how easily the proteins pass along the liquid phase, through 
the “pores” of the fixed columns, with the lighter proteins passing through 
easier than heavier proteins (Bansal et al, 2009) (figure 14). 
 
 
 
 
! 98!
 
 
 
Figure 14 
A schematic depiction of liquid chromatography (in this case high 
performance liquid chromatography (HPLC)).  The Solvent passes through 
the system under high pressure generated by the pump.  Sample is 
introduced into the solvent and passes through the HPLC column where the 
proteins are separated and are detected digitally to produce a 
chromatogram. Adapted from waters.com    
 
3.1.6  Gas phase chromatography 
Gas phase chromatography (or, more accurately, gas-liquid phase 
chromatography) is a separation process where the mobile phase is gas.  
The sample is vapourised in an inert gas, and passed over a liquid-covered 
solid chromagraphic platform.  The ease at which the vaporized sample 
passes through the liquid allows it to be separated according to its mass.  
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The high temperatures required for gas phase chromatography means it is 
generally not suited to proteomic studies (Mondello et al, 2008).     
   
3.1.7  Mass spectrometry  
 
All mass spectrometers contain three common components; an ion source, 
a mass analyser and an ion detection system (figure 15). 
 
Figure 15: 
A schematic interpretation of the basic steps involved in mass spectrometry.  
Reproduced from SGE analytical Science. 
 
• Ionisation 
During ionization the compound to be studied is bombarded with 
electrons.  These electrons cause the compound’s component molecules 
to lose an ion, making them positively charged.   
• Mass analyser 
When ionized, the molecules then pass through an accelerator, where 
they form a fine beam.  This beam then passes through a field of 
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electromagnetic energy.  This deflects the fine beam of analyte.  Two main 
factors contribute to how much the beam deflects; the mass of the 
molecule and the charge of the molecule (heavier molecules will deflect 
less than lighter molecules and molecules with +1 charge will deflect less 
than those of higher charge +2).  These two factors give each molecule its 
own mass to charge ratio (m/z) (de Hoffmann 2007).   
• Ion detection system 
The m/z ratios of the analytes molecules are recorded electronically 
through complex informatics technology.  The results are compared to 
huge databases of proteins, allowing for the content of the protein 
compound to be identified (de Hoffmann 2007).   
 
3.1.8  The Synapt HDMS system 
 
Although the basic principles of mass spectrometry are relatively simple 
(produce an ion, accelerate it, deflect the components of the beam 
according to the m/z and record the results) the technicalities of the 
procedures are much more complex.  There are numerous methods of 
ionizing the samples and hundreds of different machines that deflect the 
mass of the compound, all with slightly varying methods.  For the purpose 
of this study, the samples were performed on an Electrospray Quadrupole 
Time-of-Flight (ESI Q-ToF) Synapt high definition mass spectrometer 
(HDMS) (“the Synapt”).  
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3.1.9  Electrospray Ionization  
 
Ionization of the protein/peptide analyte is achieved by electrospray 
ionization (ESI) (figure 16).  
 
Figure 16:  Schematic interpretation of electrospray ionization, adapted from 
the University of Bristol’s Chemistry department (http://www.chm.bris.ac.uk) 
 
The analyte is dissolved in a volatile solvent and passed through a spray 
needle, which has a large potential difference  (in reference to the 
cone/counter electrode).  The needle repels those ions with similar charge 
to it, towards the oppositely charged counter electrode.  Whilst travelling 
through the space between the needle and the cone, the solvent 
evaporates.  When the droplet of solvent/analyte shrinks until the surface 
tension can no longer sustain the charge (“the Rayleigh limit”) the droplet is 
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torn apart via the Coulombic explosion, producing multiple smaller 
solvent/analyte droplets and charged analytes only.  These solvent/analyte 
compounds undergo the Coulombic explosion, until only ionic analytes 
travel through the counter electrode (Ho et al, 2003).   
 
3.1.10  The Quadrupole mass analyzer        
 
A quadrupole mass analyzer consists of four cylindrical electromagnetic 
rods in parallel to each other (see figure 17).  
 
Figure 17: A quadrupole mass analyser.  The ion sample is passed through 
the middle to the four charged rods.  When the voltage applied across the 
rods varies, only ions with specific m/z will reach the detector.  Adapted 
from the University of Bristol’s Chemistry department 
(http://www.chm.bris.ac.uk) 
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The rods have a fixed current applied to them and an alternating 
radiofrequency voltage applied across them.  The ionized analyte is passed 
through the middle of the rods with their trajectory through these rods 
dependent on the radio frequency voltage applied across them.  By 
alternating this voltage, ions of varying m/z can be focused onto the 
detecting equipment allowing different ions to be studied (Dawson et al, 
1986, de Hoffmann 2007).   
 
3.1.11  Time-of-Flight mass spectroscopy  
 
Time-of-Flight (TOF) mass spectrometry is a method of m/z detection of an 
ion by measuring the time it takes for it to pass between a source and a 
detector.  The ion passes through the source via pulsatile electrical field of 
known quantity.  This means that every ion passes into the TOF-MS with 
the same kinetic energy.  It passes along a fixed distance to the detector 
and the time it takes to reach the detector is recorded.  Ions with low mass 
reach are detected first.  With the distance travelled and the time taken to 
cross the distance known, the mass of the molecule can therefore be 
calculated (Guilhaus, et al 1995).   
 
3.1.12  Protein quantification 
Whilst standard proteomic mass spectrometry readily identifies proteins, 
quantifying these proteins is more challenging.  In order for studies to be 
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useful in identifying alteration in the proteomes between disease and control 
states, it is imperative that we can quantify these alterations.  There are two 
main methods of protein quantification using MS technology, relative and 
absolute.  Relative quantification identifies those proteins that are up or 
down regulated and this allows for a trend to be determined.  Absolute 
quantification allows for proteins to be quantified by their concentration in a 
sample (such as femtomoles or picograms per amount of cell material).  
Absolute quantification can be achieved using label or label free techniques 
(Wasinger et al, 2013).   
 
3.1.13  Label dependent absolute protein quantitation 
 
An isotope-labeled peptide behaves chemically identical to its native 
counterpart and therefore the two peptides behave identically through the 
chromatographic and/or mass spectrometric analysis (Bantscheff 2007).  
Given that a mass spectrometer can recognize the mass difference 
between the labeled and unlabeled forms of a peptide, quantification is 
achieved by comparing their respective signal intensities.  Isotope labels 
can be introduced as an internal standard into amino acids either (i) 
metabolically (during cell growth and division) or (ii) 
chemically/enzymatically (where an isotope “label” is added to a protein’s 
cysteine residue).   
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3.1.14  Label-free protein quantification 
 
There are currently two methods of label-free protein quantification, spectral 
counting and LCMS/LCMSE area under the curve.   
As the abundance of a protein and the precursor peptides increase, so to 
do the MS spectra collected from their analysis.  These spectra are then 
counted, compared to the spectra obtained from other samples and the 
differences quantified.  This allows for a change in two samples to be 
identified, but not for the magnitude of change to be known (Old et al, 
2005).  During HPLC, the peak which the sample enters the mass 
spectrometer is measured.  The area under this peak is then calculated and 
together with an internal standard of known quantity, comparison of the two 
areas under the curve can be compared and mass of the peptide 
determined.      
 
3.2  Aim 
 
The aims of this work are: 
• To study the proteome of women who did and did not develop early onset 
pre-eclampsia from samples obtained in the first trimester of pregnancy 
• Comparing the two groups, identify markers that may a) identify putative 
markers that may allow early detection of disease onset and b) suggest 
pathophysiological process involved in disease development. 
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3.3  Materials and methods 
3.3.1  Study population  
 
This was a case–control study drawn from a large prospective observational 
study for hypertensive complications of pregnancy in women attending for 
their routine first hospital visit in pregnancy at King’s College Hospital, 
London.  At this visit, women where given a patient information leaflet to 
read, prior to their ultrasound scan, and if they agreed to participate they 
signed a patient consent form.  Women who could not speak English were 
excluded from the study.  All women had a first trimester combined anomaly 
screen performed.  This consisted of a blood test for PAPP-A and βhCG 
and an ultrasound scan to measure the crown-rump length (CRL) of the 
fetus the width of nuchal translucency (NT) (figure 10). 
 
(a)                                 (b) 
 
Figure 18  
Figure 18(a) shows measurement of the crown-rump length (CRL) of a fetus 
with a gestational age of 12 weeks.  Figure 18(b) shows the same fetus with 
the normal Nuchal Translucency (NT) measurement of 1.6mm. 
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Nuchal Translucency is measured between 11+0 and 13+6 weeks 
gestation, therefore women booked outside of this gestational age range 
were excluded.  Women whose screening test deemed them at high-risk for 
having a fetus with aneuploidy were also excluded. Patients were asked to 
complete a questionnaire on maternal age, racial origin (white, black, Indian 
or Pakistani, Chinese or Japanese and Mixed), cigarette smoking during 
pregnancy (yes or no), method of conception (spontaneous or assisted), 
medical history (including chronic hypertension, diabetes mellitus, 
antiphospholipid syndrome, thrombophilia, and sickle cell disease), 
medication (including antihypertensive, antidepressant, antiepileptic, 
aspirin, steroids, betamimetic, insulin, and thyroxin), parity (parous or 
nulliparous if no delivery beyond 23 weeks), obstetric history (including 
previous pregnancy with pre-eclampsia), and family history of pre-
eclampsia (mother).  Clinical examination consisted of measuring the 
woman’s height and weight, allowing for body-mass index to be calculated.  
Blood pressure was recorded and urinalysis was also performed.  
Abdominal Doppler ultrasound was performed to visualize the left and right 
uterine artery, the pulsatility index was recorded and any notching of the 
Doppler flow noted. 
Full ethical approval was granted by the King’s College ethics committee!
(reference: 02-03-033).    
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3.3.2  Specimen collection 
 
Following study interview and clinical examination, blood was obtained from 
the antecubital fossa into an EDTA tube via a vacutainer giving set.  It was 
then taken to the research laboratory, where it was centrifuged twice at 
3000rpm for 10 minutes at 20°C.  The resulting plasma was then stored at -
80°C until immediately prior to being studied.  From the over all cohort, 30 
“pre-eclampsia” and 30 “normal” samples were analysed.   
 
3.3.3  Materials (and suppliers) 
 
• Seppro IgY14 LC2 column kit (Sigma Aldrich, Gillingham, UK).  This 
included an LC column and dilution, stripping and neutralizing buffers.   
• Rapigest surfactant (Waters Corporation, Milford, MA. USA) 
• Dithiothreitol (Melford laboratories, Ipswich UK) 
• Glu1-Fibrinopeptide B peptide (human) (Sigma Aldrich, Gillingham, UK) 
• Sodium azide (Sigma Aldrich, Gillingham, UK) 
• Iodoacetamide (Sigma Aldrich, Gillingham, UK) 
• Ammonium bicarbonate (Sigma Aldrich, Gillingham, UK) 
• Acetonitrile (Sigma Aldrich, Gillingham, UK) 
• Trypsin (Promega, Madison, WI, USA) 
• Mass spectrometry solvents (MallinckrodtBaker Inc, Phillipsberg, NJ, USA) 
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• Spin X cellulose acetate centrifuge tube filters (Cosar, Tewksbury MA, USA) 
• 2ml square 96-well trays (Beckman Coulter. Fullerton, USA) 
• 5 kDa nominal molecular weight cut off (NMWCO) spin columns (Millipore, 
Billerica, MA, USA) 
• 0.45 µm nitrocellulose filter discs (Millipore, Billerica, MA, USA). 
 
3.3.4  Sample preparation  
 
Each sample was thawed to room temperature and 200µL removed.  This 
was then diluted to 1mL with the addition of dilution buffer and centrifuged 
using a 0.22µm spin-X cellulose acetate centrifuge tube filter. 
 
 
 
3.3.5  Sample fractionation  
 
The purpose of the fractionation step was to deplete the maternal plasma of 
the 14 most abundant proteins (which, as previously mentioned, make up 
95% of the total plasma proteome) and these proteins are listed in table 15.    !
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Proteins removed by Seppro IgY-14 fractionation 
Alpha2-macroglobulin Alpha1-Acid glycoprotein 
IgG Alpha1-antitrypsin 
Fibrinogen Transferrin 
Apo-A-I HDL IgA 
Complement C3 IgM 
Haptoglobin Albumin 
 
Table 15: Proteins removed by Seppro IgY-14 
 
Fractionation utilised the ProteomeLab PF2D system (Becker Coulter, 
Fullerton, USA) via an IgY-14 LC2 chromatography column.  The 
ProteomeLab system comprised a single quaternary pump, sample loop 
injector with UV detector and fraction collection using a 2mL capacity 
square 96-well plate.   
The system was flushed with water to remove any residual organic solvent 
in the flow path (with a connector used instead of the Seppro column).  A 
method was developed to load the diluted plasma onto the IgY-14 column 
whist sequentially using dilution, stripping, neutralization and dilution buffer 
over a 50-minute cycle.  To allow equilibration of the column, during the 
final cycle of the day the last step with dilution buffer included sodium azide.  
Fractions were collected from the column during the chromatographic steps 
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and detection of protein elution was achieved using absorbance at 280nm 
with a 5Hz sampling rate.    
 
Once the Seppro column was attached, a full cycle of fractionation was 
undertaken, using 250µL of dilution buffer before the plasma sample was 
run.  Each plasma sample then underwent two depletion steps, ensuring 
there was enough sample for the mass spectrometry.  Finally between 
different plasma samples, a blank run, using the dilution buffer, was 
undertaken to ensure no cross contamination.    
 
3.3.6  Tryptic digestion of IgY-14 fractionated plasma 
 
The two IgY-14 depleted plasma samples were combined, making a total of 
approximately 1mL.  The sample was then transferred to vial containing 
lyophilised 0.1% w/v Rapigest surfactant (to help the protein to solubilise, 
allowing them to be more amenable to enzyme cleavage) and the solution 
agitated gently to allow the plasma to fully dissolve.  The contents were 
then transferred to an 5kDa NMWCO spin column and centrifuged at 
14,000rrm, 4°C, until the volume halved to approximately 50µL. The 
contents were transferred to a 0.5mL microfuge tube (Fisher Scientific Ltd, 
Loughborough, UK) and incubated in a water bath for 15 minutes at 80°C.  
5µL of 100mM dithiothreitol in 100mM ammonium bicarbonate was added 
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to plasma (to reduce any disuphide bonds), the solution agitated and 
incubated at 60°C for 15 min, followed by the addition of 5µL of 200mM 
iodoacetamide in 100mM ammonium bicarbonate and incubated at room 
tempature, in the dark, for 30 minutes (the iodacetamide binds with the 
cysteine residue of peptides, preventing (re)formation of disulphide bonds).   
A 20µg of trypsin was resolubilised in 20µL of 100mM ammonium 
Bicarbonate, and 2µL transferred to the plasma sample and thoroughly 
agitated.  The sample was incubated overnight at 37°C.  The next morning, 
2µL of formic acid was added to the sample, incubated at 37°C for 15 
minutes and filtrated through a 0.22µm Spin-X cellulose acetate centrifuge 
tube filter.  Typically 45-50µL was obtained from each depleted sample. 
The tryptically-digested sample is diluted 8 fold and combined with 200fmol 
µL-1 MassPREP glycogen phosphorylase (PhosB) tryptic digestion standard 
in 0.1% v/v aqueous formic acid.  This produced a sample containing 
approximately 300ng µL-1 depleted plasma and 100fmol µL-1 PhosB.  The 
PhosB was used as an internal standard for the estimation of protein 
concentrations. 
 
3.3.7  Liquid Chromatography-Mass Spectrometry (LC-MS E) 
Liquid chromatographic separation was performed using a NanoAcuity 
UPLC system (Waters Corperation, Milford, MA, USA).  This was comprised 
of a binary solvent, an auxiliary solvent and sample manager fitted with a 
heating and trapping module.   
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LC separation was performed using a Symmetry C18 trapping column 
(180µm x 20mm x 5 µm) and a C18 analytical column (75µm x 250 mm x 
1.7µm).  Solvent A was 0.1% v/v aqueous formic acid and solvent B was 
0.1% v/v formic acid in acetonitrile.   
The digested plasma sample/internal standard mixture was loaded to the 
trapping column and flushed with solvent B for 2 min at a flow rate of 15 µL 
min-1.  Sample elution was at a rate of 250 nL min-1 by increasing the 
organic solvent B concentration from 3% to 40% over 90 minutes.   
Each sample was conducted in three technical replicates. 
Before and after each of the technical replicates, a quality control process 
was undertaken with 50fmol of PhosB being analysed by LC-MSE.  Where 
peptide sequence coverage fell below 35% for PhosB no further samples 
were run, and the cause of the fall in peptide identification investigated and 
resolved.  Four quality control processes were carried out every 24 hours 
during sample processing.   
MSE data acquisition was performed on a Synapt HDMS instrument (Waters 
Corporation) with MSE configuration achieved through the MS method editor 
controlled by MassLynx software (v4.1).  TOF analyser of the mass 
spectrometer was calibrated using the MS/MS spectrum obtained from the 
doubly charged precursor of the GFP peptide over the range m/z 50 to 
1300.  This was validated with an average ppm error across the mass range 
of <10ppm.   
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In low energy MS, data was collected at a constant trap collision energy of 
6eV and in high energy MS, data was collected at alternating energies from 
15eV to 30eV.  All data was post-acquisition lockmass corrected using 
monoisotopic ion of the doubly charged precursor of GFP (m/z 785.8426). 
 
 
3.3.8  Data processing and database interrogation  
 
The MSE data were processed by and proteins quantified using the Identity 
and Expression algorithms in PLGS v2.4.  The data was collected in 
separate data functions.  The first contained data from low energy MS and 
the second contained data from elevated energy MS and the data from the 
Phos B runs for accurate mass correlation.  The lockmass-corrected 
spectra are deisotoped and charge-state reduced to produce a single 
accurately mass-measured monisotopic mass for each peptide and its 
related fragment ion.   
The database search parameters used the following variable modifications; 
N-terminal acetylation, deamidation of N/Q and oxidation of M residues. The 
IPI human database rel. 3.69 was appended to include the sequences for 
the internal standards. A database was then generated which included one 
random entry for each original sequence in the file and was used for all 
subsequent interrogations. 
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The protein tables from PLGS IdentityE were compiled in Excel and pivot 
tables were used to identify proteins observed in a minimum of 2 replicate 
analyses from each individual patient.  The protein abundance (as a % of 
the total loading) was then calculated for the confident identifications. The 
number of random entries in the confident protein table was used to 
determine the false positive rate for the analyses. 
 
3.3.9  Patient outcome and diagnosis of early onset pre-eclampsia 
 
For the purpose of this study the definition of early onset pre-eclampsia was 
Hypertension of SBP>140 and / or DBP >90 over two consecutive readings, 
6 hours apart, with proteinuria of 300mg/24 hrs or a protein: creatinine ratio 
of >30mg/mmol, and where not available, a + proteinuria on a urine dipstix, 
occurring after 20 weeks gestation, but before 34 weeks gestation and 
resolving post delivery.  
In addition to this definition, all patients who developed pre-eclampsia had 
abnormal uterine artery Doppler studies (either notching of the uterine 
artery Doppler (bilateral or unilateral) or an raised uterine artery Doppler PI) 
at 24 weeks gestation.     
 
3.3.10  Delivery information 
Delivery information was obtained from hospital informatics and cross-
referenced with delivery notes.  This information included gestation of 
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delivery, mode of delivery, birth weight and blood pressure reading pre-
delivery and post-delivery.    
 
3.3.11  Statistical analysis  
 
All statistical analysis was performed on the SPSS software package 
(SPSS inc., Chicago,USA).  Normally distributed data were expressed as 
mean +/- standard deviation, whereas non-normally distributed data were 
reported as median +/-interquartile range. Data distribution was assessed 
for normality via the Kolmogorov-Smirnov test.  Comparison of categorical 
data between the two groups was through Fisher’s exact test and 
continuous data were compared by the Mann Whitney U test if the data was 
skewed, or by the student’s t test if the data was normally distributed.  
Statistical significance was taken as a p value of <0.05.   
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3.4  Results 
 
3.4.1  Patient demographics  
 
All women who developed pre-eclampsia had bilateral notching of the 
uterine arteries at 20 weeks gestation, whilst those in the “normal” group did 
not.  The pre-eclampsia group developed significantly higher blood 
pressure, both at booking and (by definition) at the time of delivery, than 
those in the normal group (table 16).  The pre-eclampsia group required 
delivery before 34 weeks gestation, the normal group were delivered at 
term (>37 completed weeks of gestation).  Birth weight, plotted on 
customised growth charts, were lower in the pre-eclampsia group than the 
normal group at delivery.  
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 Controls Pre-eclampsia 
 
Maternal age Median  
(IQR) 
 
         Maternal BMI in kgm-2, Median  
        (IQR) 
 
Crown-rump length in mm, 
median (IQR) 
 
Gestation at sampling (weeks), 
median (IQR) 
 
        Racial origin 
Caucasian,  (%) 
African,  (%) 
Asian,  (%) 
 
Parity  
Nulliparous, n (%) 
 
Cigarette smoker, n (%) 
 
         31.2 
(27.5-35.8) 
 
24.2 
(21.9-27.3) 
 
63.3 
(58.0-68.5) 
 
12.4 
(12.1-12.9) 
 
 
  58 
  32.5 
  9.5 
 
 
46 
 
7 
31.6  
(25.2-37.1) 
 
28.3  
(23.5-32.7) 
 
62.9 
(57.0-68.1) 
 
12.4  
(12.0-12.8) 
 
 
36 
46 
18 
 
 
56.7 
 
3 
 
Table 16 
Demographic details of women who did and did not (Control) develop pre-
eclampsia 
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3.4.2  Quantification of plasma proteins 
 
 For each patient, the three technical replicates were compared and protein 
abundances were calculated from the IdentityE tables (as a % of the total 
loading) for each protein that observed in two or more replicates.   In total, 
1625 proteins were identified.  However only 371 of these were identified in 
two of the three technical replicates of the individual samples.  894 were 
identified in only one of these technical replicates.  These were used to 
calculate the false positive protein detection rate, which was <0.3%.  Of 
these 371 proteins, 35 were statistically significant between the normal and 
pre-eclampsia samples  (p<0.05 Mann Whitney U test) and are listed in 
table 17. 
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Over represented in pre-eclampsia 
 
Under represented in pre-
eclampsia 
 
Angiotensinogen 
Pregnancy zone protein 
Complement component C4a 
Complement component C3Bb 
Complement component C1q 
Complement C2 
Complement C1r 
Complement factor B 
hCG 
Pigment epithelium derived factor 
Alpha 1 anti protease 
Fetuin B 
Hyaluronan 
Vitronectin 
Pigment Epithelium Derived Factor 
Plasma Kallikrein 
Prothrombin 
Sex Hormone Binding Globulin 
Extracellular matrix protein 1 
Clusterin 
Coagulation factor X 
Coagulation factor V 
Pregnancy specific glycoprotein 9 
Pregnancy specific B1 glycoprotein 11 
Ceruloplasmin 
Inter alpha trypsin inhibitor 
 
 
 
Tissue Kallikrein-1 
Complement C1 inhibitor 
Thyroxine binding globulin 
Vitamin D binding globulin 
C4b binding protein 
Complement factor H 
Extracellular matrix protein 1 
AMBP 
Paraoxonase-1 
 
 
Table 17: A list of peptides that are statistically significantly (P=<0.05) 
altered in first trimester individual samples from women who did and did not 
subsequently develop pre-eclampsia.   
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Angiotensinogen was significantly raised in pregnancies that went onto 
develop pre-eclampsia (p<0.0001) (figure 19). 
 
 
 
 
 
Figure 19: Box plot of the median value for the % abundance of 
Angiotensinogen in the first trimester individual samples from women who 
did and did not go on to develop pre-eclampsia.  Angiotensinogen is 
significantly increased in the pre-eclampsia samples (p=<0.001).  The 
bottom and top of each box represents the 25th and the 75th percentile 
respectively; the line represents the median value.  Whiskers extend to the 
most extreme data points 
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Tissue Kallikrein 1 was significantly lower in the pre-eclampsia group 
compared to the normal group (figure 20). 
 
 
Figure 20: Box plot of the median value for the % abundance of tissue in the 
first trimester individual samples from women who did and did not go on to 
develop pre-eclampsia.  Tissue kallikrein is significantly decreased in the 
pre-eclampsia samples (p=<0.001).  The bottom and top of each box 
represents the 25th and the 75th percentile respectively; the line represents 
the median value.  Whiskers extend to the most extreme data points.   
The ratio of angiotensinogen to tissue kallikrein is significantly up-regulated 
in women who go on to develop pre-eclampsia than those who do not 
(p<0.0001).  In addition when plotted on a Receiver-Operator Curve (ROC) 
the area under the curve (AUC) is 0.81 (figure 21). 
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Figure 21: ROC curve for angiotensinogen: tissue kallikrein.  AUC=0.81 
(Standard Error (SE) = 0.05).  A cut-off value of >0.27 gives a sensitivity of 
0.9 (95% CI = 0.74 – 0.97), a specificity of 0.5 (0.24-0.65), positive 
predictive value (PPV) = 0.63 (0.47-0.75) and a negative predictive value of 
0.87 (0.53-0.96).   
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When the relationship between angiotensinogen and tissue kallikrein levels 
was defined there was a significant negative correlation between the two 
with a correlation coefficient r = -0.5513 (95% CI = -0.71-0.34)  (Figure 22). 
 
 
 
Figure 22: Correlation between Tissue kallikrein and Angiotensinogen.  
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Complement C3Bb and Complement factor B were significantly raised in 
first trimester samples that later develop early onset pre-eclampsia (figure 
23) 
 
 
Figure 23 (continued overleaf) 
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Figure 23: Box plot of the median value for the % abundance of complement 
factors involved in the alternative pathway of complement (Complement C3Bb 
and Complement factor B) in the first trimester individual samples from women 
who did and did not go on to develop pre-eclampsia.  All proteins are 
significantly increased in the pre-eclampsia samples (p=<0.001).  The bottom 
and top of each box represents the 25th and the 75th percentile respectively; the 
line represents the median value.  Whiskers extend to the most extreme data 
points 
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Figure 24: Box plot of the median value for the % abundance of 
complement factors involved in the classical pathway of complement 
(complement C4a) in the first trimester individual samples from women who 
did and did not go on to develop pre-eclampsia.  All proteins are 
significantly increased in the pre-eclampsia samples (p=<0.001).  The 
bottom and top of each box represents the 25th and the 75th percentile 
respectively; the line represents the median value.  Whiskers extend to the 
most extreme data points. 
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Complement factor H and Complement C4b are significantly down 
regulated in individual first trimester plasma samples of women who go on 
to develop pre-eclampsia (p<0.0001 and p<0.0003 respectively) (figure 25). 
 
 
 
Figure 25 (continued overleaf) 
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Figure 25: Box plot of the median value for the % abundance of proteins 
involved regulation of complement pathways in first trimester individual 
plasma samples from women who did and did not go on to develop pre-
eclampsia.  Both proteins are significantly decreased in the pre-eclampsia 
samples (Complement factor H p<0.0001, C4b binding protein p<0.0003).  
The bottom and top of each box represents the 25th and the 75th percentile 
respectively; the line represents the median value.  Whiskers extend to the 
most extreme data points. 
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Paraoxonase-1, a powerful anti-oxidant is significantly lowered in the first 
trimester of pregnancies that go on to develop pre-eclampsia (p=0.0034) 
(figure 26).!!
  
Figure 26: Box plot of the median value for the % abundance of 
paraoxonase-1 in first trimester individual plasma samples from women who 
did and did not go on to develop pre-eclampsia.  Levels are significantly 
lower in the pre-eclampsia samples (p=0.0034).  The bottom and top of 
each box represents the 25th and the 75th percentile respectively; the line 
represents the median value.  Whiskers extend to the most extreme data 
points  
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3.5  Discussion  
 
The results of this study show that even in the first trimester of pregnancy, 
there are significant alterations in the plasma proteome of women who later 
develop severe early onset pre-eclampsia and those who do not.   
Although this pilot study only had a relatively small number of samples 
(n=30 in each group), the methodology used is such that it overcomes 
many of the obstacles faced by other proteomic groups.  In view of the 
enormous cost attributed to undertaking proteomics and mass 
spectrometry, several groups limit the amount of mass spectrometry 
undertaken by pooling the individual samples to form (usually) two 
specimens to be studied, “disease” versus “normal”.  The problems 
associated with this are quite obvious, if only one person in a cohort has an 
abnormally raised protein concentration, then the results of the whole group 
are altered.  This is even the case for large multi-centred prospective 
studies, such as the SCreening fOr Pregnancy Endpoints (SCOPE) study 
(Blankley, et al, 2013).  
 As previously mentioned, in order to study the 5% of the proteome that is of 
interest to researchers, the remaining proteome needs to be removed.  
This, and the latest equipment, will allow a detection limit to study small 
changes between samples.  This study removed the 14 most abundant 
proteins (whereas a lot of other studies remove only the 10 or 12 most 
abundant proteins) allowing us to push our detection limit further.   
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Not only has this study shown significantly altered proteins between the two 
groups of individual plasma samples, these proteins, may allow us to 
postulate potential pathophysiological pathways involved in disease 
development and/or allow us to suggest candidate proteins which could 
allow a screening tool for the disease.     
To validate any potential marker, further work on the individual samples 
must be done.     
3.5.1  Angiotensinogen and Tissue kallikrein are altered in pre-
eclamptic samples 
 
Two proteins identifiable in the results that are associated with the 
development of hypertension are altered between the pre-eclamptic and 
normal groups.   Angiotensinogen is converted to angiotensin I by the action 
of renin, which is produced in the juxtaglomerular apparatus of the kidney.  
The angiotensinogen I is converted to angiotensin II by angiotensin 
converting enzyme.  Angiotensin II is a powerful vasoconstrictor that leads 
to systemic hypertension (Prieto et al, 2013). Whilst renin, though 
commonly thought to be the rate-limiting step of this pathway, some groups 
have suggested that the plasma concentration of angiotensinogen is and 
have shown that Increased plasma levels of angiotensinogen have been 
associated with development of hypertension in the non-pregnant subject 
(Klett et al, 2001). 
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Kallikrein belongs to the kallikrein-kinin system, which plays a role in 
inflammation, apoptosis and blood pressure control (Marcondes et al, 
2005).  Bradykinin is formed from its inert precursor, high molecular weight 
kininogen, by kallikrein.  The Bradykinin formed causes vasodilatation and 
smooth muscle relaxation that results in an overall reduction in blood 
pressure.  Kallikrein exists in several forms, mainly plasma kallikrein and 
tissue kallikrein.  Plasma kallikrein, originally thought to be part of the 
clotting cascade, is involved in inflammation and fibrinolytic activation whilst 
tissue kallikrein is found in a variety of tissues including kidney and vascular 
endothelium.  Of the many tissue kallikrein proteins, only one, tissue 
Kallikrein 1 (tK1) is a kininogenase, that is, able to convert kininogen to 
bradykinin (Madeddu et al, 2007).   
As angiotensinogen is raised and tissue kallikrein 1 is reduced in the first 
trimester of pregnancies that go on to develop pre-eclampsia, it could be 
suggested that these changes contribute to the later hypertensive 
syndrome.  It has also been shown that the Renin-Angiotensin-System 
(RAS) plays some role in spiral artery remodeling (Morgan et al, 1998).  
With alteration of the RAS (as evidenced by the significant increase in 
angiotensinogen) in the first trimester it can be suggested that this may 
represent a poorly understood component of the multifactorial 
pathogenesis of pre-eclampsia, with endothelial damage, oxidative stress 
and autoimmunity all being suggested as possible mechanisms (Yang et al 
2013).   
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Tissue kallikrein has previously been shown to be altered in pre-eclamptic 
pregnancies.  Khedun et al studied tissue kallikrein levels in women who 
were hypertensive in pregnancy, and demonstrated a reduction in plasma 
concentration of the protein (Khedun et al 2000).  Other groups have 
demonstrated how urinary tissue kallikrein: creatinine ratios were altered in 
pre-eclamptic pregnancies at 28 weeks, but the results were not strong 
enough to support a possible predictive role.  (Kyle et al1996).   
Not only are both significantly altered between the two groups, but also the 
relationship between them suggests a strong correlation (r = -0.55, 
p<0.001).  Given that both proteins can be up-regulated in inflammation, 
one could argue that it is due to the presumed heightened inflammatory 
state of pre-eclampsia that these proteins are altered.  However, as the 
relationship shown is negative and tissue kallikrein is reduced in the pre-
eclampsia group this would support the theory that this may represent a 
pathophysiological pathway and not just a non-specific inflammatory 
response. 
When the ratios of angiotensinogen to tissue kallikrein are plotted on a 
ROC curve, the area under the curve = 0.81 (SE=0.05) which suggests 
that this ratio may be able to predict the development of early onset pre-
eclampsia.  Having a cut-off value greater than 0.27 gives a sensitivity of 
0.9 (95%CI = 0.74-0.97), a specificity of 0.5 (0.24-0.65), PPV= 0.63 
(95%CI = 0.47-0.75) and a NPV of 0.87 (95%CI = 0.53-0.96).  In high-risk 
women (defined as those having had severe early onset pre-eclampsia 
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previously) PP13 had a greater ability to predict pre-eclampsia in the first 
trimester (AUC=0.87), but this has not been reproducible in low-risk 
women (Khalil et al, 2010).  Several other groups have demonstrated an 
enhanced ability to predict pre-eclampsia, but to obtain this higher overall 
accuracy the biochemical results were combined with ultrasound indices.  
Even then, the AUC was marginally greater than the one presented in this 
chapter at 0.84 (Thaliganathan et al, 2010).  Another study showed how 
early third trimester (20-24weeks) placental Growth Factor (PlGF) levels 
combined with abnormal uterine artery Doppler indices had similar findings 
to the results presented in this thesis (AUC=0.8) for predicting severe 
early-onset pre-eclampsia (Espinoza et al, 2007).  However, the clinical 
usefulness of a test for prediction of severe early-onset pre-eclampsia 
should be questioned.  This would offer limited opportunity for interventions 
to prevent disease occurrence / reduce disease severity (but could serve 
as a marker for those women where earlier, more intense surveillance is 
necessary).     
 
3.5.2  Inflammatory markers are altered in pre-eclampsia samples 
Several markers of inflammation are upregulated in the first trimester 
samples that go on to develop pre-eclampsia.  These inflammatory 
proteins are generic, non-specific proteins that include the members of the 
complement system.  With up-regulation of C4a indicating potential 
activation of the classic pathway of complement and complement factor B 
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and C3bB indicating potential activation of the alternative pathway of 
complement, this suggests that a strong inflammatory proteome is present 
in the first trimester of pregnancies later complicated by pre-eclampsia.  
This idea is supported further by the down-regulation of proteins involved in 
controlling the above pathways (Complement factor H and C4b binding 
protein). 
Whilst pregnancy itself is an inflammatory state, pre-eclampsia appears to 
be associated with an aggravated form of this state with both systemic and 
placental inflammation noted during the clinical syndrome (Redman et al, 
1999).  This may explain the crossing of the interquartile ranges between 
the normal and pre-eclampsia groups.   
Inflammatory (innate) response to stimuli is quick and (generally) non-
specific and when activated releases cytokines or chemokines that attract 
and instruct adaptive immune cells to generate antigen-specific responses 
in the form of antibodies or cytotoxic cells.  First trimester placentation induces 
a localised innate response (including uNK activation) crucial for normal spiral 
artery remodeling, which results in the release of inflammatory markers into 
the systemic circulation that are responsible for the normal systemic 
inflammatory state of pregnancy (Borzychowski et al, 2006).  It could be 
postulated that the poor placentation of pre-eclamptic pregnancies leads to a 
more aggressive form of this localized inflammatory response (due to tissue 
necrosis and increased oxidative stress) and this in turn leads to a more 
aggressive systemic inflammatory response (figure 27).   
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Figure 27: A hypothetical grey scale of increasing systemic inflammation. 
In a normal woman, although pregnancy stimulates a systemic 
inflammatory response, it is not intense enough to generate the signs of 
pre-eclampsia. To do that requires the abnormal stimulus from an 
oxidatively stressed placenta (left column: Placental Pre-eclampsia). In a 
woman with chronic systemic inflammation associated with conditions such 
as chronic hypertension, diabetes or obesity, which predispose to pre-
eclampsia, the starting point is abnormal enough such that even a normal 
placenta can stimulate a systemic response of a sufficient intensity to 
produce the signs of pre-eclampsia (right column: Maternal Pre-
eclampsia). In clinical practice there are many mixed presentations with 
both maternal constitution and placental ischaemia contributing to the 
presentation  (Adapted from Borzychowshi et al., 2006). 
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We have shown an increase in non-specific inflammatory proteins in the 
first trimester of pregnancies later affected by severe pre-eclampsia, which 
would support the idea of a heightened innate (that is, a non-specific 
inflammatory) immune response.   
 
3.5.3  Paraoxonase-1 is lower in pregnancies that go on to develop 
pre-eclampsia 
 
The powerful antioxidant Paraoxonase-1 is significantly reduced in women 
who go on to develop pre-eclampsia (p=0.0032).  Antioxidants stop free 
radicals from causing tissue damage and in-vivo levels have been studied 
as markers of cardiovascular health.  Lower levels of anti-oxidants are 
associated with a greater degree of cardiovascular disease (Madamanchi 
et al, 2005).  Higher levels of free radicals and oxidative stress have been 
found in pre-eclampsia and it could be argued that reduced paraoxonase-1 
represents either an intrinsic antioxidant deficiency that leads to pre-
eclampsia or greater consumption during oxidative homeostasis.  This is 
explored further in chapter 5. 
 
3.5.4  Potential biomarkers? 
 
Whilst this study has shown significant alteration in the first trimester 
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plasma proteome of women who go on to develop pre-eclampsia, Are any 
of these markers capable of predicting the disease?  The simple answer is, 
no.  In order for a candidate protein to be introduced into a clinically useful 
test it must go through several stages (figure 28).   
 
 
 
Figure 28:  Schematic representation of biomarker development.  (adapted 
from molecularmedicineireland.ie) 
What this study does provide is a selection of novel candidate proteins to 
undergo further prospective validation studies.    
3.6  Conclusion 
This study represents the first part of this journey; biomarker discovery.  One 
of the crucial stages of biomarker discovery is ensuring that robust study 
! 140!
design.  This was achieved in this study by: 
• Phenotypically identical specimens 
• Similar gestational age 
• Alternation of samples for mass spectrometry measurement  
In order for any of these candidate proteins to be introduced as a clinically 
viable biomarker, then large validation steps would need to be undertaken.   
What this work has identified are “themes” of potential pathophysiological 
pathways and disease markers.  In the next chapters, I shall explore whether 
these themes are reproducible – that is, do we already have the ability to 
accurately predict the onset of the disease or predict poor outcomes after the 
development of the disease by utilising the standard investigations 
undertaken during routine clinical care? 
 
 
  
 
 
 
 
 
 
 
Chapter 4  
Ability of common inflammatory markers to 
predict pre-eclampsia 
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4.1  Introduction  
 
As discussed in previous chapters, the clinical syndrome of pre-eclampsia 
occurs many months after the initial insult that lead to the systemic 
endothelial dysfunction.  These two distinct stages have led to pre-
eclampsia being seen as “a two stage disorder” (Borzychowski et al, 2006).  
Normal pregnancy is associated with a raised inflammatory condition and 
the two stages of pre-eclampsia are thought to either result from, or cause, 
this inflammatory state to become heightened in some women (Walker et al, 
2011).   
This inflammatory state is thought to be innate immune mediated.  This 
leads to a quick, non-specific response to stimuli and does not rely on the 
presence of a foreign antigen to initiate an immunological “memory”.  The 
innate system can interact with the adaptive immune system but does not 
require this interaction to function, whereas, the adaptive system cannot 
function without signals from the innate system. A systemic inflammatory 
response is not necessarily generated by antigenic stimulation. Indeed, in 
pregnancy, it almost certainly does not result from antigen stimulation by a 
genetically foreign fetus (Borzychowshi et al, 2006).     
 
4.1.1  Pre-eclampsia; a two-stage disorder 
One of the initial insults thought to play a significant role in developing pre-
eclampsia is the poor invasion of embryonic trophoblast into the maternal 
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spiral artery vasculature.  In a nutshell, this causes hypoxia, placental 
necrosis and predisposes to fibrin and thrombus formation (Walker et al, 
2011).  This now “damaged” placenta results in alteration of the finely 
balanced angiogenic-antiangiogenic partnership with an increase in 
circulating anti-angiogenic markers.  These then lead to a series of 
pathological changes that result in the clinical syndrome of pre-eclampsia 
(explained further in figure 29).    
 
 
 
 
Figure 29:  The two stages in the development of pre-eclampsia; Pre-
clinical stage 1 pre-eclampsia occurs in early pregnancy when insufficient 
trophoblast invasion leads to poor placentation resulting in placental 
hypoxia. Stage 2 occurs systemically when an oxidatively stressed placenta 
releases factors into the maternal circulation, which cause the maternal 
systemic inflammatory response and endothelial dysfunction that lead to the 
clinical signs of pre-eclampsia (Adapted from (Borzychowshi et al, 2006).   
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4.1.2  Inflammation  
Inflammation is “an essential response provided by the immune system that 
ensures survival during infection and tissue damage” (Ramma et al, 2011).  
It allows the host tissue to repair and removes harmful stimuli.  As 
inflammation is usually initiated by the innate immune system, cells involved 
in the innate response are pivotal in the inflammatory processes (Akira et al, 
2006) (these cells are depicted in figure 30) 
 
 
Figure 30: The innate immune response functions as the first line of 
defense against infection. It consists of soluble factors, such as complement 
proteins, and diverse cellular components including granulocytes 
(basophils, eosinophils and neutrophils), mast cells, macrophages, dendritic 
cells and natural killer cells (adapted from Dranoff et al, 2004) 
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Even though deemed non-specific, different tissue damage results in 
different aspects of the inflammation pathways to be activated.  These 
tissue/pathogen specific receptors induce the production of inflammation 
mediators, which include cytokines, (such as tumour necrosis factor (TNF) 
and members of the interleukin (IL) family) and chemokines.  These 
accelerate the progression of inflammation through modifying vascular 
endothelial permeability as well as recruiting neutrophils and excess plasma 
(containing antibodies and complement factors) (Ahmed et al, 2011).   
Chemokines recruit T lymphocytes that, in turn, secrete large amounts of 
cytokines and a subgroup of T lymphocytes that are the most prolific 
producer of cytokines are known as T-helper cells, or CD4 cells.  Whilst 
vast types of cytokines are produced, they are generally split into two 
functions.  The first group are pro-inflammatory, consisting of interferon-
gamma, IL-2 and TNF-beta, and activate macrophages (and are involved in 
phagocyte dependent protective responses).  The T helper cells that 
produce these are known as Th1, and form the basis of cell-mediated 
immunity.  In order to halt the cascade of inflammation, a second group of T 
helper cells produce anti-inflammatory cytokines (mainly members of the 
interleukin family) and are referred to as Th2 cells.  They also produce 
antibodies, activate eosinophils and inhibit several macrophage functions 
(and are therefore involved in phagocyte independent protective responses) 
and form the basis of humoral immunity (Romagnani et al, 1999).  Th2 
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cytokine production also occurs in non-lymphoid tissue (including the 
trophoblastic tissue).  In the non diseased, non pregnant state there is a 
perfect equilibrium between the Th1 and Th2 states. 
The duration of inflammation depends on the extent of tissue damage and 
in most cases the excessive production of cytokines mediate release of 
acute phase proteins (including c-reactive protein (CRP) and coagulation 
factors) leading to systemic markers of local inflammation.   
   
4.1.3  Inflammation and pregnancy  
 
Pregnancy was initially thought to be anti-inflammatory, with a predilection 
for Th2 or humoral immunity.  Pregnancies with a prominence of Th1 type 
immunity were thought to be at greater risk of developing poor outcomes 
such as miscarriage, preterm birth and pre-eclampsia (Challis et al, 2009).  
However, evidence supporting this was contradictory.  Mor et al (2011) 
propose that these inconsistencies were due to researchers seeing 
pregnancy as a single “immune event”.  They argue that pregnancy is split 
into three distinct immunological states, a pro-inflammatory first trimester 
(Th1 mediated), an anti-inflammatory second trimester (Th2 mediated) and 
a return to a heightened inflammatory state in the third trimester. 
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4.1.4  Measuring markers of inflammation in clinical practice  
 
It is common practice to investigate the aetiology of symptoms or monitor 
disease activity by monitoring markers of inflammation.  These markers 
include acute phase proteins and the cells involved in innate immunity 
(leucocytes).  Leucocytes are measured clinically as part of a full blood 
count.      
 
4.1.5  The Full Blood Count  
Haemoglobin, White blood cells and platelet count are measured in the UK 
via the Full Blood Count (FBC).  Being one of the most commonly 
requested haematological investigations, it provides screening for anaemia, 
infections, inflammation, some clotting disorders and can be used to 
diagnose malignancy.  The elements of a FBC sample (with normal non-
pregnant and pregnant values) are listed in table 18 overleaf. 
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Parameter 
(units) 
Non$ 
pregnant 
Pregnant* 
1st Trimester 
 
Pregnant* 
3RD 
Trimester 
Haemoglobin 
(g/L) 
115 - 
160 
110-140 105-140 
Platelets 
(x109/L) 
150 - 
400 
150-400 150-400 
Mean Cell 
Volume (fL) 
78 - 100 78-100 78-100 
RBC (x1012/L) 3.8 - 5.8 3.4-4.55 2.7-4.4 
 
Mean 
Corpuscular 
Haemoglobin  
(pg) 
27 - 32 27-32 27-32 
Red Cell 
Distribution 
Width (%) 
11.5 - 
15.0 
11.5-15 11.5 - 15 
White Blood Cell 
(x109/L) 
4 - 11 6-14 5.9-16.9 
Neutrophils 
(x109/L) 
2 - 7.5 3-10 6 - 17 
Lymphocytes 
(x109/L) 
1.0 - 4.5 1-4.5 1 - 4.5 
Monocytes 
(x109/L) 
0.2 - 0.8 1-1.1 0.1 - 1.4 
Eosiniphils 
(x109/L) 
0.04 - 
0.40 
0-0.6 0 - 0.6 
Basophils 
(x109/L) 
<0.1 <0.1 <0.1 
 
Table 18 Full Blood Count, its components and normal values in non 
pregnant women and women in the 1st* and 3rd* trimester of pregnancy 
($adapted from Nelson-Piercy, 2006, * Adapted from Abbassi-Ghanavati et 
al, 2009) 
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4.1.6  Leucocytes in the non-pregnant state 
The main function of leucocytes in both the pregnant and non-pregnant 
population is to fight infection, with each leucocyte subtype having their own 
function (table 19, overleaf).   
In addition there has been a lot of work assessing the potential of 
leucocytes as markers of the inflammation.  In 1974, Freidman et al were 
the first to link leucocyte count as a predictor for myocardial infarction and 
since then studies have cemented the association of raised leucocyte count 
with atherosclerosis and cardiovascular events (Hoffman et al, 2003).  
Raised neutrophil and low lymphocyte counts were both shown to be a 
better predictor of cardiovascular disease (hazard ratio (HzR) for raised 
neutrophil count – 2.06, HzR for lower lymphocyte count – 0.41).  However, 
when assessed together, lymphocyte to neutrophil ratio was the best 
predictive marker with an HzR of 2.73 (p<0.001) (Horne et al, 2005) 
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Leucocyte 
component 
         Appearance  % in 
       adults 
Function/  
Target 
Lifetime  
Neutrophil  
 
62% Bacteria 
/Fungi 
6hr -  
several 
days 
 
 
 
    Lymphocyte 
 
30% B cells 
release 
antibodies 
and activate 
T cells.  T 
cells have 
many 
components 
antibacterial 
and immune 
functions. 
Years 
for 
memory 
cells.  
Weeks 
for all 
others  
Monocyte 
 
5.3% Migrate to 
other tissues 
and 
differentiate 
into tissue 
resident 
macrophages 
Hours 
to days 
Eosinophil 
 
2.3% Larger 
parasites 
Modulate 
allergic 
inflammatory 
responses 
8-12 
days  
Basophil 
 
0.4% Release 
histamine for 
inflammatory 
response 
Hours 
to days  
 
Table 19: Leucocyte overview (adapted from Wikipedia) 
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4.1.7  Leucocytes in pregnancy  
 
Pregnancy is associated with a physiological leucocytosis that is thought to 
represent both the generalized systemic inflammatory state associated with 
normal implantation and placentation (Canzoneri et al, 2011) and a means 
of protecting the fetus from ascending infection (Korgun et al, 2002) with the 
main reason for this leucocytosis being due to a rise in neutrophil count 
(Von Dadelszen et al, 1999).   
 
4.1.8  Leucocytes in pre-eclampsia      
 
Pre-eclampsia is associated with endothelial activation and dysfunction 
which in turn leads to a heightened inflammatory state.  This inflammatory 
state is thought to cause a leucocytosis, greater than that seen in normal 
pregnancy, and again, neutrophilia plays the largest part in creating the 
leucocytosis (Canzoneri et al, 2009).  
Despite the evidence that there is a significant rise in neutrophil count 
during pre-eclampsia, there is limited work on leucocyte count before pre-
eclampsia develops.  The PIERS group (2011) included total leucocyte 
count in their model to predict pre-eclampsia, but found it was unable to do 
so.     
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4.2  Aim 
 
The aim of this work is to identify parameters from a full blood count, 
obtained in the first trimester of pregnancy, that are altered between women 
who go on to develop pre-eclampsia and those who do not. 
 
 
4.3  Methods   
 
A retrospective case-control study of women who delivered at University 
Hospitals of Coventry and Warwickshire NHS Trust (UHCW) between 1999-
2010 (n=50,712) was performed. UHCW is a large tertiary referral teaching 
hospital in the West Midlands serving a multi ethnic low socio-economic 
population. Women were included if they were diagnosed with pre-
eclampsia between 1999 and 2010 with pre-eclampsia being defined as a 
blood pressure ≥ 140/90mmHg (with Korsokoff V used to determine 
diastole) with proteinuria of either 0.3g/L/24hrs or (+) proteinuria on urinary 
dipstix analysis (ISSHP, 2001).  For each woman diagnosed with pre-
eclampsia, a control was selected (from women who had the same 
estimated delivery date) who did not develop pre-eclampsia.  Both sets of 
women were identified from this hospital database and their mode of 
delivery and neonatal outcomes were retrieved.  Severe pre-eclampsia was 
diagnosed in line with the ACOG guidelines (one or more of the following 
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features: Blood pressure of 160 mm Hg systolic or higher or 110 mm Hg 
diastolic or higher on two occasions at least 6 hours apart while the patient 
is on bed rest / Proteinuria of 5 g or higher in a 24-hour urine specimen or 
3+ or greater on two random urine samples collected at least 4 hours apart / 
Oliguria of less than 500 mL in 24 hours / Cerebral or visual disturbances / 
Pulmonary edema or cyanosis / Epigastric or right upper-quadrant pain / 
Impaired liver function / Thrombocytopenia / Fetal growth restriction).  
Following delivery, midwives entered the antenatal history and delivery 
details into the hospital database (Evolution, CSC Healthcare IT).   
Women were excluded if they first visited the midwife (the booking visit) 
after 14 weeks gestation, if she had any past history of liver or 
haematological disease, had multiple pregnancies or was less than 20 
years old.  Smoking can cause neutrophilia, so women who self reported 
that they were smokers were also excluded.  
When the woman first presented to her midwife the midwife performed a 
series of investigations known as the ‘booking bloods’.  These consisted of 
blood group, antibody screen, infection screen and a FBC.  For the FBC, 3-
4ml of blood was collected into an EDTA (ideal concentration 1.5-2.2mg/ml) 
anti-coagulate sample bottle from the patient’s antecubital fossa and the 
sample was mixed well.  The blood was then placed in an automated cell 
analyser (SIEMENS Advia 2120, USA), which counts the components of the 
FBC, flagging any morphologically abnormal cells in the process.    
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The first trimester blood results were obtained from the Clinical Results 
Recording System (CRRS).  Neutrophil to Lymphocyte ratio was calculated 
by dividing the neutrophil count by the lymphocyte count.  Those who had 
abnormal parameters on FBC or liver function test were excluded.    
The SPSS computer programme (SPSS v19, Chicago, USA) was used for 
the statistical analysis and statistical significance was defined as p=<0.05.  
We compared categorical variables using the χ2 test and continuous 
variables using t-tests. Non-parametric data were analysed by the Mann-
Whitney-U test. 
 
4.  Results  
 
4.4.1  The whole pre-eclampsia group  
4.4.2  Maternal demographics 
 
992 consecutive women met the inclusion criteria (had pre-eclampsia, 
singleton pregnancy, older than 20 years and had FBC and LFT within the 
normal range) 67 self-classified themselves as smokers and were excluded, 
leaving 925 women.  These were matched against 925 women who did not 
develop pre-eclampsia.  The demographics of these participants are listed 
in table 20. 
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As expected, women in the pre-eclampsia group were significantly more 
likely to have an increased BMI (p=0.03), have higher booking blood 
pressure (p=0.01), deliver before 37 weeks gestation and deliver a baby 
that was less than the 10th GROW centile (both p<0.001).  
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 Patient group 
Mean 
 (Standard deviation) 
P 
value 
Pre-eclampsia  Control   
Age (years) 25.1(3) 24.7(2.8) 0.7 
Height (cm) 162 (7) 160(8) - 
Weight (kg) 70.8 (20)        64.5(15.5) - 
BMI (Kg/m2) 26.9 (8) 25.1(5.3) 0.03 
Gestation at 
booking 
13.9 (1.7) 13.8 (1.5) 0.64 
SBP at 
booking 
121 (17) 112(14.5) 0.01 
DBP at 
booking 
75 (11.3) 67 (10.9)  0.01 
DBP at 
diagnosis of 
PET* 
160 
(17.8) 
119 
(14.5) 
- 
DBP at 
diagnosis of 
PET* 
106 (14) 70 (8.7) - 
Delivery before 
37 weeks (n 
and %) 
79 (8.6%) 47 (5.1%)         <0.001 
SGA <10th 
GROW centile 
(n and %) 
152 
(16.5%) 
53 (6%) <0.001 
 
Table 20: Demographic features for the “pre-eclampsia” and the “normal” 
group (BMI = Body Mass Index, PET = pre-eclampsia, n=number, GROW 
=gestation related optimised weight) *In the control group this reading 
represents the highest third trimester blood pressure.   
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4.4.3  Full Blood Count comparisons  
There were no differences in the standard measured parameters of first 
trimester FBC samples between the two groups, Although neutrophil count 
appeared higher in the pre-eclampsia group, this did not reach significance 
(p=0.063).  Table 21 demonstrates the difference between the normal and 
pre-eclampsia groups. 
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Parameter Normal  Pre-
eclampsia 
p value* 
(median with IQR) 
Haemoglobin 
(g/L) 
122 (18) 121 (18) 0.76 
Platelets (x 
109/L) 
217 (29) 223 (32) 0.11 
WBC  
(x 109/L) 
7.6 (1.7) 8.2 (2.1) 0.54 
Neutrophil  
(x 109/L) 
4.5 (1.5) 5.1 (1.6) 0.06 
Lymphocyte 
(x 109/L) 
2.4 (6.1) 2.03 (7.4) 0.09 
Monocyte 
 (x 109/L) 
0.5 (0.3) 0.6(0.3) 0.82 
Eosinophil  
(x 109/L) 
0.15 
(0.01) 
0.17 (0.02) 0.60 
Basophil (x 
109/L) 
<0.01 <0.01 - 
N:L ratio 2.04 2.47 <0.001 
 
 
Table 21:  First trimester Full Blood Count parameters between women who 
went on to develop pre-eclampsia in the third trimester (the Pre-eclampsia 
group) and those who did not (the normal group).  WBC=White Blood Cell, 
N: L ratio= Neutrophil to lymphocyte ratio.  Significance taken as p<0.05. 
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4.4.4  Neutrophil to Lymphocyte ratio  
Although not a commonly reported parameter of the FBC, the Neutrophil to 
lymphocyte ratio was raised in women who went on to develop pre-
eclampsia (p<0.001), with the difference between the two groups 
represented in figure 31: 
 
 
 
 
Figure 31:  Box plot of the median value of neutrophil to lymphocyte ratios 
in first trimester FBC samples from women who did and did not go on to 
develop pre-eclampsia.  The bottom and top of each box represents the 25th 
and the 75th percentile respectively; the line represents the median value.  
Whiskers extend to the most extreme data points 
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To assess the incremental predictive ability of the neutrophil to lymphocyte 
ratio to predict the onset of pre-eclampsia, a Receiver-Operator 
Characteristic (ROC) curve was produced (figure 32, below), with the area 
under the curve (AUC) calculated (AUC = 0.7237). 
 
 
 
Figure 32:  Receiver Operator Characteristic curve of neutrophil to 
lymphocyte ratio values in predicting the development of pre-eclampsia 
(AUC = 0.7237 (95% CI 0.7009 – 0.7466); at a cut off of 2.47 Sensitivity 
=0.81 (95%CI 0.73-0.87), specificity =0.56 (95%CI 0.48-0.65), PPV=0.63 
(95% CI 0.56-0.70), NPV=0.77 (0.67-0.84).  
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4.4.5  The Severe pre-eclampsia group  
 4.4.6  Maternal demographics  
144 women met the inclusion criteria (had severe pre-eclampsia as defined 
by the ACOG), singleton pregnancy, older than 20 years and had FBC and 
LFT (within the normal range) 8 self-classified themselves as smokers and 
were excluded, leaving 136 women.  These were matched against 136 
women with the same estimated delivery date who did not develop pre-
eclampsia.  The demographics of these participants are listed in table 22. 
 
Women in the severe pre-eclampsia group were significantly more likely to 
have an increased BMI (p=0.01), deliver before 37 weeks gestation and 
deliver a baby that was less than the 10th GROW centile (both p<0.001).  
There was, however, no difference between booking blood pressures 
between the two groups.   
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 Patient group 
 (Mean (standard deviation)) 
P 
value 
Pre-
eclampsia  
Control   
Age (years) 25.7(3.1) 24.4(2.9) 0.09 
Height (cm) 162 (7) 160(8) - 
Weight (kg) 70.8 (20) 64.5(15.5) - 
BMI (kg/m2) 27.1(8.2) 25.0(5.6) 0.01 
Gestation at 
booking 
13.2 (1.6) 13.6 (0.9) 0.64 
SBP at 
booking 
(mmHg) 
124 (17) 113(14.5) 0.01 
DBP at 
booking 
(mmHg) 
79 (11.3) 67 (10.9)  0.01 
SBP at 
diagnosis of 
PET* 
(mmHg) 
163 (17.8) 117 (13.9) - 
DBP at 
diagnosis of 
PET* 
(mmHg) 
       106 
(14) 
71 (8.3) - 
Delivery 
before 37 
weeks (n 
and %) 
54 (39.7%) 7 (5.2%)       <0.001 
SGA <10th 
GROW 
centile (n 
and %) 
152 (16.5%) 53 (6%)       <0.001 
 
Table 22 Demographic features for the “Severe pre-eclampsia (ACOG)” and 
the “normal” group (BMI = Body Mass Index, PET = pre-eclampsia, 
n=number, GROW =gestation related optimised weight) *In the control 
group this reading represents the highest third trimester blood pressure.   
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Full Blood Count comparisons  
In women who went on to develop severe pre-eclampsia, there was a 
significant difference in neutrophil count (p=0.03).  Other haematological 
findings between the two groups were not significant.  Table 23 
demonstrates the difference between the normal and pre-eclampsia groups.  
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Parameter Normal  Pre-
eclampsia 
p value* 
(median with IQR) 
Haemoglobin 
(g/L) 
128 (21) 126 (15) 0.79 
Platelets (x 
109/L) 
225 (31) 236 (39) 0.15 
WBC (x 
109/L) 
7.8 (1.6) 8.5 (2.0) 0.58 
Neutrophil  
(x 109/L) 
4.6 (1.6) 6.7 (2.1) 0.03 
Lymphocyte 
 (x 109/L) 
2.5 (6.3) 2.09 (7.4) 0.08 
Monocyte 
 (x 109/L) 
0.6 (0.3) 0.6(0.3) 0.83 
Eosinophil  
(x 109/L) 
0.18 
(0.01) 
0.2 (0.01) 0.58 
Basophil  
(x 109/L) 
<0.01 <0.01 - 
N:L ratio 1.99 2.53 <0.001 
 
Table 23:  First trimester Full Blood Count parameters between women who 
went on to develop severe pre-eclampsia in the third trimester (the Pre-
eclampsia group) and those who did not (the normal group).  WBC=White 
Blood Cell, N: L ratio= Neutrophil to lymphocyte ratio.  Significance taken as 
p<0.05. 
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Neutrophil to Lymphocyte ratio  
The Neutrophil to lymphocyte ratio was significantly raised in women who 
went on to develop severe pre-eclampsia (p<0.001), with the difference 
between the two groups represented in figure 33 (below): 
 
 
 
 
Figure 33:  Box plot of the median value of neutrophil to lymphocyte ratios 
in first trimester FBC samples from women who did and did not go on to 
develop severe pre-eclampsia.  The bottom and top of each box represents 
the 25th and the 75th percentile respectively; the line represents the median 
value.  Whiskers extend to the most extreme data points 
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To assess the incremental predictive ability of the neutrophil to lymphocyte 
ratio to predict the onset of severe pre-eclampsia, I again produced a ROC 
Curve (figure 34, below) and from this, the AUC (AUC = 0.834) was 
calculated. 
 
 
Figure 34:  Receiver Operator Characteristic curve of neutrophil to 
lymphocyte ratio values in predicting the development of severe pre-
eclampsia (AUC = 0.84 (95% CI 0.79 – 0.91); at a cut off of 2.53, sensitivity 
0.914 (95% CI=0.85-0.95), specificity = 0.6 (95% CI = 0.51-0.67), PPV=0.68 
(95% CI = 0.6-0.74), NPV=0.87 (95% CI 0.8 – 0.93).  
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4.5  Discussion 
 
This study assesses the difference in commonly tested haematological 
parameters undertaken in the first trimester of pregnancy from women who 
do and do not go on to develop pre-eclampsia.  It evolves from work 
presented in this thesis, which demonstrates that women who later develop 
pre-eclampsia have a distorted plasma proteome in the first trimester of 
pregnancy and part of this altered state involves changes in markers of 
inflammation.   
 
4.5.1  Summary and discussion of key findings  
 
The maternal demographics between the women who developed pre-
eclampsia and those that did not were on a whole expected and did not 
differ greatly from those discussed in chapter 2.  The pre-eclampsia group 
was statistically more likely to have an increased BMI, have a raised 
booking blood pressure and have a growth restricted baby (less than 10th 
GROW centile).  
Despite the fact that pre-eclampsia has been shown to be an excessive 
inflammation state (Borzychowshi et al, 2006), this excessive inflammation 
is not widely evident in the first trimester, and although various studies have 
shown up-regulation in certain IL and TNF concentrations (Freeman et al, 
2004) there is no difference in the common leucocytes between the normal 
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and pre-eclampsia groups.  However, this is to be expected.  Before the 
systemic clinical syndrome of pre-eclampsia develops, the main site for pre-
clinical pathological changes is placental tissue (Sibai et al, 2005).  This 
area of localized inflammation is unlikely to produce an overt inflammatory 
state that would significantly alter the leucocyte population. 
In cardiovascular literature, there is evidence that long before a major 
pathological event, such as myocardial infarction, or diagnosis with angina 
(both of which are associated with alteration in leucocytes, thought to 
represent the inflammatory state of the disease), there are subtle changes 
suggesting a low-grade inflammation and this low-grade inflammation can 
be assessed by measuring the neutrophil to lymphocyte ratio (Bhat et al, 
2013). 
In this study we studied two populations of women with pre-eclampsia.  The 
first were women who developed pre-eclampsia according to the ISSHP 
guidelines (the ISSHP group), which does not account for the severity of the 
disease.  The second group of women were those who developed severe 
pre-eclampsia, as defined by the ACOG (the ACOG group).  Both of these 
groups had raised neutrophil to lymphocyte ratios compared to women who 
did not develop pre-eclampsia, suggesting a marked low-grade 
inflammation.  The neutrophil to lymphocyte ratio was able to predict pre-
eclampsia more accurately in the ACOG group than the ISSHP group (AUC 
= 0.834 versus AUC= 0.7237).  These are both greater than other studies 
involving first trimester markers for pre-eclampsia.  Baumann et al (2008) 
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reviewed several markers to predict late onset pre-eclampsia, showing that 
when soluble Eng, Inhibin-A and sFlt1 were combined the AUC was 0.656.  
This could be due to their definition of late pre-eclampsia, and whether late 
pre-eclampsia is associated with greatly exaggerated endothelial damage.  
Conversely, the AUC from my study is less than that reported by Bosio et 
al(2001).  They showed that using p-Selectin in the first trimester had the 
ability to predict pre-eclampsia (AUC=0.93).  P-Selectin was expressed by 
platelets and endothelial cells upon activation and involved in inflammation, 
and is thought to reflect disturbance of the vascular system.  However, in 
subsequent work P-Selectin has only limited ability to predict pre-eclampsia, 
with a detection rate of 59% and a false positive rate of 5%, making it 
inappropriate as a screening tool (Monte et al, 2011).          
Imtiaz et al (2012) studied leucocyte concentration and neutrophil to 
lymphocyte ratios in a general population as a systemic inflammation in 
chronic diseases.  They found that the neutrophil to lymphocyte ratio was 
increased in people with previously undiagnosed diseases that commonly 
affect the cardiovascular system, such as diabetes and hypertension.  
These findings were not present in non-vascular diseases such as asthma 
and arthritis.  This may suggest that the neutrophil to lymphocyte ratio is a 
marker of inflammation due to endothelial injury.  This is further supported 
by the numerous works involving the neutrophil to lymphocyte ratio as a 
marker for severity of cardiovascular disease (Bhat et al, 2013). 
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Neutrophilia accounts for the leucocytosis seen in pre-eclampsia 
(Canzoneri et al, 2009) and with a lack of first trimester studies that review 
neutrophils in women who develop pre-eclampsia, this could represent a 
(unidentified) long-standing up-regulation existing from early pregnancy (or 
before).  As neutrophilia is a marker of inflammation, an increased 
neutrophil count may suggest an increased level of inflammation (Butterfield 
et al, 2006).     
 
 
 
4.5.2  Strenghts of this study  
One of the main strengths of this case-control study is that the data were 
retrospectively analysed from robust prospectively collected information 
entered into the maternity information system.  Midwives were trained on 
data entry and, in addition, at the end of the pregnancy the data was 
checked for completeness by administration teams, cross referencing 
patient records for procedure/diagnosis coding and payment reasons.   
The gestation cut-off of 14 weeks meant that physiological variation in 
leucocyte concentration was minimised and to reduce selection bias further, 
the study consisted of 925 consecutive women, rather than randomly 
generating the pre-eclampsia group.   
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4.5.3  Weakness of the study   
The definition of pre-eclampsia is specific, but there is a possibility of falsely 
diagnosing pre-eclampsia (for example, hypertension in the presence of a 
urinary tract infection, or urine contamination from amniotic fluid).  Including 
women in the pre-eclampsia group who did not have the disease, may 
account for the difference in results between the ISSHP and the ACOG 
group.   
In addition, women who truly had pre-eclampsia may have been 
categorised as having similar disorders such as pregnancy-induced 
hypertension that could have classified them within the “normal” cohort.  
The control group consisted of women who were matched to women 
developing pre-eclampsia by their estimated due date.  In hindsight, it may 
have been more advantageous to match women according to their age 
(although in both the ISSHP and ACOG group the difference in ages 
between the case and control cohorts was not significant). 
This case-control study consisted of women from the West-Midlands, which 
has one of the highest rates of cardiovascular disease in England.  
Therefore the difference in booking blood pressures between the normal 
and pre-eclamptic groups may be due to pre-existing hypertension, which 
may not be reflective of the pregnancy population as a whole.   
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4.6  Conclusion   
Full Blood Counts are routinely performed in pregnant women at the 
beginning of their pregnancy.  Not only do they usually take place before 16 
weeks gestation (that is, before placentation is completed) but also, the test 
is relatively cheap.  Given that this study has shown the neutrophil to 
lymphocyte ratio is increased in women who go one to develop pre-
eclampsia, this may serve as a predictor for the disease.   
What this study does not assess is whether we are able to predict those 
who will have poor outcome in pre-eclampsia.  In order to do this, I have 
continued with the theme of assessing commonly ordered investigations in 
women diagnosed with pre-eclampsia and whether they are able to predict 
those, that when diagnosed with the disease, will have a poorer outcome.  
This is presented in the following chapter.       
 
 
 
 
 
 
 
 
 
 
 
 
 
Chapter 5 
 
Inflammatory and antioxidant markers to 
predict poor outcome in women diagnosed 
with pre-eclampsia  
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5.1  Introduction 
 
Failure of the implanting trophoblast to properly invade the maternal 
spiral arteries has been widely accepted to play a key role in the 
pathogenesis of pre-eclampsia but the mechanism by which this occurs 
and the consequence of this event, remain unclear.  However, what is 
becoming clear, is the role placental oxidative and endoplasmic 
reticulum stress plays towards the development of the clinical disease 
(Steegers et al, 2010).  The placenta appears to be the principal source 
of free radical synthesis but maternal leucocytes and the maternal 
endothelium are also likely contributors. In addition studies have 
suggested an important role for placental trophoblast NAD(P)H oxidase 
in free radical generation in preeclampsia (Raijmakers et al, 2004). 
 
5.1.1  Oxidative Stress 
Oxidative stress occurs when the generation of free radicals (that is, 
substances with one or more unpaired electrons) exceeds the capacity 
of antioxidant defense mechanisms (that is, pathways that provide 
protection against harmful effects of free radicals) (Poston et al, 2004).  
Free radicals primarily consist of oxygen (collectively known as oxygen 
free radicals or reactive oxygen species (ROS)) or nitrogen (known as 
reactive nitrogen species (RNS)) metabolites and many are by-
products of common aerobic cellular processes.  They are primarily 
! 175!
formed in mitochondria, where the superoxide anion is generated from 
complex I and III of the electron transfer chain.  The superoxide anion 
(O!2-) is formed by the univalent reduction of triplet-state molecular 
oxygen (3O2).  This process is regulated enzymatically by NAD(P)H 
oxidases and xanthine oxidase and non-enzymatically by redox-
reactive compounds such as semi-ubiquinone compound).  O!2- is 
detoxified by manganese superoxide dismutase enzyme (MnSOD) in 
mitochondria and by copper/zinc superoxide dismutase enzyme 
(Cu/ZnSOD) in cytoplasm.  The SOD enzymes convert O!2- into 
hydrogen peroxide (H2O2) that in turn can be converted into water.   
Alternatively in the presence of transition metals, O!2- can be converted 
into the highly reactive hydroxyl radical !OH, the most potent of all ROS 
(see figure 35) (Cindrova-Davies et al, 2009).  In physiological 
conditions, moderate levels of ROS and RNS play a role in cell 
proliferation and survival.  However, when this redox homeostasis is 
disturbed, there is oxidative stress that can lead to cell death and 
contribute to disease development (Trachootham et al, 2008). 
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Figure 35:  An overview of redox generation and clearance. The 
superoxide anion (O2−) is formed by the univalent reduction of triplet-
state molecular oxygen (3O2). This process is regulated enzymatically 
by NAD(P)H oxidases and xanthine oxidase or non-enzymatically by 
redox-reactive compounds (e.g. semi-ubiquinone compound). O2− is 
detoxified by manganese (if in mitochondria) or copper/zinc (if in 
cytosol) superoxide dismutase enzyme (MnSOD or Cu/ZnSOD). SOD 
converts superoxide into hydrogen peroxide (H2O2), which can 
subsequently be converted into water by the enzymes catalase or 
glutathione peroxidase. Alternatively, H2O2 can be converted into the 
highly reactive hydroxyl radical (OH) in the presence of reduced 
transition metals via the Fe2+-dependent Fenton reaction. GSH – 
glutathione; GSSG – glutathione disulphide.  (Adapted from Cindrova-
Davies, 2009). 
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5.1.2  Anti-oxidants 
As mentioned, antioxidants play a crucial role in redox homeostasis 
and these exist in enzymatic and non-enzymatic forms.  In general anti-
oxidants work by stopping free radicals by removing the unpaired 
electron(s), reducing the substrate and being oxidised themselves in 
the process.  Non-enzymatic anti-oxidants include vitamin C, vitamin E, 
quinones, carotenoids and bilirubin (Rock et al, 1996). 
Given the effect free radicals and oxidative stress may play in the 
pathophysiology of many diseases, a significant number of trials have 
been undertaken with a view to assessing the effect anti-oxidant 
supplementation has in preventing disease development and 
progression.  However, when these trials have been assessed in robust 
systematic reviews the results were not as expected.  Supplementation 
with some antioxidants (Beta carotene, vitamin A and vitamin E) 
increased mortality (Bjelakovic et al, 2007).   
Despite this negative association with exogenous antioxidants, 
endogenous antioxidants have been used as a marker of health.  In 
particular bilirubin has been shown to be protective against 
cardiovascular morbidity.  
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5.1.3  Bilirubin 
Bilirubin is a powerful antioxidant with the ability to prevent lipid 
(amongst others) oxidation with greater efficacy than vitamin E (Otero 
Regino et al, 2009).  It is formed via the breakdown of haem, the 
oxygen-carrying component of red blood cells.  This is described further 
in figure 36: 
 
 
Figure 36: The antioxidant-redox cycle of the Haemoxygenase /Bilirubin 
system. 
Haemoxygenase (HO) itself is a powerful antioxidant and is protective in 
various pathophysiological states such as cardiovascular and 
neurodengerative diseases, whilst the HO-derived bilirubin is an efficient 
scavenger for ROS and RNS (Jansen et al, 2010).  Physiological 
concentrations of bilirubin are therefore beneficial, but when elevated 
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bilirubin is neurotoxic. 
In 1994, Schwertner et al showed an inverse association between bilirubin 
and coronary artery disease and since then there have been many studies 
that showed the similar association between low bilirubin levels and worse 
clinical outcomes in other vascular and respiratory disorders. This included 
secondary analysis of the seminal Framingham study that showed how 
elevated (but still physiological) levels of bilirubin had a reduced incidence of 
cardiovascular morbidity (Lin et al, 2006; Horsfall et al, 2011; Vitek et al, 
2012). 
 
5.1.4  Anti-oxidants and pre-eclampsia  
Pregnancy is a state of heightened oxidative stress, with both an increase in 
circulating levels of oxidised low-density lipoproteins and a reduction in the 
total antioxidant capacity compared to non-pregnant individuals.  Pregnancy 
is also associated with a systemic inflammation characterised by a greater 
activation of circulating lymphocytes and granulocytes, both of which 
produce a large number of ROS, testimony that these two pathways are 
interlinked (Burton et al, 2011).  
Both oxidative stress and systemic inflammation are more pronounced in 
pre-eclampsia.  However, as mentioned in previous chapters, the nature in 
which the placental injury leads to these heightened pathways, and how they 
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lead to the clinical syndrome, remain unclear.  Redman and Sargent (2009) 
describe two scenarios.  The first, is due to reduced uteroplacental arterial 
perfusion from inadequate remodeling of the spiral arteries, which causes a 
state in which the placenta is chronically hypoxic.  The second scenario is 
due to intermittent blood flow through the spiral arteries that causes 
ischaemic reperfusion of the placenta.  This hypoxia/reoxygenation is a 
potent stimulus to the activation of xanthine oxidase, an important source of 
superoxide generation, which is abundantly expressed in cytotrophoblast, 
syncytiotrophoblast, and villous stromal cells (Raijmakers et al, 2004).  This 
leads to an environment of increased oxidative stress and increased ROS, 
provoking release of sFLT1, causing the heightened inflammatory state and 
the resulting maternal systemic syndrome (Redman et al, 2009).   
The role oxidative stress has on the development of the pre-eclamptic 
placenta is explored further in figure 37.   
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Figure 37: Proposed association between placental oxidative stress and 
maternal vascular dysfunction in preeclampsia. It is hypothesized that free 
radical generation through xanthine oxidase or NAD(P)H oxidase in the 
placenta leads indirectly to maternal neutrophil activation. In the maternal 
circulation, a vicious cycle of maternal endothelial and neutrophil activation 
may result in sustained NAD(P)H oxidase activity and release of superoxide 
(Adapted from Raijmakers et al, 2004) 
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5.2  Aim 
 
The first aim of this work was to assess the ability of bilirubin concentration 
to predict poor outcome in women who develop the disease.  Secondly, this 
work also evaluated the ability of the neutrophil to lymphocyte ratio 
(discussed in the previous chapter) to predict poor maternal and fetal 
outcome at the time of diagnosis with pre-eclampsia.   
 
 
5.3  Method 
A retrospective observational study of women who delivered at University 
Hospitals of Coventry and Warwickshire NHS Trust (UHCW) between 1999-
2010 (n=50,712) was performed.  Women were included if they were 
diagnosed with pre-eclampsia between 1999 and 2010.  Pre-eclampsia was 
defined as a blood pressure ≥ 140mmHg/90mmHg (with Korsokoff V used to 
determine diastole) with proteinuria of either 0.3g/L/24hrs or (+) proteinuria 
on urinary dipstix analyisis.  On diagnosis of pre-eclampsia “pre-eclampsia 
bloods” were taken.  These haematological and biochemical tests consisted 
of FBC, urea & electrolytes, uric acid level and liver function test (a 
component of the liver function test is bilirubin).  Following delivery, midwives 
entered the antenatal history and delivery details into the hospital database 
(Evolution, CSC Healthcare IT, USA). Women diagnosed with pre-eclampsia 
in a singleton pregnancy were identified from this hospital database and their 
mode of delivery and neonatal outcomes were retrieved. Poor maternal 
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outcomes were defined as placental abruption, HELLP syndrome, eclampsia 
and maternal death. Poor fetal outcomes were defined as Apgar’s less than 
7 at 5 minutes post delivery, low birth weight (<10th centile at birth), 
unexpected admission to neonatal unit and late fetal demise.   
Women were excluded if they had any past history of liver disease; the liver 
function test showed any abnormal liver function parameters, had multiple 
pregnancies or were less than 20 years old (Bilirubin levels stabilise after 20 
years of age (Wilding et al, 1972)).  As smoking can cause change in plasma 
bilirubin levels smokers were excluded from the study (Van Hoydonck, 
2001). Haematological parameters and bilirubin levels were obtained from 
the Clinical Results Recording System (CRRS).  
The SPSS computer programme (SPSS v19, Chicago, USA) was used for 
the statistical analysis and statistical significance was defined as p<0.05.  
Categorical variables were compared using the χ2 test and continuous 
variables using t tests. Non-parametric data were analysed by the Mann-
Whitney-U test. Comparisons of bilirubin quintile levels (with the median 
range acting as reference) are presented as two tailed p values.  
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5.4  Results  
992 consecutive women met the inclusion criteria (pre-eclampsia, singleton 
pregnancy, older than 20 years and had liver function tests within the normal 
range) with 67 self-classified themselves as smokers and were excluded, 
leaving 925 women. The demographic data of the women has already been 
discussed and can be found in chapter 4.   
The median time between the blood tests being performed and the poor 
outcome was 5.4 days (interquartile range = 1-13 days). 
 
5.4.1  Bilirubin  
 
The lowest quintile of bilirubin levels were associated with a greater risk of 
requiring a caesarean section for fetal distress (p=0.001 aOR=2.25 (95% 
CI=1.27-5.61) (Table 24).   
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 CS for fetal distress  Poor maternal outcome  Poor infant outcome  
Bilirubin 
Level 
(mg/L)$ 
Crude OR  
(95% C.I.) 
Adjusted OR^ 
(95% C.I.) 
Crude OR 
(95%C.I.) 
Adjusted OR^ 
(95% C.I.) 
 
Crude OR 
(95%C.I.) 
Adjusted OR^ 
(95% C.I.) 
 
1st quintile 
0-0.21 
(n= 157) 
 
2.96 
(1.52-5.74)* 
 
2.25 
(1.27 – 5.61)* 
3.05 
(1.63-5.72)* 
 
3.12 
(1.2-6.87)* 
3.9 
(2.5-5.6)* 
2.5  
(1.25-5.19)* 
2nd quintile 
0.22-0.43 
(n=204) 
 
1.49 
(0.86-2.61) 
 
0.94 
(0.51-2.0) 
1.91 
(0.98-3.67) 
 
1.85 
(0.76-2.64) 
1.3 
(0.86-1.71) 
1.24 
(0.97-1.88) 
3rd quintile 
0.44-0.65 
(n=270) 
 
REFERENCE REFERENCE REFERENCE REFERENCE REFERENCE REFERENCE 
4th quintile 
0.66-0.87 
(n=190) 
 
1.69 
(0.99-2.86) 
 
1.63 
(0.12-3.95) 
1.66 
(0.85-3.3) 
 
2.77 
(0.59-4.54) 
1.55 
(1.2-2.6) 
0.97 
(0.2-1.8) 
5th quintile 
0.88-1.05 
(n=104) 
 
0.59 
(0.38-0.97)* 
 
0.65 
(0.15-1.31) 
1.14 
(0.56-2.30) 
 
1.31 
0.66-2.84) 
0.86 
(0.41-1.30) 
0.91 
(0.34-1.79) 
^ Adjusted for age, BMI, ethnicity, gestation at delivery, Diastolic and Systolic blood pressure at diagnosis and amount of 
proteinuria. 
*p=<0.05 
$ To convert mg/L of bilirubin to µmol/L multiply by 17.1 
 
 
Table 24: Ability of Bilirubin to predict poor outcome in women with pre-eclampsia 
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The area under the receiver operator characteristic curve was 0.78 (95% 
confidence limit 0.65 - 0.89).  Sensitivity was 0.87, specificity was 0.55, positive 
predictive value was 0.7 and negative predictive value was 0.86 (Figure 38). 
 
 
 
 
Figure 38:  Receiver Operator Characteristic curve of bilirubin concentration to 
predict delivery by caesarean section for fetal distress (AUC = 0.78 (95% CI 0.65 
– 0.89). At a cut off of 0.17mg/L; Sensitivity =0.87 (95% CI 0.72-0.96), specificity 
=0.55 (95% CI 0.43-0.68).  
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Maternal poor outcomes; placental abruption (n=31), HELLP syndrome (n=78), 
eclampsia (n=2) and maternal death (n=1) were grouped together for the logistic 
regression analysis due to too the small number of individual incidences.  The 
first quintile of bilirubin levels were associated with a poor maternal outcome after 
adjusting for age, BMI, ethnicity and gestation of delivery (p=0.002 aOR3.12 
(95% CI=1.2-6.87) (table 16). The AUC=0.73, with a cut off of 0.17 mg/L; 
sensitivity = 0.93 (95% CI 0.85-0.99), specificity = 0.42 (95% CI 0.3-0.57).  Poor 
infant outcomes were also relatively few (Apgar’s less than 7 at 5 minutes of life 
n=53, low birth weight (<10th centile at birth) n= 30, unexpected admission to 
neonatal unit n=37 and late fetal demise n= 11).  Hence a combined measure of 
all these poor infants outcomes born to pre-eclamptic mothers was used for the 
multivariate analysis. When bilirubin concentrations were in the lowest quintile, 
there were more poor infant outcomes after adjusting for age, BMI, ethnicity and 
gestation of delivery, Blood pressure and proteinuria (p=0.015, aOR 2.5 (95%CI 
1.25-5.19)).  However, the sensitivity of the lowest quintile for predicting poor 
fetal outcome was poor (0.61 (95% CI 0.48 – 0.73). 
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5.4.2  Neutrophil to Lymphocyte Ratio 
The lowest quintile of NLR was associated with a lower incidence in fetal distress 
necessitating delivery by CS and maternal complications (including HELLP and 
placental abruption) while conversely, the highest quintile of NLR was associated 
with a greater number of complications when compared to the median quintile.  
There was no difference in fetal / neonatal complications between the reference 
groups and the other NLR ratios (See table 25).   
In the poor maternal outcome group the AUC was 0.7239 (95% CI 0.59 - 0.86, 
p=<0.002).  At a cut-off of 5, the sensitivity was 0.9, with a specificity of 0.36.  !
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 CS for fetal distress  Poor maternal outcome Poor infant outcome  
NLR 
 
Crude OR  
(95% C.I.) 
Adjusted OR^ 
(95% C.I.) 
Crude OR 
(95%C.I.) 
Adjusted OR^ 
(95% C.I.) 
 
Crude OR 
(95%C.I.) 
Adjusted OR^ 
(95% C.I.) 
 
1st quintile 
0-1.24 
(n= 113) 
 
1.14 
(0.72-2.0) 
 
1.25 
(0.83 – 1.78) 
0.72 
(0.60-0.85)* 
 
0.78 
(0.67-0.9)* 
0.89 
(0.6-1.13) 
1.02 
(0.74-1.5) 
2nd quintile 
1.24-2.48 
(n=204) 
 
1.2 
(0.86-2.61) 
 
1.17 
(0.7-1.98) 
1.38 
(0.86-2.18) 
 
1.44 
(0.87-2.27) 
1.42 
(0.94-1.60) 
1.13 
(0.77-1.58) 
3rd quintile 
2.48-3.71 
(n=252) 
 
REFERENCE REFERENCE REFERENCE REFERENCE REFERENCE REFERENCE 
4th quintile 
3.71-4.95 
(n=239) 
 
1.42 
(0.98-1.98) 
 
1.60 
(1.0-2.54) 
1.34 
(0.84-2.1) 
 
1.24 
(0.91-1.62) 
1.32 
(0.84-2.81) 
1.19 
(0.82-1.86) 
5th quintile 
4.95-6.20 
(n=117) 
 
1.72 
(1.08-2.85)* 
 
1.53 
(1.09-1.91)* 
1.69 
(1.13-1.98)* 
 
1.4 
(1.12-1.67)* 
1.36 
(0.82-2.3) 
1.1 
(0.82-1.97) 
^ Adjusted for age, BMI, ethnicity, gestation at delivery, Diastolic and Systolic blood pressure at diagnosis and amount of proteinuria. 
*p=<0.05 
 
Table 25 Ability of Bilirubin to predict poor outcome in women with pre-eclampsia 
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5.4.3  Correlation between bilirubin and neutrophil to lymphocyte     
ratio 
The relationship between bilirubin and NLR concentrations suggests that 
there is a correlation between the bilirubin and Neutrophil to lymphocyte ratio 
values in women with pre-eclampsia of (correlation coefficient r=-0.4 (95% -
0.4525 to -0.3444) r2=0.1599, p=<0.001) (see figure 39). 
 
 
 
 
 
Figure 39: Correlation between bilirubin (in mg/L) and neutrophil to 
lymphocyte ratio in women diagnosed with pre-eclampsia. 
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5.  Discussion 
This is novel data because this is the first study to have found an association 
between bilirubin levels in the lowest quintile (of the normal range) along 
side NLR in the highest quintile and poor outcomes in mothers and infants in 
women with pre-eclampsia.   
 
5.5.1  Summary and discussion of key findings  
 
Previously Kozic et al (2011) investigated the ability of abnormal liver 
function tests to predictor poor clinical outcomes in pre-eclampsia.  These 
authors found a strong association between abnormally elevated bilirubin 
levels and poor clinical outcomes in women with pre-eclampsia. However, 
bilirubin levels within the normal range were not stratified and it is thus likely 
that Kozic compared two different grades of pre-eclampsia from the known 
spectrum of the clinical presentation of the disorder (e.g., the abnormal liver 
function representing a form of HELLP).    
 
Given the potent anti-oxidant properties of bilirubin, our data suggests that 
low levels of bilirubin leave the mother and fetus susceptible to the syndrome 
and clinical presentation of pre-eclampsia.  The higher concentrations of 
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bilirubin did not, as initially hypothesised, confer protection from developing 
poorer outcomes than the median group.  
This may be due to the more severe form of pre-eclampsia having a higher 
oxidative stress response and therefore consuming more anti-oxidants e.g. 
bilirubin.  Or it could be that there is just not a direct causal relationship.   
The neutrophil to lymphocyte ratio, used as a marker of systemic 
inflammation, was raised in women who had greater number of poor 
maternal outcomes or required delivery by caesarean section for fetal 
distress.  From this it could be reasoned that in pre-eclamptic pregnancies, 
greater systemic inflammation is an independent marker of poor pregnancy 
outcomes.  Conversely, NLR at the lower quintile (which could be taken as a 
marker of reduced systemic inflammation) was associated with fewer poor 
maternal outcomes.  There was no significant difference in the number of 
caesarean sections for fetal distress between the lowest and median quintile 
groups. 
Interestingly, NLR could not identify those pregnancies that would have 
poorer infant outcome.  Whether this is due to systemic inflammation not 
having a direct link on the fetus is unlikely.  A more plausible reason could 
be that the study was insufficiently powered to assess the link between NLR 
and infant outcome. 
Given the link between inflammation and oxidative stress, it would be 
suggestive that there is a relationship between bilirubin and NLR.  Given a 
correlation coefficient of -0.4 it would suggest that, whilst there is a link 
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between the two, it is not a strong one.  The clinical syndrome of pre-
eclampsia is complex and finding a strong correlation between the two is 
unlikely from clinical studies.  However, given that the link is negative, it is 
more in keeping that this is a true relationship.  If the link were positive, it 
would more likely be due to an up-regulation of many disease processes 
rather than a true association. 
 
5.5.2  Strenghts of this study  
 
The strength of this study lies in the thoroughness of the database used to 
collect the information.  Using standardised hospital notes (“the green notes 
(patient hand-held) notes”), standardised definitions and robust protocols for 
managing pre-eclampsia meant that this study overcame the largest hurdle 
that faces retrospective data, missing data.    
 
5.5.3  Weaknesses of this study  
The results suggest that lower levels of bilirubin can aid the prediction of 
those fetuses that do not cope well with labour (and therefore require 
delivery by emergency caesarean section).  However, possibly due to 
relatively low numbers of poor outcomes, further work would be needed 
before bilirubin levels could be used to accurately detect those women at risk 
of poor maternal and neonatal outcomes.   
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Fetal distress necessitating delivery by caesarean section is, unfortunately, 
quite often a subjective decision.  Despite training on cardiotocograph (CTG) 
interpretation being robust and the interpretation of a CTG together with a 
more objective fetal blood sample (FBS) being advocated, quite often the 
indication for CS is intuitively made my the senior member of the delivery 
suite team.  It could be that some of these CS were carried out 
unnecessarily.   
The question whether the study was appropriately powered needs to be 
addressed.  Retrospective studies are limited by number of patients 
available and therefore at risk of type II error.  Given that for both CS for fetal 
distress and poor maternal outcome with attained levels of statistical 
significance (P<0.05) we can assume that for these the study was 
appropriately powered.  The study number was limited by the number of 
women who had pre-eclampsia, so whilst this number was appropriately 
powered for the maternal complications and risk of caesarean section, it may 
be that it was insufficiently powered to study infant outcomes.    
 
5.6  Conclusion  
These findings suggest that the commonly ordered haematological and 
biochemical tests in women diagnosed with pre-eclampsia can, in addition to 
establishing those with HELLP or renal injury, predict those women who are 
at risk of developing further complications of the disease.  Further 
prospective work is required to validate these as a potential screening tool.    
  
 
 
 
 
 
 
 
Chapter 6 
General discussion and conclusion 
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6. Discussion  
6.1 Introduction  
The vast spectrum that is pre-eclampsia encompasses many different 
clinical presentations, with varying fetal and maternal considerations. Whilst 
the extent to which these various manifestations occur may alter, systemic 
inflammation and endothelial dysfunction are universally present.  Once 
diagnosed, the only cure for the disease is delivery of the placenta and this 
can lead to dilemmas for clinicians as to the best time to deliver a 
(potentially) preterm baby, risking complications of prematurity or to 
continue with the pregnancy and risk complications of pre-eclampsia.  
National guidelines exist to aid in the management of the disease but no 
current intervention can reverse effect that the disease.  Instead most 
treatments aim to prevent further worsening of the condition (Von 
Dadelszen et al, 2011). 
The overall aim of this thesis was to develop markers that could potentially 
work towards predicting pre-eclampsia. Prediction of pre-eclampsia would 
allow optimal allocation of the resources needed to deliver high-risk 
obstetric care.  The thesis comprised epidemiological, laboratory (basic 
science) and clinical studies.  Firstly, I undertook one of the largest cohort 
studies of risk factors for developing pre-eclampsia in the UK.  This study 
contained a significant number of women from ethnic minorities and the 
large number of women within the cohort allowed the currently accepted 
risk factors to be challenged.  To identify novel plasma markers that are 
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altered in women who go on to develop pre-eclampsia I performed a 
quantitative proteomic analysis of individual first trimester plasma.  The 
proteomic work identified several novel results not previously been 
identified.  Although encouraging, before a biomarker can be identified as a 
possible predictor of pre-eclampsia it must undergo several robust 
prospective studies.  This necessary process can take years, so a 
retrospective study was then undertaken that assessed the ability of 
commonly ordered clinical tests to predict the onset of pre-eclampsia.  
However, simply predicting pre-eclampsia whilst useful may have limited 
clinical application.  So the same cohort was used to identify clinical 
parameters that could predict those women who are at risk of poorer 
outcomes when diagnosed with the condition.   
 
6.2 Summary of key findings  
6.21 The epidemiological study  
Identification of risk factors for developing pre-eclampsia is important as it is 
currently the only established way to predict who is at risk of developing the 
disorder in clinical settings.  However, several known risk factors (such as 
ethnicity) are not featured in protocols for preventing and managing 
hypertensive disorders of pregnancy (NICE, 2010).  Using a database of 
109576 women, the first part of the study was to assess the impact 
conventional risk factors have on developing pre-eclampsia for this multi-
ethnic cohort.  As expected; Black ethnicity, Age, BMI and previously 
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diagnosed diabetes and hypertension all increase the likelihood of 
developing the condition.  Having such a large cohort, these risk factors 
were then able to undergo further analysis.  This is the first study to show 
that there is significant racial variation in both the standard risk factors for 
developing pre-eclampsia and the risk of having a significant morbidity 
amongst the three largest ethnic minorities in the UK.  To consider why 
these disparities may be the case we looked at the variation in 
cardiovascular and metabolic diseases amongst these groups.  Miller 
(2007) suggests that the difference in the incidence and presentation of 
many cardiovascular diseases lies in the difference in adhesion molecules 
and cytokines, that lead to altered inflammatory states.  If this theory of 
altered inflammatory states applies to pre-eclampsia, this may account for 
the variation in clinical presentation.   
 
6.22 Proteomic studies 
Another leading theme of this thesis was to identify markers of pre-
eclampsia that could potentially be used to predict the onset of the disease 
from as early as the first trimester of pregnancy.  Since Levine et al’s (2004) 
seminal piece of work illustrating alteration in plasma concentrations of 
angiogenic proteins at 20 weeks gestation in women who go on to develop 
pre-eclampsia, there has been much research aimed at predicting the onset 
of the disease.  Whilst many proteins have been identified as potential 
markers, none are used in clinical practice.  There are several reasons for 
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this lack of usefulness of the current biomarkers.  The first is usually as a 
result of poor study design.  The cost of running proteomic studies can be 
immense and to reduce overheads many groups use pooled plasma 
samples in their biomarker discovery stage (usually running just two 
samples, disease versus normal states).  When individual samples are then 
interrogated they fail to reproduce the initial exciting results (Barker et al, 
2005).  In the proteomic chapter of this thesis, not only were individual 
plasma samples ultilised, these samples were also run in triplicate, to 
reduce the incidence of false positive discoveries. Another strength of my 
study is that the samples used were matched for age, BMI, ethnicity and 
gestational age.  This allowed biological variation to be as minimised as 
much as possible. In my study markers of inflammation, hypertension and 
oxidative stress were all altered in the pre-eclampsia group.  This is the first 
study to show how angiotensinogen, paraoxonase-1, Kallikrein, vitamin D 
binding protein and certain complement proteins are altered in the first 
trimester of pregnancies that subsequently developed early onset severe 
pre-eclampsia.   
There are currently no clinically useful biochemical tests to predict the onset 
of pre-eclampsia in low-risk women.  Chappell et al (2013) have recently 
studied the diagnostic accuracy of PIGF in its ability to predict delivery 
within 14 days due to pre-eclampsia in women suspected of the disease.  
PIGF <5th Centile was able to predict the onset of the disease with 
Sensitivity of 0.96 (95% C.I. 0.85-0.99) and an AUC of 0.87.  Only 14 days 
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warning of pre-eclampsia gives clinicians insufficient time to alter obstetric 
management. In contrast the results presented in chapters 3 and 4 were on 
samples taken more than 16 weeks prior to disease onset. I demonstrated 
an angiotensinogen to kallikrein ratio greater than 0.267 had a sensitivity of 
0.9 (95% C.I. 0.8-0.96) and an AUC of 0.831 (SE=0.042, 95% CI 0.74-0.91) 
for predicting early onset severe pre-eclampsia. Thus the angiotensinogen 
to kallikrein ratio may allow for the development of an accurate first 
trimester predictor of the disease. Further, larger prospective studies are 
needed to validate these novel findings.  
 
 6.23 Clinical inflammatory markers studies  
 
A common pattern within the literature (and this thesis) is the role 
inflammation plays in pre-eclampsia; although whether this causes the 
disease or results from the disease is in dispute.  Either way, the finding of 
an inflammatory state in pre-eclampsia has been repeatedly demonstrated 
(Redman et al, 1999).  The findings in chapter 3 support these studies by 
demonstrating a raised inflammatory proteome in first trimester pregnancies 
that later develop pre-eclampsia.  
 
 The nature of antenatal care in the UK is such that on a woman’s first visit 
to see her midwife (the booking visit) she undergoes several haematological 
investigations to screen for conditions such as anaemia.  As the majority of 
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women book during the first trimester, it would be extremely useful to 
identify markers from these booking tests that may predict those women 
who develop pre-eclampsia.   
 
In chapter 4 I demonstrated that there is an increased neutrophil: 
lymphocyte ratio (a marker of a heightened inflammatory state) in women 
who later develop pre-eclampsia.    The results suggest that this ratio may 
be able to predict the onset of severe pre-eclampsia.  
 
6.24 Predicting poor outcome  
 
Although 2-8% of women get pre-eclampsia, not all of them will have a poor 
outcome.  In fact, the majority of women with pre-eclampsia will have a mild 
form with no complications.  As Chappell (2013) discussed, much resources 
are spent on monitoring these women suggesting that being able to predict 
those at risk of a poor outcome would be very clinically useful in terms of 
better recourse allocation. In chapter 5 I have found that, commonly ordered 
haematological and biochemical investigations may help towards pre-
eclampsia prediction.  Bilirubin and the neutrophil to lymphocyte ratio both 
have the ability to predict poor outcomes after the disease process is 
detected clinically. 
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However their were relatively low numbers of adverse outcomes in my data 
suggests that much larger studies would be required to corroborate these 
findings. 
6.25  A potential screening test? 
An ideal screening tool would be 100% sensitive and 100% specific; that is, 
it would be positive for all those with the disease and negative for all those 
who did not.  Unfortunately no screening tool is ideal.  The predictive ability 
of the findings presented in this thesis all have AUC > 0.7 indicating that 
they have a relatively good overall predictive value.  However, AUC on its 
own offers relatively limited clinical information.  To assess a screening 
tool’s predictive ability, sensitivity, specificity, positive predictive value and 
negative predictive value should be evaluated (Deeks et al, 2004).  Whilst 
the results shown have relatively high sensitivity (>0.85) their corresponding 
specificity are not so encouraging.  Despite this, these results still may have 
the potential to predict the onset of the disease in medical practice.  With a 
high sensitivity, most women who are going to develop the disease will 
screen positive.  With a lower specificity, it means that some women who 
will not develop the disease will also screen positive.  In clinical terms this 
means that few women who will develop pre-eclampsia will not have 
enhanced surveillance and/or intervention treatment (currently aspirin, with 
its relatively low side effects) and some women who will not develop the 
disease will have unnecessary monitoring.  These findings are in keeping 
with the conclusion from a systematic review that suggests that any 
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screening tool for pre-eclampsia should have high sensitivities (Cnossen et 
al, 2004). 
 
6.3 Disease pathogenesis   
The aim of this study was not to try and understand the initial insult that 
causes pre-eclampsia.  However, with any disease where there is a lack of 
understanding regarding its development, it is tempting to suggest markers 
of pathophysiological pathways that answer some of the many unanswered 
questions. 
• Different ethnicities appear to be at risk of different clinical 
presentations of pre-eclampsia.  Some of these differences may be a 
result of either different fat distribution and alteration in the resulting 
inflammatory states or different ethnicities predilection towards 
insulin resistance and heightened oxidative stress. 
• The first trimester proteome of women who develop pre-eclampsia 
have increased markers of inflammation and oxidative stress, 
suggesting that these may play a role in the early pathophysiology of 
the disease. 
•  Markers of both inflammation and oxidative stress are again present 
at the onset of the disease and during the clinical presentation of the 
disease and there appears to be a correlation between the two. 
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These findings may help to answer some of the questions regarding the 
pathophysiology of the disease, but they also throw open several other 
questions; does a heightened inflammatory state (representing existing 
endothelial damage) pre-exist before the onset of the disease?  If oxidative 
stress plays such an important role in the development of the disease, why 
does treatment with anti-oxidants not prevent disease development (Poston 
et al, 2004)? 
 
Conclusion 
This thesis evolved during a time of great excitement and trepidation at the 
possibility of finding one of the holy grails of obstetrics – predicting the 
onset of pre-eclampsia.  With its associated morbidities, healthcare costs 
and impact on future cardiovascular health much energy and resources 
have been spent trying to develop a risk score, similar to that found in 
screening for fetal aneuploidy, to predict the onset of pre-eclampsia.  
Unfortunately this test has of yet to be discovered.  The excitement has 
turned to cynicism, especially towards the field of proteomics; now often 
compared to “finding a needle in a haystack”.  Hopefully the results 
presented in this thesis offer some renewed interest in this quest.  The 
epidemiology chapter reveals the importance of including ethnicity when 
assessing risk of developing pre-eclampsia and the proteomics chapter 
illustrates how the different markers altered in the first trimester that may 
eventually lead to the development of screening tool for the disease. The 
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next two chapters explored how markers of inflammation and oxidative 
stress currently available in obstetric practice that are altered in pre-
eclamptic pregnancies.  
Specifically, the data presented in this thesis add to this existing knowledge 
by providing: 
• One of the largest cohort studies of risk factors for pre-eclampsia 
involving a multi-ethnic UK population. 
• For the first time, differences in the rates of pre-eclampsia across 
different BMI and revealing how Black women are at risk of 
developing pre-eclampsia at lower BMI than White women. 
• Differences occur between age related risk of developing pre-
eclampsia across ethnicities.  
• The finding that White women are more at risk of developing poor 
maternal outcomes that Black or S Asian women, whereas S Asian 
women with pre-eclampsia are more likely to have fetal 
complications. 
• Evidence that Angiotensinogen is raised and Kallikrein is lower in the 
first trimester of pregnancies that subsequently develop pre-
eclampsia.  These findings may suggest how these proteins play a 
role in the development of hypertension later in the pregnancy. 
• A ratio of angiotensinogen to kallikrein > 0.27 predicts the onset of 
pre-eclampsia with a sensitivity of 0.9 (95% CI 0.74-0.97), specificity 
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of 0.5 (95% CI 0.24-0.65), PPV = 0.63 (95%CI 0.47-0.75) NPV =0.87 
(95%CI 0.53-0.96), with an AUC of >0.81 (SE=0.05). 
• Confirmatory evidence of raised inflammatory markers and down 
regulation of inhibitors of inflammation in the first trimester.  
• Evidence of down regulation of paraoxonase-1 in the samples that 
develop pre-eclampsia. 
• Findings that show how the neutrophil to lymphocyte ratio is raised in 
the booking bloods of women who go on to develop pre-eclampsia. 
• Confirmation that bilirubin and neutrophil to lymphocyte ratio can 
predict poor outcomes in women diagnosed with pre-eclampsia and 
how these two parameters have mild correlation.  
 
Like most research projects, this thesis has led to many further questions 
that need to be answered.  Further research areas I intend to pursue 
include: 
 
• Undertaking a prospective large cohort study starting pre-pregnancy.  
This would hopefully answer once and for all the question of which 
came first, the pre-eclampsia or the inflammation. 
• Develop a large statistical model of demographics (including 
ethnicity), first trimester proteomics together with ultrasound 
parameters to form a robust screening tool to predict the onset of 
pre-eclampsia 
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• Hone current chemoprophylactic agents towards those deemed at 
risk from the model, therefore reducing the number of women 
receiving medication unnecessarily.   
 
From the findings presented in this thesis (and the further research 
planned) there is not only the possibility of being able to predict the 
onset of pre-eclampsia, but this work may also further the understanding 
of the diseases origin.   
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